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The glial cell-line derived neurotrophic factor (GDNF) and neurturin (NTN) 
belong to a structurally related family of neurotrophic factors. GDNF and NTN 
exert their effects through a multi-component receptor system consisting of the 
GDNF family receptor alpha (GFRα) and the co-receptor RET and/or NCAM. 
GDNF preferentially binds to GFRα1, while GFRα2 is the cognate receptor for 
NTN.  
This study focused on the biochemical and morphological effects of ligand-
activated GFRα1 and GFRα2 isoforms. In the initial part of the study, GDNF 
and NTN were found to activate distinct miRNA precursors in cells 
endogenously expressing RET, NCAM and GFRα2 but not GFRα1, indicative of 
specificity in ligand-receptor cross-talk.  
There are at least three alternatively spliced isoforms of GFRα2 in the 
nervous system: GFRα2a, GFRα2b, and GFRα2c. Quantitation using highly 
specific and sensitive quantitative real-time PCR revealed comparable 
expression levels of these isoforms in various regions of the human brain, lending 
evidence to the idea that the isoforms may have physiological roles in the nervous 
system. These isoforms showed ligand-selectivity in MAPK (ERK1/2) and Akt 
signaling, and regulated different early response genes. When stimulated with 
GDNF or NTN, both GFRα2a and GFRα2c, but not GFRα2b, promoted neurite 
outgrowth in transfected Neuro2A cells. In co-expression studies, GFRα2b was 
found to inhibit ligand-induced neurite outgrowths mediated by GFRα2a, 
GFRα2c, and GFRα1a, another member of the GDNF family receptor. 
Furthermore, activation of GFRα2b also inhibited neurite outgrowths induced 
by retinoic acid and the inhibitory activities were RhoA dependent. On the other 
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hand, the ligand-induced neurite outgrowths through GFRα2a and GFRα2c 
isoforms showed distinct signaling mechanisms.  
Differential biochemical and neuritogenic activities also exist with the GFRα1 
receptor isoforms, GFRα1a and GFRα1b. When co-expressed, GFRα1b 
antagonized neurite outgrowth mediated by GFRα1a, in a RhoA-ROCK 
dependent manner.  
The results from this study suggest a novel paradigm for the regulation of 
growth factor signaling and neurite outgrowth via an inhibitory splice variant of 
the receptor. Thus, depending on the expressions of specific GFRα2 and GFRα1 
receptor spliced isoforms, GDNF and NTN may promote or inhibit neurite 
outgrowth through the same multi-component receptor complex. The emerging 
view is that the combinatorial interactions of the spliced isoforms of GFRα1, 
GFRα2, RET and NCAM may contribute to the complexity of multi-component 
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The glial cell-lined derived neurotrophic factor (GDNF) and neurturin (NTN) belong 
to a structurally related family of neurotrophic factors. GDNF and NTN exert their 
effects through a multi-component receptor system. GDNF and NTN bind to specific 
GDNF family receptors (GFRα), which are linked to the plasma membrane by a 
glycosyl-phosphotidylinositol (GPI) anchor. These receptors then transduce 
intracellular signals by activating the co-receptor, RET (a transmembrane tryrosine 
kinase), and/or NCAM. GFRα1 and GFRα2 are the preferred receptors for GDNF and 
NTN, respectively. Both ligands have potent trophic effects in many neuronal systems, 
including the midbrain dopaminergic neurons, making it a strong therapeutic 
candidate for several neurodegenerative diseases. Clinical trials I/II using GDNF and 




Despite the many efforts to unravel the biological functions of GDNF, the 
mechanisms underlying receptor-ligand interactions and signalings remain unclear. 
Our laboratory and several others have previously identified alternatively spliced 
isoforms of GFRα1 and GFRα2. The biological significance of these alternative 
spliced variants remains uncertain. Hence, it is the intention of this work to gain a 
better understanding of the biochemical properties, cellular functions and biological 
activities of the alternatively spliced GFRα2 receptor isoforms. 
 




This piece of work focused primarily on the study of the interactions of GDNF and 
NTN with the alternatively spliced GFRα2 isoforms. GFRα2 receptor is spliced to 
produce three isoforms, namely GFRα2a (contains all 9 exons), GFRα2b (lacking 
exon 2), and GFRα2c (lacking exon 2 and 3). In order to gain a better understanding 
of the biological significance, the expression levels of GFRα2 isoforms in different 
regions of the human brain were determined and their  biochemical activities and 
phenotypical functions in inducing morphological changes, were characterized in 
vitro. The study was then extended to another structurally related family of receptors, 
the GFRα1 isoforms. 
1.4 Organization of the thesis 
 
This thesis is organized into five sections according to the results and findings. The 
first study focused on ligand-receptor specificity using a human neuroblastoma cell 
line that endogenously expresses the GFRα2 and the co-receptors, RET and NCAM 
(Chapter 3). The second section deals with the biochemical and neuritogenic activities 
of GFRα2 receptor isoforms using transfected Neuro2A cell models (Chapter 4). The 
third section deals with the mechanism underlying the neurite outgrowth inhibitory 
activities of the GFRα2b in more detail (Chapter 5). This is then followed by the 
studies of GFRα1 isoforms and demonstrations of some similarities between GFRα1b 
and GFRα2b on regulating neurite outgrowths inhibitions (Chapter 6). The final 
section (Chapter 7) focuses on the signaling differences underlying neurite outgrowth 
mechanisms of GFRα2a and GFRα2c isoforms. The thesis concludes with some 
suggestions for future works (Chapter 8). 
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2.1 The neurotrophic factors 
 
 Neurotrophic factors are polypeptides that are crucial  for the growth, 
differentiation and survival of neurons in the developing nervous system, and also 
play roles in functional maintenance of neurons in the mature nervous system (Blesch, 
2006).  Nerve growth factor (NGF) was the first neurotrophic factor discovered which 
was first shown to be target derived. The discovery and understanding of NGF led to 
the formulation of the Neurotrophic Factor Hypothesis, which postulates that: 
“…once a developing neuron has grown its process into its target, it competes with 
other developing neurons of the same type for a limited supply of a neurotrophic 
factor provided by the target” (Yuen et al., 1996). In this hypothesis, the successful 
competitors for neurotrophic factor survive, while the unsuccessful ones die.  
 The fact that some but not all isolated neurons responded to NGF, led to the 
speculation that there are likely to be more neurotrophic factors and their effects 
should be neuron specific. Thereafter, other members of the NGF family 
(neurotrophins) were discovered, which include brain derived neurotrophic factor 
(BDNF), neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5).  
 In the early 1990s, in the pursuit to discover dopaminergic neuron specific 
supporting factors,  glial cell line-derived neurotorphic factor (GDNF) was purified 
from culture supernatants of the glial cell line B49 and the gene cloned  (Lin et al., 
1993). Other GDNF family members, Neurturin (Kotzbauer et al., 1996), Artemin 
(Baloh et al., 1998) and Persephin (Milbrandt et al., 1998) were subsequently 
identified and the genes cloned. More than one decade after the discovery of GDNF, 
the continuing efforts and interests are now focusing on understanding the functions 
and signaling mechanisms of this family of ligands (GDNF family of ligands, GFLs) 
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and receptors (GDNF family of receptors alpha, GFRα) in neuronal and non-neuronal 
systems.  
2.2 GDNF family of ligands (GFLs) 
 
Glial cell-line derived neurotrophic factor (GDNF), Neurturin (NTN), Artemin 
(ARTN) and Persephin (PSPN) are cysteine-knot proteins and are structurally related 
neurotrophic factors (Airaksinen and Saarma, 2002; Kobori et al., 2004). These GFLs 
have been shown to support the growth, maintenance and differentiation of a wide 
variety of neuronal and extra-neuronal systems (Saarma and Sariola, 1999). 
Structurally, GFLs belong to the transforming growth factor beta (TGF-β) 
superfamily, sharing the seven conserved Cys residues (depicted in Figure 1.1). GFLs 
are biosynthesized as precursors and further processed into the mature forms of 
disulfide-bonded dimeric, basic and secretory proteins.  
GDNF and the other GFLs act as trophic factors for many central and peripheral 
neuronal systems, such as the sensory, enteric, sympathetic, and parasympathetic 
(Airaksinen and Saarma, 2002; Airaksinen et al., 1999). GDNF also has functions in 
some non-neuronal systems, such as in kidney development and spermatogonial 
differentiation (Sariola, 2001; Sariola and Saarma, 1999). Because GDNF has potent 
neurotrophic effects on midbrain dopaminergic neurons and other neuronal systems, it 
is perhaps not surprising that GDNF is considered a useful therapeutic for some 
neurodegenerative diseases. Indeed, GDNF has been used in clinical trials and the 
results are favorable in some reports (Gill et al., 2003; Slevin et al., 2005) but not in 
others (Nutt et al., 2003; Peggy, 2005). It is now believed that the failure of some of 
these clinical trials may simply be technical variability resulting in the suboptimal 
bioavailability of GDNF (Salvatore et al., 2006) and statistical errors (Hutchinson et 
al., 2006). The difficulty of delivering large proteineous factors may one day be 
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circumvented by the use of small molecular mimetics which show biochemical 
properties similar to GDNF and the other GFLs (Bespalov and Saarma, 2007). 
Although NTN and GDNF are structurally related, the tissue distributions of their 
cognate receptors do not share significant overlaps, indicative of possible distinct 
functional roles (Golden et al., 1999; Widenfalk et al., 2000). When compared to 
GDNF, the chronic administration of NTN produces specific neurochemical changes 
only in the ventrolateral striatum with no detectable adverse effects, raising the 
possibility that NTN may also serve as a useful therapeutic (Hoane et al., 1999). A 
Phase I clinical trial using an in vivo Adeno-associated Virus Type 2 (AAV2) 
mediated delivery of the gene encoding NTN (CERE-120) is currently underway 
(http://www.clinicaltrials.gov).  
With the better understanding of structure-functions of the molecules, 
physiological roles and signaling mechanisms of GFLs, it may enable the rational 
development of efficacious therapeutics for diseases related to this family of ligands 
and receptors. 
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Figure. 1.1 Amino acids sequence alignment of mature GDNF family ligands 
(GFL). A, Amino acids sequence alignment of rat GDNF, human Artemin (hART), 
human Neurturin (hNTN), and human Persephin (hPSP). Boxed regions show 
position of the conserved cysteine residues. Secondary structure elements are 
indicated above the alignment (“α” for α-helix; “β” for β strand). Regions in color 
correspond to color scheme shown in B. B, Representation of backbone of the GDNF 
dimer. The first (blue) and second (red) fingers, and the heel (green) region of the 
molecule are shown. Figure B, adapted from Baloh et al, 2000. 
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2.3 GDNF family receptors 
 
GFLs exert their effects through a multi-component receptor system consisting of 
the GDNF family receptor alpha (GFRα), RET (rearranged during transformation) 
and/or NCAM (neural cells adhesion molecules) (Airaksinen et al., 1999; Paratcha et 
al., 2003). The GFRα family consists of four members (GFRα1 to 4) that are linked 
to the plasma membrane via glycosyl-phosphotidylinositol (GPI) anchor. The 
homologs of the genes encoding these receptors are found in different chromosomes 
(Table 1.1). GFRα receptor family members share 30-45% amino acid identity, with 
similar conserved cysteine residue arrangements (Figure 1.2), suggesting that their 
secondary structures may also be conserved (Scott and Ibanez, 2001).  A comparison 
of these GFRα receptors amino acids reveals internal structural homologies within the 
conserved cysteine rich sequences, suggesting common putative domain structures for 
these receptors.  
 
Table 1.1 Chromosome locations of Mus muculus and Homo sapiens GFRα 
receptors genes.  The genetic loci are described in the NCBI Mapviewer, build 36 for 
both organisms.  
 
 Gene of receptor Chromosome Location 
Mouse GFRα1 19 D2-D3;  29.0 cM 
 GFRα2 14 D3-E1 
 GFRα3 18 B1 
 GFRα4 2 F1 73.9 cM 
Human GFRα1 10q26 
 GFRα2 8p21.3 
 GFRα3 5q31.1-q31.3 
 GFRα4 20p13-p12 
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Figure 1.2 Amino acid sequence comparison of GFRα1, GFRα2, GFRα3, and 
GFRα4. The amino acid sequence of rat GFRα1, GFRα2, human GFRα3, and 
chicken GFRα4 are aligned and the conserved cysteines are boxed in red. Sequences 
predicted to correspond to α helix (blue) and β strand (purple) are highlighted. 
Predicted N-terminal signal peptide sequences and the C-terminal hydrophobic 
regions are underlined. Figure modified from Scott and Ibanez, 2001.  
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Each GFL is known to bind itself to a preferential GFRα receptor (depicted in 
Figure 1.3). GFRα1 is found to be the cognate receptor for GDNF (Jing et al., 1996; 
Treanor et al., 1996). NTN signals through its preferred receptor GFRα2 (Baloh et al., 
1997; Buj-Bello et al., 1997; Klein et al., 1997; Widenfalk et al., 1997). Artemin and 
Persephin signals through GFRα3 and GFRα4, respectively. 
Upon ligand binding to these GFRα receptors, intracellular signals are transduced 
through the trans-membrane receptor tyrosine kinase, RET. Recent findings suggest 
that NCAM may also function as the co-receptor for GFLs-GFRα signaling (Paratcha 
et al., 2003), adding to the  complexity of the signaling mechanism of GFLs and 
GFRα. 
The key role of GDNF and its receptor GFRαl in enteric nervous system 
development is conserved from zebrafish to humans. The role of Neurturin, signals 
via GFRα2, for parasympathetic neuron development is also conserved between 
chicken and mice. The role of Artemin and Persephin that signals via GFRα3 and 
GFRα4, respectively, is currently unknown in non-mammals. Recent phylogenetic 
study (Airaksinen et al., 2006; Hatinen et al., 2006)  indicates that orthologs of all 
four GFL are present in mammals, as well as in bony fish (teleost) (Figure 1.4A). 
Orthologs of all GFRα receptors are also present in all vertebrates classes, from bony 
fish to mammals (Figure 1.4B). However, Persephin is missing from chicken genome, 
while frog genome lacks ortholog of Neurturin (Hatinen et al., 2006), suggesting 
functional redundancy in early tetrapods. The functional significance of non-
mammalian GFLs and GFRα signaling remains unclear.   
Recently, distantly related GFRα-like structures have been identified. Based on 
the conserved pattern of cysteines (and the presence of some amino acid residues), 
these sequences include Gas1, growth arrest specific 1 protein, (Cabrera et al., 2006; 
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Schueler-Furman et al., 2006) and GRAL (GDNF Receptor Alpha Like), a protein 
found in some regions of the central nervous system of unknown function (Li et al., 
2005). In addition, genomic sequences encoding a predicted protein in echinoderm 
sea urchin (Strongylocentrotus purpuratus) that shows clear homology to vertebrate 
GFRα and GRAL proteins but no known function has been identified and this 
hypothetical protein is called GDNF family receptor-like (GFRL) (Hatinen et al., 
2006). Unlike the GFRα1-4, GRAL and Gas 1 function independently of GFLs. 
Hence, these related proteins may have distinct ligands which are not GFLs. 
 
Figure 1.3. Schematic diagram of GFLs binding to GFRα receptors. GDNF, NTN 
(Neurturin), ART (Artemin), and PSP (Persephin) bind to preferred GFRα receptors 
(indicated by solid, black arrows), and activate (indicated by dashed, red arrows) 
transmembrane Ret tyrosine kinase receptor to transduce intracellular signaling 
(indicated by solid, red arrows). Promiscuous binding between GFL and non-
preferred receptors are also shown (dotted, black arrows). 
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Figure 1.4. Phylogenetic analysis of GDNF Family Ligands (GFL) and GFR 
superfamily proteins. A, The tree was generated by comparing the mature part of the 
GFLs (NRTN for Neurturin, PSPN for Persephin, and ARTN for Artemin) using the 
maximum likelihood method. Threadworm (Strongyloides stercoralis) TGFP-like 
protein was used as the outgroup. Note the absence of PSPN in chicken and NRTN in 
clawed frog. B, Phylogenetic tree of GFR superfamily proteins in selected animal 
species. The tree was generated by comparing the conserved part of the proteins. The 
branches lengths are proportional to the expected proportion of amino acid differences 
among groups. Figures adapted from Airaksinen et al, 2006. 
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2.4 Alternatively spliced isoforms of GFRs and their co-receptors 
 
Alternative splicing is prevalent in many mammalian genomes and is a means of 
producing functionally diverse polypeptides from a single gene (Blencowe, 2006). 
Recently, genome-wide microarray and large-scale computational analyses of 
expressed sequence tag and cDNA sequences have estimated that greater than 50% of 
human multi-exon genes are alternatively spliced (Modrek and Lee, 2002). 
Comparative genomic analyses further demonstrate that the greatest amount of 
conserved alternative splicing occurs in the central nervous system (Kan et al., 2005). 
In many systems, alternative splicing events have been shown to produce isoforms 
with distinct activities and biochemical properties as a means for diverse biological 
functions (Lee and Irizarry, 2003).  
Multiple alternatively spliced variants of GFRα1 (Dey et al., 1998; Sanicola et al., 
1997; Shefelbine et al., 1998), GFRα2 (Dolatshad et al., 2002; Wong and Too, 1998) 
and GFRα4 (Lindahl et al., 2001; Lindahl et al., 2000; Masure et al., 2000) have been 
reported. The alternatively spliced isoforms of GFRα1 have been shown to exhibit 
distinct biochemical functions (Charlet-Berguerand et al., 2004; Yoong et al., 2005). 
Similarly, alternatively spliced isoforms of the GFRα co-receptors, RET (de Graaff et 
al., 2001; Lee et al., 2002a; Lorenzo et al., 1997) and NCAM (Buttner et al., 2004; 
Povlsen et al., 2003) have been reported. Ret9 and Ret51 are the two spliced isoforms 
of RET, both of which have been shown to possess distinct biochemical and 
physiological functions (de Graaff et al., 2001; Lee et al., 2002a; Lorenzo et al., 
1997). These observations are consistent with the emerging view that the 
combinatorial interactions of the spliced isoforms of GFRα, RET and NCAM may 
contribute to the multi-component signaling system in producing the myriad of 
observed biological responses. The existence of multiple splice isoforms of GFRα, 
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RET and NCAM and the possible combinatorial interactions of these spliced isoforms 
will invariably increase the complexity of the signaling of this multi-component 
system.  This complexity is further increased by the existence of cross talks of 
different GFLs with the same GFRα isoform. 
 
2.5 GFRα2 and GFRα1 receptor  
 
At least three alternatively spliced isoforms of GFRα2 receptor have been 
identified in mammalian systems, namely GFRα2a (1393 bp), GFRα2b (1077 bp) and 
GFRα2c (993 bp) (Dey et al., 1998; Sanicola et al., 1997; Shefelbine et al., 1998). 
GFRα2 isoforms differ only in their N-terminal, with GFRα2b lacking exon 2 (of total 
9 exons), and GFRα2c lacking exons 2 and 3. All three isoforms have been detected 
in various human and murine tissues (Too, 2003; Wong and Too, 1998) as well as in 
the rat myenteric plexus (Dolatshad et al., 2002).  
GFRα1 has previously been shown to respond to GDNF and NTN (Pezeshki 
et al., 2001; Wang et al., 2000), with preferential pairing to the former (Baloh et al., 
2000; Creedon et al., 1997). GFRα1 is spliced to produce two isoforms, namely the 
GFRα1a and GFRα1b (Dey et al., 1998; Shefelbine et al., 1998). These 2 isoforms 
are highly homologous, with a difference of only five amino acids (140DVFQQ144), 
and lacking in GFRα1b. GFRα1a appears to be structurally organized into 3 distinct 
domains (Eketjall et al., 1999). The Domain 3 (residues 239-346) of GFRα1a has 
been crystallized and used to model Domain 2 (Leppanen et al., 2004). Interestingly, 
the predicted Domain 2 (residues 150-238) helices (Airaksinen et al., 1999) show the 
same positions of cysteine residues which are thought to form disulfide bridges, as 
observed in the helices in Domain 3. Both Domain 2 and 3 are involved in the binding 
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of GDNF. A similar structural organization of GFRα3a has also been proposed based 
on crystal structure of Artermin- GFRα3 ectodomains 2 and 3 (Wang et al., 2006). It 
is now generally believed that the GFRαs share such structural organizations. 
Based on the structural organization, Domains 1 and 2 of the GFRα are 
thought to be linked by an extended loop (residues 114-144). Interestingly, the smaller 
spliced isoforms of GFRα1 (GFRα1b) and GFRα2 (GFRα2b and GFRα2c) showed 
exon deletions which reside in Domain 1. The absence of the five amino acids 
(140DVFQQ144) in GFRα1b isoform or the deleted 5’ exons in GFRα2b and 
GFRα2c may confer significant structural differences between the spliced isoforms 
and resulting in different functional consequences. It will be of great interest in the 
future if Domain 1 of GFRα1a and GFRα2a can be structurally determined along 
with the other ligand binding domains (Domain 2 and 3) for a more precise definition 
of the receptors as a whole. 
 










Chapter 3  Part I: Glial cell-line derived neurotrophic factor 
and Neurturin regulated the expressions of distinct miRNA 
precursors through the activation of GFRα2. 
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3.1 Background and objectives 
 
GFLs exert their effects through a multi-component receptor system consisting of 
the GFRα, RET and NCAM (Airaksinen et al., 1999; Paratcha et al., 2003).  Each 
GFL is known to bind preferentially to one GFRα in vitro and the activation of the 
multi-component receptor system show some degree of promiscuity in their ligand 
specificities (Airaksinen et al., 1999; Cik et al., 2000; Horger et al., 1998; Scott and 
Ibanez, 2001; Wang et al., 2000). Mice lacking in GDNF, GFRα1 or RET share 
common phenotypes of kidney agenesis and the absence of many parasympathetic 
and enteric neurons (Cullen-McEwen et al., 2001; Enomoto et al., 1998; Enomoto et 
al., 2001). Mice lacking NTN or GFRα2 show similar deficits in parasympathetic and 
enteric innervations but notable differences have been reported (Heuckeroth et al., 
1999; Rosenthal, 1999; Rossi et al., 1999). These phenotypic differences may be due 
to different genetic background of the mice used or more interestingly, suggests the 
possibility of GDNF crosstalk through GFRα2 in vivo. GDNF has been used in 
clinical trials and the results were favorable in some (Gil et al., 2002; Slevin et al., 
2005) but not in other reports (Nutt et al., 2003; Peggy, 2005). These differences are 
currently being addressed and are likely to be due to technical differences (Salvatore 
et al., 2006). Although cross talk in the development may not be significant 
(Airaksinen and Saarma, 2002), it may be highly relevant when exogenous GFLs are 
applied in vivo.  It is not known if the cross talks by different GFLs with the same 
multi-component system produce the same biological responses. This chapter 
addressed this issue by examining the changes in microRNA expression when the 
same receptor multi-component was stimulated by two related GFLs, GDNF and 
NTN.  
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It is interesting to note that the recent studies of genome-wide transcription 
suggest that more of the genome are transcribed than currently annotated and much of 
this is noncoding.  From full-length cDNA sequencing of human cDNA clones, 
greater than half of the transcripts found are noncoding (Ota et al., 2004b). In the 
mouse, a large number of the FANTOM3 cDNAs lack any protein-encoding sequence 
and are annotated as noncoding RNAs, which out numbered the protein coding 
transcription units (Carninci et al., 2005). With the increasing number of noncoding 
RNAs found, it is currently unknown if they are functional or, merely transcriptional 
noise. However, recent evidence suggests distinct roles of some of these transcripts in 
the nervous system (Cao et al., 2006; Mehler and Mattick, 2006; Presutti et al., 2006).  
Among several classes of noncoding RNAs, microRNA has been a focus of recent 
intense research. 
MicroRNAs (miRNAs) are small non-coding RNAs that serve as important post-
transcriptional regulators of gene expression in metazoan (Pillai et al., 2006). To date, 
a large number of miRNAs have been identified in several organisms, including 
vertebrates and plants (Dugas and Bartel, 2004; Harfe, 2005). The number of miRNA 
genes appeared to be greater than 1% of the predicted genes in human (Aravin and 
Tuschl, 2005; Berezikov et al., 2006; Lim et al., 2003).  To date, more than three 
thousand eight hundred mature miRNAs from different species have been listed in the 
database from Sanger Center (http://microrna.sanger.ac.uk/sequences/index.shtml), 
more than 400 are of human origin. In many respects, miRNA genes resemble protein 
coding genes in that they may possess introns (Rodriguez et al., 2004) and are 
transcribed by RNA polymerase II (Lee et al., 2004).  In addition, the transcripts from 
miRNA genes are capped, spliced and polyadenylated (Cai et al., 2004). Pre-miRNA 
sequences are predicted based on the folded structures and are derived from primary 
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transcript, pri-miRNA (Bartel, 2004). The mature miRNA (21-24 nucleotides) is 
located in the hairpin structure of pre-miRNA (Lee et al., 2002b) . This maturation 
process is highly regulated (Thomson et al., 2006; Zeng, 2006). Biogenesis and 
maturation of miRNA involved a few stages. In the nucleus, primary miRNA 
transcript (pri-miRNA) is excised by an RNaseIII type endonucleus Dosha to produce 
a duplex RNA that contains 5’ phosphate and 3’ –OH, and usually with a 2 
nucleotides overhang at 3’ end precursor miRNA (pre-miRNA) approximately 60-70 
nucleotides long. The pre-miRNA is then exported to cytoplasm by Exportin 5 (Exp 5) 
and further cleaved by another RNaseIII type endonucleus, Dicer, to produce the 21-
24 nucleotides miRNA duplex, with 2 nucleotides over hang at both ends (Zeng, 
2006).  
miRNAs have extensive regulatory roles  including the involvement in 
development, cell proliferation, cell death, and morphogenesis (Ambros, 2003; 
Kasashima et al., 2004; Kawasaki and Taira, 2003; Pillai, 2005; Sunkar and Zhu, 
2004). A large number of these miRNAs were detected in brain, at different stages 
(Sempere et al., 2004). The current view is that miRNAs in the nervous system may 
be important for cell fate decisions, neural connectivity, cell shape and adhesion, and 
synapse function (Presutti et al., 2006). 
 It is currently unknown if GDNF and NTN may regulate the expression of 
miRNAs in various cellular processes.  In this study, the human BE(2)-C cells, which 
expresses GFRα2 but not GFRα1, was used to examine the regulation of some 
miRNA precursors (pre-miRNAs and pri-miRNAs) by GDNF and NTN. Interestingly, 
the results showed that despite the promiscuity of ligand-receptor interaction, GDNF 
and NTN regulated the expression of distinct miRNA precursors through the 
activation of the MAPK (ERK1/2) signaling pathways. 




3.2.1 Neuroblastoma BE(2)-C cells express GFRα2, NCAM and RET 
 
The quantitative real time PCR assays designed to amplify GFRα1, GFRα2, 
NCAM and RET were highly sensitive (detection limit of ten copies per reaction) and 
specific, showing only single product of the predicted size corresponding to each 
amplicon as observed by gel electrophoresis (appendix I). The amplification 
efficiencies of cDNA at different concentrations level of RNA were greater than 95% 
and identical to the respective standards used. Melt curve analyses of the amplicons 
using cDNA showed the predicted melting profiles and all amplicons were validated 
by DNA sequencing.   
Using these assays, NCAM, RET and GFRα2 but not GFRα1, were detected 
in BE(2)-C cells (Fig. 3.1A). In BE(2)-C cells, GFRα1 transcript level was below the 
detection limit of the assay and estimated to be less than 1:106 when expressed as the 
ratio of GFRα1 to GAPDH. Gel electrophoresis of the PCR products further 
confirmed the expressions of GFRα2, RET, and NCAM, and the absence of GFRα1 in 
BE(2)-C cells (Fig. 3.1B). The significant expressions of GFRα2, NCAM and RET in 
BE(2)-C cells thus provided a suitable model for further studies. 




Figure 3.1. Expression levels of GFRα, RET and NCAM transcripts in human 
neuroblastoma BE(2)-C cells measured by quantitative real time PCR. A, GFRα2, 
RET and NCAM were expressed at significant levels when compared to GFRα1. The 
expression of GFRα1 was below the detection limit of the assay (< 1:106, when 
expressed as the ratio of GFRα1 to GAPDH). B, Amplification of GFRα1 (lane 1), 
GFRα2 (lane 2), RET (lane 3) and NCAM (lane 4) from BE(2)-C cells using primers 
as described in the Material and Methods. No visible band was observed with control 
samples either with a single primer or the absence of the template (data not shown).  
Loading marker shown, M, marker 100-1000bp, with increament of 100bp each band. 
The results were expressed as mean ± S.E.M. of at least three independent 
experiments.  
 
3.2.2 Regulation of MAPK (ERK1/2) phosphorylation by GDNF and 
NTN 
 
Both GDNF and NTN activated MAPK (ERK1/2) rapidly in BE(2)-C cells 
(Fig. 3.2A). The responses to GDNF and NTN were similar in kinetics and 
sustainable over a period of six hours (Fig. 3.2B). The MEK1/2 inhibitor, U0126, 
inhibited GDNF and NTN induced phosphorylation of MAPK (ERK1/2) in a dose-
dependent manner (Fig. 3.2C).  At the concentration used, there was no evidence of 
cell deaths as measured by MTT conversion assay (data not shown). This result 
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suggests that GDNF and NTN activate MAPK signaling by phosphorylation on 




Figure 3.2. GDNF and NTN induced MAPK (ERK1/2) phosphorylation in BE(2)-
C cells. A, Cells were stimulated with either GDNF or NTN and phosphorylated 
ERK1/2 was detected by Western Blot. B, Kinetic analyses of GDNF and NTN 
induced ERK1/2 phosphorylation. The blots were stripped and re-probed with anti-
pan ERK1/2 antibody for the verification of protein loading (bottom panels). C, 
Concentration dependent inhibition of MAPK activation by U0126 in GDNF and 
NTN stimulated BE(2)-C cells. The cells were pretreated for 20 minutes with 
different concentrations of U0126 inhibitor before exposure to GDNF or NTN for a 
further 10 minutes. The results were expressed as standard deviations of triplicate 
measurements and similar results were observed for three independent experiments. 
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3.2.3 Regulation of miRNA precursor expressions by GDNF and 
NTN 
 
Regulation of miRNAs by GDNF ligands is currently not known. Whether GDNF 
and NTN may regulate the expression of miRNAs in various cellular processes 
remains unclear. In order to address the issue of ligands receptor specificity, the 
human BE(2)-C cells, which express GFRα2 but not GFRα1, were used to examine 
the regulation of some miRNA precursors (pre-miRNAs and pri-miRNAs) by GDNF 
and NTN. 
A total of 23 pairs of pre-validated primers designed to anneal to the hairpin of 
miRNA precursors (Schmittgen et al., 2004) were used to quantify cDNA samples 
prepared from BE(2)-C cells. Initial attempts to co-reverse, transcribe and accurately 
quantify both U6 and the miRNA precursors simultaneously were unsuccessful. The 
amplification of U6 from cDNA samples prepared from 1 µg of RNA consistently 
show Ct values of about 14 cycles (Fig. 3.3A). This is equivalent to the amplification 
of 107 copies of GFRα2 which has a similar amplicon size and PCR efficiency (3.5 
cycles per log dilution). The failure to detect amplicon after 40 cycles (detection limit 
equivalent to one copy per reaction) defines the expression levels of the miRNA 
precursors as undetectable. BE(2)-C was found to express eight of the twenty-three 
distinct miRNA precursors (miR-16, miR-18, miR-21, miR-24-2, miR-92-1, miR-93-
1, miR-107 and miR-124a-2). All amplicons showed distinct melt curves (Fig. 3.3B) 
and the sizes were verified by gel electrophoresis (Fig. 3.3C). GDNF was found to 
transiently up-regulate the expressions of miR-21 and miR-24-2 precursors 
significantly (Fig. 3.4A). Interestingly, NTN was found to down-regulate the 
expression of miR-92-1 precursor (Fig. 3.4B). No significant changes in the 
expression of the other miRNA precursors were observed.  





Figure 3.3. Real time PCR amplifications of miRNA precursors. Gene specific 
primers designed to the hairpin of miR-107 and miR-147 precursors were used for 
amplification using cDNA samples prepared from BE(2)-C cells. A, Real time PCR 
quantification plot showing amplifications of U6 and miR-107. miR-147 amplicon 
was not detected, even after 40 cycles of amplification. No template controls showed 
background fluorescence, even after 40 cycles of amplification. B, Melt curve 
analyses after 40 cycles of amplification. Melt curve analyses after amplifications 
showed distinct peaks of miR-107 and U6 products. C, Gel electrophoresis of short 
hairpin products after amplification by real time PCR. Amplifications were carried out 
using primers for the precursors of miR-107 (lane 1), miR-124a-2 (lane 2), miR-92-1 
(lane 3), miR-93-1 (lane 4), miR-21 (lane 5), miR-24-2 (lane 6), miR-16 (lane 7), 
miR-18 (lane 8) and U6 (lane 9). The amplified products and the 25 bp DNA marker, 
with increment of 25 bp each band (M) were resolved in a 4% agarose gel. Similar 
results were obtained for at least three independent experiments. 






Figure 3.4. Regulation of miRNA precursors expressions by GDNF and NTN. 
miRNA precursors expression levels in BE(2)-C cells were expressed as fold changes 
on stimulation with GDNF (A) and NTN (B) over a period of six hours. Eight distinct 
miRNAs precursors were detected in BE(2)-C cells. Similar results were obtained for 
at least three independent experiments. Error bars indicate standard deviations of 
triplicate measurements. Significant differences in gene expression between ligand 
stimulated and control samples were calculated using paired Student’s t-test. A value 
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To determine the contribution of MAPK pathway in the regulation of the 
expression of miRNA precursors, U0126 was used to inhibit MEK1/2 activation (Fig. 
3.5). At the sub-maximal dose (2.5 µM), U0126 inhibited the up-regulation of miR-21 
(Fig. 3.5A) and miR-24-2 (Fig. 3.5B) precursor expressions induced by GDNF, and 
the down-regulation of miR-92-1 precursor expression by NTN (Fig. 3.5C). 
 
3.2.4 Differentiation of BE(2)-C cells with GDNF and NTN 
 
Both miR-21 and miR-24-2 have previously been shown to be up-regulated in TPA 
differentiated HL-60 (Kasashima et al., 2004) and retinoic acid induced 
differentiation of embryonic stem cells (Houbaviy et al., 2003). As these miRNA 
precursors were similarly up-regulated by GDNF in BE(2)-C cells (Fig. 4.4A), the 
morphology of BE(2)-C cells when induced by GDNF and NTN was examined over a 
period of five days. Morphological differentiation of BE(2)-C cells was induced by 
retinoic acid but not GDNF or NTN (Fig. 3.6A). The expression levels of miR-21 and 
miR-24-2 precursors in BE(2)-C cells were significantly increased by retinoic acid 
(Fig. 3.6B).  Interestingly, miR-92-1, which was down-regulated by NTN, was up-
regulated by retinoic acid instead (Fig. 3.6B).  
 





Figure 3.5. Inhibition of miRNA precursor expressions by U1026 in ligand 
stimulated cells. Cells were pretreated for 20 minutes with 2.5 µM of U0126 before 
exposure to GDNF or NTN. The up-regulation of miR-21 (A) and miR-24-2 (B) 
precursor expressions by GDNF was abolished in the presence of U0126. Similarly, 
the down-regulation of miR-92-1 by NTN (C) was abolished by U0126. The results 
were reproduced in at least three independent experiments. Error bars indicate 
standard deviations of triplicate measurements. Significant differences in the 
expression of the genes between ligand stimulated and control samples were 
calculated using paired Student’s t-test. A value of P< 0.05 was considered significant 
(**P< 0.001, *P< 0.05). 














Figure 3.6.   Retinoic acid-induced differentiation of BE(2)-C cells. A, Treatments 
of BE(2)-C cells with retinoic acid, GDNF or NTN. Cells (20,000) were seeded on six 
well plates overnight in DMEM supplemented with 10% FBS. Cells were then 
incubated in 0.5% FBS supplemented media, with or without all-trans retinoic acid (5 
µM), GDNF (50 ng/ml) or NTN (50 ng/ml), and were incubated for three days. 
Retinoic acid treated cells showed neurite extension but not GDNF or NTN. 
(magnification x200) The experiment was repeated at least three times with similar 
results. B, Regulation of miRNA precursors expressions in BE(2)-C by retinoic acid. 
The expressions of miR-21, miR-24-2 and miR-92-1 precursors were up-regulated by 
retinoic acid over a period of six hours. Similar results were obtained for at least three 
independent experiments. Error bars indicate standard deviations of triplicate 
measurements. Significant differences in expression of miRNA precursors between 
ligand stimulated and control samples were calculated using paired Student’s t-test. A 
value of P< 0.05 was considered significant (**P< 0.001, *P< 0.05). 





The results from this study reveal a novel function of GFRα2 in the regulation 
of miRNA precursors. This function is mediated by MAPK (ERK1/2) and the 
downstream regulation of distinct miRNA precursors is dependent on the ligand used.  
GFRα2 and GFRα1 share about 48% amino acid identity, and the nearly 
complete conservation of cysteine residues suggests that these two receptors have 
similar three-dimensional structures and share similar functions (Jing et al., 1997; 
Scott and Ibanez, 2001). This is consistent with evidence from transfected cells and 
primary cultures where GDNF and NTN have similar properties in activating the 
multi-component receptor complex (Airaksinen et al., 1999; Baloh et al., 1997; 
Charlet-Berguerand et al., 2004; Coulpier et al., 2002; Scott and Ibanez, 2001; Wang 
et al., 2000). Furthermore, midbrain dopaminergic neurons which only express 
GFRα1 appear to survive equally well with both GDNF and NTN in vitro and in vivo 
(Horger et al., 1998), and respond to neither ligands in the absence of GFRα1 
(Cacalano et al., 1998). However, there are observations of distinct functional 
differences with the use of specific ligands. Although GDNF and NTN promote the 
survival of dopaminergic neurons through GFRα1 (Akerud et al., 1999; Cacalano et 
al., 1998), only GDNF possesses neuritogenic and hypertrophic effects (Akerud et al., 
1999). In cultured sympathetic neurons, GDNF is able to promote the survival of 
culture sympathetic neurons through GFRα2 but NTN is unable to promote survival 
through GFRα1 (Buj-Bello et al., 1997). Furthermore, GDNF but not NTN, is able to 
promote the axonal growth of DRG neurons through GFRα1 (Paveliev et al., 2004). 
The emerging view is that the crosstalk of exogenously applied GDNF and NTN with 
the non-preferred receptors may result in distinct functions. Concurrent with this 
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study, Lee et al have recently shown that GDNF and NTN have distinct and 
differential biochemical effects on cells expressing only  GFRα1 (Lee et al., 2005b). 
In order to address the significance of GDNF and NTN crosstalk in regulating the 
expression of miRNA in a defined system, a cell that expresses the multi-component 
receptor complex with only one particular GFRα is required. The distinct advantage 
of using quantitative real time PCR over conventional end-point PCR-based assays is 
that it allows the reliable quantitative definitions of specificity, sensitivity and 
efficiency (Wong and Medrano, 2005). Using the highly specific, efficient and 
sensitive quantitative real time PCR assays developed in this study, BE(2)-C cells are 
found to express NCAM, RET and GFRα2, but not GFRα1. The presence of GFRα2 
but not GFRα1 in BE(2)-C cells is consistent with the previous observation (Kobori et 
al., 2004) but is not so in a recent report using semi-quantitative PCR (Hansford and 
Marshall, 2005). Consistent with the suggestion that both GDNF and NTN can 
activate the same multi-component receptor system, GDNF has been shown to induce 
the enhancement of phosphorylation and enzymatic activity of tyrosine hydroxylase 
through the activation of GFRα2 (Kobori et al., 2004).  
GDNF and NTN are known to similarly activate a number of signaling pathways, 
including the extracellular signal-regulated kinase (ERK), phosphatidylinositol 3-
kinase (PI3K)/AKT, p38 mitogen-activated protein kinase (MAPK) and c-Jun N-
terminal kinase (JNK) (Ichihara et al., 2004; Pezeshki et al., 2003; Takahashi, 2001; 
Trupp et al., 1999), and regulate the expressions of various immediate early response 
genes (Fukuda et al., 2003; Pezeshki et al., 2003). Intriguingly, stimulation with 
GDNF and NTN resulted in similar kinetics of activation of ERK1/2 but regulated the 
expressions of distinct miRNAs. The rapid changes in gene expression of miR-21, 
miR-24-2 and miR-92-1 paralleled that of the rapid induction of the early response 
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genes (Murphy et al., 2004; Sng et al., 2004). Interestingly, miR-92-1 which was 
rapidly down-regulated by NTN remained unaffected by GDNF stimulation, but was 
instead found to be up-regulated by retinoic acid stimulation.  Recently, neurotrophins 
have been shown to regulate the expression of a miRNA (miR-132) through a cAMP 
dependent pathway, resulting in changes in neuronal morphology (Vo et al., 2005).  
The stimulation of GFRα2 by either GDNF or NTN did not result in neurite 
outgrowth in BE(2)-C cells. However, when stimulated by retinoic acid, these cells 
showed extensive neurite outgrowth and up regulations of miR-21, miR-24-2 and 
miR-92-1.  
Analyses of the proximal sequences of miR-21, miR-24-2 and miR-92-1 by 
computational prediction of eukaryotic promoters (Scherf et al., 2000) reveal the 
existence of multiple regulatory elements. This suggests that the expressions of these 
miRNAs may be regulated by multiple pathways similar to other RNA polymerase II 
mediated transcripts (Lee et al., 2004; Sng et al., 2004). The binding of NGF to TrkA 
receptor was known to activate two or more distinct signaling pathways and the 
inhibition of a single pathway can affect the expressions of the transcription of some 
genes (Marek et al., 2004). It is likely that the differential regulations of distinct 
miRNAs expressions by GDNF and NTN in BE(2)-C cells may similarly require the 
concerted signaling of multiple signaling pathways. The integration of signaling 
pathways regulating the expression of these miRNAs may provide a means for a more 
precise transcriptional control depending on whether one or more pathways are 
activated. With the myriad of distinct signaling pathways induced by activated RET 
(Ichihara et al., 2004; Takahashi, 2001), GDNF and NTN acting through the same 
receptor complex appear to activate two or more signaling mechanisms. Such an 
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integration of these pathways is a subject for further investigation (depicted in Fig. 




Figure 3.7. Proposed model for multiple pathways required for selection and 
activation of specific transcriptional factors in regulation of microRNA (miRNA) 
precursors expression. MAPK was activated upon binding of GDNF or NTN to 
GFRα2 and co-receptor RET. GDNF and NTN may differently activate another 
pathway upon binding to GFRα2 (Pathway “a” for GDNF, and Pathway “b” for NTN). 
GDNF activations of MAPK together with Pathway “a” may be required for the 
activation of transcriptional factor/s “X” that regulate/s the expression of miR21, 
whereas NTN activated MAPK together with Pathway “b” may be specific for the 
activation of transcriptional factor/s “Y” which regulate/s the expression of miR92-1. 
Such integration of two or more pathways differently activated by GDNF and NTN may 
contribute to the specificity of the regulation of miRNA expressions through GFRα2 
and co-receptor RET.  
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miRNAs are now thought to be involved in a number of physiological and 
developmental processes (Croce and Calin, 2005; Harfe, 2005; Miska, 2005). Both 
miR-21 and miR-24-2, which were up-regulated by GDNF and retinoic acid but not 
NTN in BE(2)-C cells, have been demonstrated to be involved in cell proliferation 
and differentiation, and are over-expressed in various human cancers (Chan et al., 
2005; Houbaviy et al., 2003; Iorio et al., 2005; Kasashima et al., 2004). NTN but not 
GDNF rapidly down-regulates miR-92 expression in BE(2)-C cells. Interestingly, 
retinoic acid showed an opposite up-regulation of the same miRNA. Although miR-92 
has previously been shown to be amplified and over-expressed as a polycistronic 
miRNA cluster (Ota et al., 2004a) and up-regulated in expression in some cancers 
(Calin et al., 2004), the function of miR-92 is still to be determined. The specific 
regulation of the expressions of these miRNAs by GDNF and NTN suggests distinct 
functions associated with the activation of GFRα2. It is likely that many more 
miRNAs may be involved in various cellular processes and that the expressions of 
specific clusters of these miRNA may be cell type specific. 
miRNAs are thought to exert their functions by binding to complementary 
sequences on target mRNAs, inducing cleavage of mRNAs or repression of protein 
translation (Bartel, 2004; Ke et al., 2003; Nelson et al., 2003; Pillai, 2005). The 
search for miRNA targets by various algorithms (John et al., 2004; Krek et al., 2005; 
Lewis et al., 2003) has been met with some success although a recent study has 
shown that some targets do escape prediction (Nakamoto et al., 2005). To date, the 
specific targets of miR-21, miR-24-2 and miR-92-1 remain unknown and predictions 
by various algorithms suggest more than a hundred putative targets for each of these 
microRNAs.  
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In conclusion, this study showed the differential regulation of distinct miRNA 
precursors by GDNF and NTN through the same GFRα2 and the multi-component 
receptor system. BE(2)-C cells preferentially express GFRα2a and  GFRα2b isoforms 
(Chapter 5, Figure 5.3). It is unknown if GDNF or NTN preferentially activate one 
particular GFRα2 isoform or both isoforms concurrently, resulting in the expression 
of the distinct miRNAs. The differential effects of two related ligands acting on the 
same multi-component receptor system and the possibility that specific isoforms may 
contribute to the observed differences illustrates the complexity of the interactions of 
























Chapter 4 Part II: Differential expressions, biochemical 
activities, and neuritogenic activities of the alternatively 
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4.1 Background and objectives 
 
To date, at least 3 alternatively spliced isoforms of GFRα2 receptor have been 
identified in mammalian systems, namely GFRα2a (1393 bp), GFRα2b (1077 bp), and 
GFRα2c (993 bp) (Figure 4.1). Little is known about the biochemical and signaling 
property of GFRα2 receptor and the significance of GFRα2 alternative splicing. It is 
unknown if these isoforms serve distinct or redundant function. To gain a better 
insight into the biological relevance in the central nervous system, the expression 
levels of the isoforms in different regions of the human brain were quantified by 
highly specific real time PCR assays. The biological functions of the isoforms were 
then examined in a neuronal differentiation model using Neuro2A cells.   
Cultured clonal cell lines can serve as useful experimental models for 
investigating cellular morphologies and biochemical events during neuronal 
differentiation. It has some advantages over most alternatives such as primary 
cultured neurons. With clonal cell cultures, the cellular states can be controlled 
externally by changing the compositions of the media and conditions. In addition, the 
morphological, biochemical and molecular biological aspects of the cells can be 
analyzed quantitatively as all the cells are clonal. Primary cultured neurons have a 
distinct limitation in that in vivo neurons usually bear neurites on the day of 
preparation and the models may represent ‘re-morphogenesis’, such as ‘re-
neuritogenesis’ and ‘re-neurite outgrowth’, in the culture dishes. Given the 
limitations, the integration of insights from both primary culture systems and clonal 
cell lines can provide better understandings of the general mechanisms involved in 
neural morphogenesis. 
Neuroblastoma cells are widely used as cultured clonal cell line models for the 
studies of neuronal differentiation (Clagett-Dame et al., 2006; Edsjo et al., 2006). 
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Neuro2a, a mouse neuroblastoma cell line, when differentiated by a variety of agents 
has been shown to induce axon-like and dendrite-like processes (Wu et al., 1998). 
Under normal growth conditions, Neuro2a cells spontaneously sprout a basal level of 
neurites. However, treatments with a variety of stimuli cause these cells to develop 
extensive neurites similar to changes observed in hippocampal and cortical cultures 
(Ahmari et al., 2000; Washbourne et al., 2002). Greater than 98% of proteins 
identified by quantiative tissue proteomic analyses of Neuro2a and the whole mouse 
brain are identical (Ishihama et al., 2005). Furthermore, the transcriptomes of 
Neuro2a and neural stem cells during neural development and differentiation have 
been shown to share extensive similarities (Bulfone et al., 2005). These studies 
suggest Neuro2A to be a suitable model for the analyses of the biological functions of 
the GFRα2 isoforms. Furthermore, Neuro2a cells express RET and NCAM but not  
GFRα1 or GFRα2 (see Figure 4.4).  
Here, we show that ligands activation of the isoforms differentially activated 
MAPK (ERK1/2) and AKT signalings, and regulated distinct early response genes. 
Furthermore, both GDNF and NTN induced neurite outgrowth through GFRα2a and 
GFRα2c, but not GFRα2b. This study thus, provides the first piece of evidence of a 








4.2.1 Differential expression profiles of GFRα2 spliced variants 
 
The expression level of GFRα2 spliced variants in specific regions of the brain is 
currently unknown. To address this issue, sequence independent real time PCR assays 
have been developed to quantify each of the spliced variants with high specificity and 
sensitivity. 
In order to discriminate between the three spliced variants of human GFRα2, exon 
overlapping primers were designed across exon 1 and 2, 1 and 3 or 1 and 4. This is to 
enable the specific detection and quantification of GFRα2a, GFRα2b and GFRα2c, 










Figure 4.1. Real time PCR primers and genomic organizations of the human 
GFRα2 isoforms. Schematic diagram of exon organization of human GFRα2 
isoforms and design of specific primer for quantitative real time PCR. A specific 
forward primer, [2a 15+9F] for GFRα2a, [2b 17+7F] for GFRα2b, and [2c 18+5F] for 
GFRα2c was designed across specific exon junction, while a common reverse primer 
(553R) was designed for amplification of all GFRα2 isoforms. 
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As the amplification products of GFRα2a (545 bp), GFRα2b (233 bp) and 
GFRα2c (172 bp) were different in sizes, it is critical to determine the optimal cycling 
parameters for the selective amplification of each of the transcript. A dwell time of 30 
seconds for annealing, 60 seconds for denaturation at 95oC and another 60 seconds for 
extension at 72oC was found to be optimal for the amplifications of all three isoforms. 
The slopes of the plots of Ct versus log10 mole of the human GFRα2a, GFRα2b, and 
GFRα2c standards were 3.37 ± 0.30 (r2 = 0.98), 4.12 ± 0.41 (r2 = 0.99), and 3.82 ± 
0.54 (r2 = 0.99) respectively (Fig. 4.2). The detection limits of the assays were 
estimated to be fewer than 100 copies of transcripts per reaction. The samples were 
diluted in parallel with the standards. The specificity of amplifying a particular 
isoform when compared to the other variants was greater than 106 fold (Fig. 4.2). 
Hence, when using GFRα2a exon overlapping primers, the amplifications of GFRα2b 
and GFRα2c were at least 106 fold less efficient than amplifying GFRα2a. 
Using these highly sensitive and specific assays, the expression levels of the 
GFRα2 alternatively spliced isoforms were quantified in the caudate nucleus, cortex, 
putamen, substantia nigra, sub-thalamic nucleus and thalamus of the human brain (Fig. 
4.3). The three GFRα2 isoforms were detected at significant levels (> 104 
copies/reaction) in all areas of the brain, with expression levels highest in the cortex. 
In the cortex, all three isoforms were expressed at comparable levels, with GFRα2b 











Figure 4.2. Quantitative real time PCR assay for human GFRα2 isoforms. 
Amplifications of five log10 dilutions of GFRα2a (A), GFRα2b (C), and GFRα2c (E), 
plasmids standards. Negative controls with no templates (Water) were carried out 
simultaneously. The slopes of the plots of Ct versus –log10 mol of GFRα2a, GFRα2b 
and GFRα2c were 3.37 ± 0.30 (r2 = 0.98), 4.12 ± 0.41 (r2 = 0.99), and 3.82 ± 0.54 (r2 
= 0.99), respectively. Equal quantities (6 attomol) of GFRα2 isoforms were amplified 
separately using GFRα2a (B), GFRα2b (D) and GFRα2c (F) exon specific primers. 









Figure 4.3. Real time PCR quantifications of GFRα2 isoforms expression in 
different human brain regions.  Expression levels of human GFRα2 isoforms in 
different human brain regions were determined using specific primers designed for 
GFRα2 isoforms. The expression levels were normalized to the levels of GAPDH in 
the same tissue. The results were expressed as mean ± S.E.M. (n=3). Significant 
differences in percentage of differences between expressions of isoforms were 




4.2.2 Establishment of Neuro2A cell models stably expressing GFRα2 
isoforms. 
 
To investigate the biological significance of alternatively spliced GFRα2 isoforms, 
stable transfectants were generated using Neuro2a cells. Neuro2a cells express Ret 
and NCAM endogenously, but not GFRα1 or GFRα2 receptors (Fig. 4.4). The 
expression levels of GFRα2 isoforms in stably transfected Neuro2a cells (Fig. 4.4) 
were comparable to those expressed in the human cortex (Fig. 4.3).  





Figure 4.4. Establishment of Neuro2A cells models stably expressing GFRα2 
isoform. Expression levels of GFRα2 isoforms in Neuro2A transfected with different 
GFRα2 isoforms were quantified using quantitative real time PCR, with specific 
primers. Cells transfected with vehicle control pIRES showed no expression of any 
GFRα2 isoforms and GFRα1 receptor, while each transfected cell line expressed 
significant levels of one GFRα2 isoforms. Endogenous expression levels of Ret and 
NCAM were comparable in all GFRα2 isoforms transfected cell lines.  
 
4.2.3 GFRα2 isoforms differentially activated ERK1/2 and Akt 
 
Using the Neuro2A cells stably expressing GFRα2 isoforms, the ligand induced 
signaling mechanisms of GFRα2 isoforms were investigated. When stimulated with 
NTN, all the three isoforms induced the rapid phosphorylation of ERK1/2 (Fig. 4.5). 
However, when stimulated with GDNF, GFRα2a and GFRα2c but not GFRα2b (Fig. 
4.5) induced significant increase of ERK1/2 phosphorylation (> 2 fold). The kinetic 
and fold change of ERK1/2 phosphorylation was further elucidated using a dot-blot 
assay (Fig. 4.6A-C). The extent of ERK1/2 phosphorylation was similar when 
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NTN. However, GFRα2b showed rapid and significant phosphorylation of ERK1/2 
only with NTN stimulation but not by GDNF (Fig. 4.6B). Both GDNF and NTN 
induced ERK1/2 phosphorylation in a dose response manner in GFRα2a (Fig. 4.6D) 
and GFRα2c (Fig. 4.6F) transfectants. As compared to the stimulation with NTN, 
GFRα2b, when stimulated with GDNF, showed no significant increase in ERK1/2 
phosphorylation even at the highest dose (Fig. 4.6E). No significant increase in the 
phosphorylation of ERK1/2 was observed in vector (pIRESneo) control transfected 




Figure 4.5. Ligand stimulated ERK1/2 activations in GFRα2 isoform transfected 
Neuro2A cells. Cells were stimulated in serum free media, with or without GDNF or 
NTN (50 ng/ ml) for the time indicated. Five micrograms of protein were loaded and 
separated by SDS electrophoresis, phosphorylated ERK1/2 was detected by Western 
Blot. Blots were stripped and reprobed with pan antibody for loading control. 
Experiments were repeated three times with two individual clones, showing similar 
results.  
 











Figure 4.6. Kinetic analysis and dose response of GDNF and NTN regulation of 
ERK1/2 activation in GFRα2 isoform transfected Neuro2A cells. A-C, Kinetic of 
GDNF and NTN induced ERK1/2 activations in GFRα2a (A), GFRα2b (B) and 
GFRα2c (C). Cells were treated with or without 50 ng/ml of GDNF or NTN for time 
indicated. D-E, Dose response of GDNF and NTN induced ERK1/2 activations in 
GFRα2a (D), GFRα2b (E) and GFRα2c (F) isoforms. Cells were treated for 10 
minutes with ligand, of dose indicated. For these studies, 5 µg of protein were loaded 
per well for dot blot assay and immuno-blotted for phospho-ERK1/2. Standard 
deviations were shown for triplicate wells. Experiments were repeated three times for 
two individual clones with similar results. Significant differences in fold change of 
phosphorylated EKR1/2 between ligand stimulated and control samples were 
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Next, the ligand regulated phosphorylation of Akt using GDNF or NTN was 
investigated (Fig. 4.7). NTN induced rapid and significant phosphorylation of Akt in 
all three isoform transfectants. However, GDNF induced the rapid and significant 




Figure 4.7. Ligand stimulated Akt activations in GFRα2 isoform transfected 
Neuro2A cells. Cells were stimulated in serum free media, with or without GDNF or 
NTN (50 ng/ml) for time indicated. Five micrograms of protein were loaded and 
phosphorylated Akt was detected by Western Blot. Blots were stripped and reprobed 
with pan antibody for loading control. Experiments were repeated three times for two 
individual clones, with similar results.  
 
The other GDNF family of ligands (GFLs), Artemin and Perserphin, did not 
induce significant phosphorylation of ERK1/2 or Akt in any of the GFRα2 isoform 
transfectants (data not shown). Additionally, neither GDNF nor NTN was found to 
activate p38 and JNK in any of the GFRα2 isoform transfectants, even at 
concentration levels as high as 100 ng/ml and over one hour of ligand stimulations 
(data not shown).  
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4.2.4 [125I]GDNF bound equally well to all three GFRα2 isoforms 
 
  As GDNF failed to induce a significant increase in the phosphorylation of 
ERK1/2 in GFRα2b transfectant (Fig 4.5, 4.6), it is possible that GDNF may not bind 
to this isoform. In order to address this possibility, a ligand displacement study using 
[125I]GDNF was conducted. GDNF displaced the binding of [125I]GDNF to the three 
GFRα2 isoforms with similar potencies (Fig. 4.8). The IC50 for the displacements of 
cells transfected with GFRα2a, GFRα2b and GFRα2c were 3.27+/-0.02, 2.79 +/-0.16 
and 2.31+/-0.09 (Mean +/- SD), respectively. Parental Neuro2A or cells transfected 
with pIRESneo showed no significant binding to [125I]GDNF (data not shown). This 





Figure 4.8. Displacement of [125I ]GDNF by unlabeled GDNF in GFRα2 isoform 
transfected Neuro2A cells. Transfectants were incubated with 50 pM of [125I]GDNF 
in the absence or presence of increasing concentrations of unlabeled GDNF at 4˚C for 
four hours. The unbound ligand was removed at the end of incubation and the 
radioactivity associated with the cells was determined. The percentage of inhibition 
was expressed as mean +/- SD (n = 3) of the amount of cells associated radioactivity 
in presence over the absence of unlabeled GDNF. Similar results were obtained for 
four independent experiments. 
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4.2.5 GFRα2 isoforms activated different transcriptional genes 
 
The differential activations of ERK1/2 and Akt (Fig. 4.5, 4.6, 4.7) suggest the 
possibility that downstream biochemical mechanisms of GFRα2 isoforms may differ. 
To explore this issue, the regulation of early response genes in ligand induced 
activation of GFRα2 isoforms was measured. Early response or immediate early 
genes are classes of genes that are rapidly and transiently activated in response to 
intracellular signaling cascades. They encode for inducible transcription factors, 
including the Fos, Jun and Egr protein family (Sng et al., 2004). However, regulation 
of these genes in GFRα2 by GDNF or NTN stimulation is seldom reported. In this 
study, the changes in gene expression of the fos family (c-fos, fosB), jun family (c-jun, 
jun-b), egr family (egr1-4) and GDNF inducible transcription factors, mGIF and 
mGZF1 in response to GDNF and NTN were measured. These factors have 
previously been shown to be activated with GDNF or NTN (Fukuda et al., 2003; 
Kozlowski et al., 2000; Pezeshki et al., 2003; Trupp et al., 1999; Yajima et al., 1997).  
The kinetics of gene activation over a period of six hours were quantified by 
real time PCR (Fig. 4.9). Distinct ligand induced early response gene expressions 
were observed with the activation of the different GFRα2 isoforms. GFRα2a, when 
stimulated by GDNF or NTN, up-regulated egr-1 by as much as four to five folds (Fig. 
4.9A, B). GFRα2b, when stimulated by GDNF or NTN, up-regulated fosB by greater 
than ten folds, when compared to the control (Fig. 4.9C, D). When stimulated with 
GDNF or NTN, GFRα2c up-regulated the expressions of egr-1 and egr-2 (Fig. 4.9E, 
F). With the other genes, no significant changes were observed with GDNF or NTN 
stimulations (data not shown). These results show that GFRα2 isoforms when 
stimulated induced distinct transcription of specific sets of early response genes.  










Figure 4.9. Kinetic analyses of the regulations of early response genes by GDNF 
and NTN in GFRα2 isoform transfectants. Fold change of mRNA expressions of 
early response genes in cells expressing GFRα2a (A), GFRα2b (C) and GFRα2c (E) 
when stimulated with GDNF, and GFRα2a (B), GFRα2b (D) and GFRα2c (F) when 
stimulated with NTN at the designated period of time. The expression levels were 
measured by quantitative real time PCR. Similar results were obtained for more than 
three separate experiments. Error bars indicate standard deviations of triplicate 
measurements from one study. Significant differences in expression of genes between 
ligand stimulated and control samples were calculated using paired Student’s t-test. A 
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4.2.6 Neurite outgrowths were induced by GFRα2a and GFRα2c, but 
not GFRα2b 
 
Neuro2A is an excellent in vitro model system for studying signaling 
pathways mediating neurite outgrowth. Under normal growth conditions, most 
Neuro2a cells spontaneously sprout a basal level of neurites. However, treatments 
with a variety of stimuli cause these cells to develop extensive neurites similar to 
changes observed in primary neuronal cultures (Chapter 4, Background and 
objectives). To investigate possible morphological changes induced by the activation 
of the GFRα2 isoforms, the transfectants were stimulated with either GDNF or NTN.   
Both GFRα2a and GFRα2c transfectants showed extensive neurite outgrowths 
when stimulated with either GDNF or NTN, comparable to the effects of retinoic acid 
(Fig. 4.10A, B). Unexpectedly, neither of the ligands induced neurite outgrowth in 
cells expressing GFRα2b (Fig. 4.10A, B). Immunocytochemical staining for beta III-
tubulin further confirmed these observations (appendix II). Cells expressing GFRα2b 
extended neurite-like structures when treated with retinoic acid, indicating the 
potential for neurite outgrowth (Fig. 4.10). GDNF and NTN have no neuritogenic 
effect on control vector transfected Neuro2A cells (Fig. 4.10). 
To further examine the morphological changes in these cells, two major 
cytoskeletal components, F-actin and high-molecular-weight neurofilament protein 
(NF-H), which are involved in neurite outgrowth dynamics, were visualized by 
fluorescent staining. With ligand (GDNF or NTN) stimulated GFRα2a and GFRα2c 
transfectants, NF-H-positive filopodia (axon-like processes) were relatively long and 
form thick threads. Protrusions with F-actin staining were observed at the edges of the 
thick NF-H positive axon-like elements and cell bodies (Fig. 4.11).  








Figure 4.10. Differential neuritogenic activities of ligand activated GFRα2 
isoforms. Cells were seeded on six well plates and incubated for 16-18 hours in 
media containing 10% serum. The cells were then exposed to GDNF or NTN (50 ng/ 
ml) for three more days in 0.5% serum containing media. Retinoic acid (RA) (5 µM) 
was used as a positive control for cell differentiation. A, Digital phase contrasts 
images (magnification x200) of Neuro2A cells stably expressing GFRα2a, GFRα2b, 
GFRα2c or pIRES vector control when treated with RA, GDNF or NTN. B, 
Percentages of cells bearing neurites which were at least twice the length of the cells 
bodies. More than 600 cells were counted per well, on at least three different fields. 
Experiments were repeated twice with three individual clones, with similar results. 
Significant differences in the percentage of cells bearing neurites between ligands 
stimulated and control samples were calculated using paired Student’s t-test 
(**P<0.002).  
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Engorgements were seen at some terminal structures which were both NF-H and F-
actin positive (Fig. 4.11). Long extensions were not obvious with cells expressing 
GFRα2b when stimulated with either ligand. Instead, F-actin positive staining was 
found at the periphery of these cells where NF-H was not found to co-localize 
extensively (Fig 4.11f).  These observations provide further evidence of the lack of 
neurite outgrowths in ligands stimulated cells expressing GFRα2b and the 




Figure 4.11. Immunocytochemistry of cytoskeletal component in ligand treated 
Neuro2A cells expressing GFRα2 isoforms. Confocal images for double 
immunostaining of heavy chain neurofilament (NH-F) (green) and F-Actin (red) in 
GFRα2a (a-c) or GFRα2b (d-f) transfectants treated with GDNF. Double 
immunostaining reveals the co-localization (yellow) of cytoskeletal components, NF-
H and F-Actin along the neurites, while only F-Actin stained at growth cones (arrows). 
Scale bars, 20 µm.  
 





This study demonstrates the distinct biochemical and neuritogenic activities of 
alternatively spliced GFRα2 isoforms. All three GFRα2 isoforms were detected in the 
human cortex. Using transfected Neuro2A cells model, it has been shown that GDNF 
and NTN mediated differential signaling mechanism and regulated distinct early 
response genes in GFRα2 isoforms. Ligand activated GFRα2a and GFRα2c, but not 
GFRα2b, induced neurite outgrowth in Neuro2A transfectants.  
The expression of GFRα2 mRNA has been reported (Golden et al., 1998; Golden 
et al., 1999; Sanicola et al., 1997; Trupp et al., 1998; Widenfalk et al., 1997) in the 
cortex of the human, mouse and rat brain. However, the probes used in these studies 
cannot distinguish the expressions of the isoforms. In the present study, all three 
isoforms in the human brain regions were specifically amplified using exon 
overlapping primers (Too, 2003). In the human brain, all three GFRα2 isoforms were 
expressed at comparable levels, with GFRα2c significantly higher than the other two 
isoforms. Compared to the other regions of the human brain, the cortex expressed the 
highest level of the isoforms. The functional significance of these isoforms in the 
cortex is yet to be defined. Interestingly, the high expressions of the GFRα2 isoforms 
in the cortex, a region of the brain involved in learning complex tasks, and the 
observation that mice knocked out by GFRα2 show significant impairment in several 
memory tasks (Voikar et al., 2004) may suggest a possible role of GFRα2 signaling in 
the development and/or maintenance of cognitive abilities that help in solving 
complex learning tasks. 
GDNF and NTN are known to similarly activate a number of signaling pathways, 
including the extracellular signal-regulated kinase (ERK), phosphatidylinositol 3-
kinase (PI3K)/AKT, p38 mitogen-activated protein kinase (MAPK) and c-Jun N-
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terminal kinase (JNK)  (Ichihara et al., 2004; Pezeshki et al., 2003; Takahashi, 2001; 
Trupp et al., 1999), and regulate the expressions of various immediate early response 
genes (Fukuda et al., 2003; Pezeshki et al., 2003). In this study, it is intriguing to note 
that the activation of specific signaling pathways, but not the early response genes, 
was dependent on the ligands used. For instance, GDNF was found to potently 
activate ERK1/2 through GFRα2a and GFRα2c in a dose and time dependent manner, 
but does not activate GFRα2b significantly. This was not due to the failure of GDNF 
to interact with GFRα2b as GDNF displaced bound 125I-GDNF equally well with all 
three isoform transfectants. Similarly, GDNF activated AKT through GFRα2b and 
GFRα2c, but not through GFRα2a. However, NTN showed similar activations of 
ERK1/2 and AKT through all the three isoforms. Such ligands specificity in 
activation of GFRα2 receptor isoforms was consistent to those observed in Chapter 3.  
Unlike GFRα2a and GFRα2c, GFRα2b transfectants did not induce neurite 
outgrowth when activated by either GDNF or NTN. Both GFRα2a and GFRα2c (but 
not GFRα2b) activated the early response gene, egr-1 (also known as NGFI-A, krox-
24, zif-268, and TIS-8), consistent with a role of egr-1 in neuronal differentiation 
(Pignatelli et al., 1999; Knapska and Kaczmarek, 2004).  
Together, the results from this study showed that the three GFRα2 isoforms have 
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5.1 Background and objectives 
 
  In the previous chapter, we have shown the differential biochemical and 
neuritogenic activities of GFRα2 isoforms when activated by the ligands, GDNF or 
NTN. Besides the distinct regulations of MAPK, AKT signaling and early response 
genes, there were also startling phenotypic differences with the activation of the 
GFRα2 isoforms. Both GDNF and NTN have been shown to induce neurite outgrowth 
in some neuronal cells (Baloh et al., 2000; Lin et al., 1993; Wanigasekara and Keast, 
2005; Zihlmann et al., 2005). Despite the presence of functional cognate receptors, 
both GDNF and NTN failed to induce neurite outgrowths in other neuronal cells 
(Hansford and Marshall, 2005; Kobori et al., 2004).  In view of the results where 
ligand activation of GFRα2a and GFRα2c, but not GFRα2b, induced neurite 
outgrowth in Neuro2A cells (Chapter 4), it is possible that the preferential expression 
of these spliced isoforms in some of these neuronal cells may underlie the phenotypic 
differences observed with ligand stimulation. 
 The Rho family of small GTPases is intimately involved in various processes 
involving actin cytoskeleton reorganization in eukaryotic cells, including neurite 
outgrowth and differentiation (Govek et al., 2005). There are at least 20 Rho GTPases 
encoded in the human genome (Wherlock and Mellor, 2002).  RhoA (Ras 
homologous member A), Rac1 (Ras-related C3 botulinum toxin substrate 1) and 
Cdc42 (cell division cycle 42) are the three well-studied members of the Rho family. 
Recent findings show that Rho GTPases play important roles in the regulation of 
neuronal morphogenesis, including axon outgrowth and guidance, polarity, dendrite 
elaboration and synapse plasticity and formation (Luo, 2000). While Rac1 and Cdc42 
have been shown to positively regulate neuritogenic activities, RhoA has been shown 
to be a negative regulator. Attractive cues regulate Rac1 and Cdc42 activities, while 
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repulsive cues activate RhoA activity, which in turn transduce intracellular signals 
and differentially regulate growth cones actin dynamics (Dickson, 2001). RhoA and 
its effector ROCK are the important mediator of neurite growth inhibition regulated 
by various inhibitory factors, including Nogo, myelin protein MAG, and 
lysophosphatidic acid (LPA). Although the downstream signaling/s that link/s RhoA 
and ROCK to the actin cytalskeletal reorganization remain to be elucidated, LIM 
kinase (LIMK) appears to be involved. LPA activations of RhoA and ROCK have 
been shown to phosphorylate and activate LIMK, which in turn phosphorylate and 
subsequently inactivate the actin-associated protein, cofilin (Maekawa et al., 1999; 
Ohashi et al., 2000). Cofilin is the key regulator of actin dynamics at the leading edge 
of neurite growth cone. It is a small (19kDa) ubiquitous protein, that binds and 
dissociates actin monomer from the pointed end of actin filaments, thus generating 
new actin barbed ends for polymerizations of actin filaments (DesMarais et al., 2005). 
Such regulated polymerizations and depolymerizations of actin filaments are 
important for neurite growth cones dynamics. Phosphorylation and inactivation of 
cofilin will cause rearrangement of actin cytoskeletal, leading to growth cone collapse 
and outgrowth inhibition (Hsieh et al., 2006). 
 Eight Rho proteins (Rac1, Rac2, RhoA, RhoB, RhoG, TC10, TCL, and Cdc42) 
are known to be activated by RTKs, including RET (Schiller, 2006). In response to 
GDNF, several proteins in neuroblastoma cells are phosphorylated on tyrosine and 
reorganized actin cytoskeleton which are mediated by both Rho-dependent and -
independent signaling pathways (Murakami et al., 1999). However, it is not known if 
this response to GDNF is mediated by the activation of specific GFRα isoforms.  
 This chapter focuses on the mechanisms underlying the functions of GFRα2b 
isoform and neuritogenic activity.  Using co-expression models, ligand activated 
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GFRα2b was found to inhibit neurite outgrowth induced by other GFRα receptor 
isoforms. Furthermore, ligand activated GFRα2b also attenuated retinoic acid induced 



























5.2.1 GFRα2b inhibited neurite outgrowths mediated by other 
GFRα2 isoforms 
 
 As GFRα2b transfectant did not induce neurite outgrowth when stimulated with 
ligand, the possibility that this isoform may affect the morphological changes induced 
by the activation of GFRα2a and GFRα2c was explored. Stably transfected Neuro2A 
cells co-expressing GFRα2b and GFRα2a or GFRα2c were established. Using the 
pIRES-bicistronic vector, GFRα2a or GFRα2c was expressed in the 5’ multiple 
cloning site (MCS-A), while GFRα2b was expressed in the 3’ multiple cloning site 
(MCS-B). For control, cells with only GFRα2a or GFRα2c expressed using pIRES-
bicistronic vector, at MCS-A, showed similar neurite outgrowths activities as 
previously obtained (data not shown). This was also the case for GFRα2b expressed 
in MCS-B (data not shown).  
 Ligand induced stimulation of cells co-expressing GFRα2a and GFRα2b showed 
significantly less neurite outgrowth (Fig 5.1). However, these cells extended neurite 
when treated with retinoic acid. Similarly, ligand stimulation of cells co-expressing 
GFRα2b and GFRα2c showed significantly fewer neurite outgrowths (Fig 5.1). These 
observations suggest that GFRα2b, when co-expressed, antagonizes ligand induced 
neurite outgrowths of other GFRα2 isoforms.  
5.2.2 GFRα2b inhibited neurite outgrowth mediated by GFRα1a 
 
 Extending this finding, the possible inhibitory effect of the activation of GFRα2b 
on the neurite outgrowth induced by ligand in cells co-expressing GFRα1a was 
explored. Cells expressing only GFRα1a showed significant neurite outgrowths when 
stimulated by GDNF, NTN or retinoic acid (Fig 5.2). Interestingly, when stimulated 
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by either GDNF or NTN, cells co-expressing GFRα2b and GFRα1a showed 
significantly less neurite outgrowths. These observations indicate that the activation 
of GFRα2b inhibits neurite outgrowths induced by the activation of GFRα2a, 

















Figure 5.1. GFRα2b inhibited neurite outgrowths of GFRα2a and GFRα2c in co-
expression models. To investigate effect of GFRα2b on ligand-induced neurite 
outgrowths of other GFRα2 isofroms, GFRα2b was stably co-expressed with GFRα2a 
or GFRα2c in Neuro2A cells. A, Phase contrasted images (magnification x200) of 
cells treated with retinoic acid (RA) (5 µM), GDNF or NTN (50 ng/ml). B, 
Percentages of cells bearing neurite were counted for cells bearing neurite twice 
longer than cells body. Experiments were repeated twice in three separate clones, with 
parallel results. Significant differences in percentage of cells bearing neurites between 










Figure 5.2. Ligand activated GFRα2b antagonized neurite outgrowths induced 
by ligand activated GFRα1a in co-expression model. A, B, Antagonizing effects of 
GFRα2b on ligand activation of GFRα1a isoforms mediated neurites outgrowths. 
Neuro2a cells were stably expressing GFRα1a or co-expressing GFRα1a with 
GFRα2b (GFRα1a+ GFRα2b). A, Phase contrast images (magnification x200) of cells 
treated three days with retinoic acid (RA) (5 µM), GDNF or NTN (50 ng/ml). B, 
Percentages of cells bearing neurite were counted for cells bearing neurite twice 
longer than cells body. Experiments were repeated twice in three separate clones, with 
parallel results. Significant differences in percentage of cells bearing neurites between 
ligand stimulated and control samples were calculated using paired Students t-test 
(**P<0.002). 
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5.2.3 Knock-down of GFRα2b resulted in an increase in neurite 
outgrowths 
 
 The above observations of the GFRα2b induced inhibition of neurite outgrowth 
were extended by investigating the BE(2)-C cells that have previously been shown to 
endogenously express GFRα2 receptors (Chapter 4) (Kobori et al., 2004; Yoong et al., 
2006). These cells co-express GFRα2 isoforms, with comparable levels of GFRα2a 
and GFRα2b (Fig. 5.3A) and significantly lower level of GFRα2c (data not shown). It 
has previously been shown that retinoic acid, but not GDNF or NTN induce neurite 
outgrowth in BE(2)-C cells (Chapter 3) (Kobori et al., 2004; Yoong et al., 2006). 
From the above evidence of GFRα2b inhibiting the neuritogenic activity of GFRα2a 
in the co-expression model, it is reasonable that a similar mechanism may underlie the 
effects of GDNF or NTN in BE(2)-C cells. 
 In order to test the hypothesis that the activation of GFRα2b may inhibit neurite 
outgrowths induced by GFRα2a or GFRα2c in BE(2)-C cells, the expression of 
GFRα2b was silenced using siRNA. As GFRα2b has no unique sequences when 
compared to GFRα2a, the design of a GFRα2b isoform specific siRNA posed a 
significant challenge. A series of siRNA duplexes were then designed with sequences 
overlapping exons 1 and 3 of GFRα2b (refer to Table 9.2, Chapter 9, Materials and 
Methods). Of the five designs tested, only the siGFRα2b-13+7 showed significant 
discrimination in silencing GFRα2b over GFRα2a (Fig. 5.3B). This particular siRNA 
design, siGFRα2b-13+7, down regulated the expression of GFRα2b to less than 10% 
of the control, with no significant reduction in the expression of GFRα2a.  
 When GFRα2b expression was silenced, the BE(2)-C cells extended neurite-like 
structures when stimulated with either GDNF or NTN (Fig. 5.3C, D). This 
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observation supports the notion that the activation of GFRα2b inhibits neurite 
outgrowth induced by ligands stimulation of GFRα2a.   
 
5.2.4 Signaling and biochemical activities of GFRα2 isoforms in the 
co-expression model 
 
 To further investigate the signaling and biochemical events underlying ligand 
activation of GFRα2b in the co-expression model, the stimulation of MAPK (ERK1/2) 
was first examined. Previous data showed that GDNF stimulated ERK1/2 
phosphorylation in GFRα2a or GFRα2c, but not GFRα2b transfectants (Chapter 4, 
Fig. 4.5, 4.6).  In the co-expression models, both GDNF and NTN induced rapid and 
transient phosphorylations of ERK1/2 (Fig. 5.4A).  
 Interestingly, when stimulated with either GDNF or NTN, there were no changes 
in the expression of either egr-1 or egr-2. However, significant up-regulations of the 
expression of fosB were observed in the co-expression of GFRα2b with GFRα2a (Fig. 
5.4B, C) or with GFRα2c (Fig. 5.4D,E).  These observations showed that the 
activation of co-expressed GFRα2b with either GFRα2a or GFRα2c resulted in the 
activation of fosB, an early response gene, reminiscent of that observed in GFRα2b 
transfected alone (Fig. 4.9). 
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Figure 5.3. Silencing of GFRα2b expression in human BE(2)-C cells. A, The 
expression levels of GFRα2a and GFRα2b in BE(2)-C cells were determined using 
quantitative real time PCR.  B, Effects of various designs of siRNA sequences on the 
expressions of GFRα2a and GFRα2b in BE(2)-C. siRNA duplex (20 pmol) was 
transfected into cells and total RNA was harvested six hours later. The expressions of 
GFRα2a and GFRα2b were then measured by quantitative real time PCR. Significant 
differences between the expression of the two isoforms after silencing with each of 
the siRNA designs were calculated using paired Students t-test (**P=0.001).  C, D, 
Neurite outgrowths of BE(2)-C cells after silencing of GFRα2b. C, Cells were 
stimulated with retinoic acid (RA) (5 µM), GDNF or NTN (50 ng/ml) in the absence 
or presence of siGFRα2b-13+7. Pretreatment of cells with siGFRα2b-13+7 and 
subsequent stimulation with GDNF or NTN resulted in the formation of neurite-like 
structures (arrows). (Phase contrast image, magnification x200)  D, Percentages of 
cells bearing neurites which were at least twice the length of the cells bodies, with or 
without presence of siRNA, siGFRα2b-13+7. Similar results were obtained from 
replicates of three individual experiments. Significant differences in percentage of 
cells bearing neurites between ligand stimulated and control samples were calculated 




























Figure 5.4. ERK1/2 signaling and the regulation of early response genes in the 
Neuro2A cells co-expressing GFRα2b with either GFRα2a or GFRα2c. A, 
Western blot analyses of the activation of ERK1/2.  Neuro2A cells stably co-
expressing the isoforms, GFRα2a and GFRα2b (GFRα2a + GFRα2b), or GFRα2c and 
GFRα2b (GFRα2c + GFRα2b) were treated with GDNF, NTN or Sorbitol for the 
period of time indicated. Phospho-specific antibodies to ERK1/2 were used for 
detection and the blots reprobed with pan antibody serving as controls for protein 
loadings. B-E, Kinetic analyses of GDNF or NTN regulated expressions of early 
response genes in the co-expression models. Expressions of fosB, egr-1, and egr-2 
were measured with quantitative real time PCR in cells stably co-expressing GFRα2a 
with GFRα2b when stimulated with GDNF (B) or NTN (C); Cells stably co-
expressing GFRα2c with GFRα2b were stimulated with GDNF (D) or NTN (E). 
Significant differences in expression of genes between ligand stimulated and control 
samples were calculated using paired Student’s t-test. A value of P<0.05 was 
considered significant (**P<0.001, *P<0.05). 
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5.2.5 GFRα2b inhibited retinoic acid induced neurite outgrowth 
 
 Next, we examined the possibility that GFRα2b may affect neurite outgrowth 
induced by retinoic acid, a non-GFLs stimulus. Using Neuro2A expressing GFRα2b, 
retinoic acid treatment resulted in extensive neurite outgrowths. Both GDNF and 
NTN dramatically reduced the number of cells bearing neurite-like structures (Fig. 
5.5). These suggest that GFRα2b may have a broad inhibitory activity on neurite 




Figure 5.5. Ligand activated GFRα2b antagonized neurite outgrowth induced by 
retinoic acid. A, B, Retinoic acid (RA) (5 µM) induced neurite outgrowth in GFRα2b 
expressing Neuro2A cells. When treated together with GDNF or NTN (50 ng/ml), 
neurite outgrowth induced by RA is significantly attenuated. A, Phase contrast images  
(magnification x200) of Neuro2A cells stably expressing GFRα2b, treated with RA, 
GDNF or NTN for three days. B, Percentages of cells bearing neurite were counted 
for cells bearing neurite twice longer than cells body. Experiments were repeated 
twice in three individual clones, with similar results. Significant differences in 
percentage of cells bearing neurites between ligand stimulated and control samples 
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5.2.6 Ligand induced GFRα2b neurite inhibition is RhoA dependent 
 
 The Rho family of small GTPases and its associated regulators have been 
implicated in the modulation of neurite formation, axonal pathfinding, and dendritic 
arborization (Dickson, 2001; Van Aelst and Cline, 2004). Thus, it is of interest to 
examine the possibility that GFRα2b may activate the Rho family of GTPases. The 
possible involvement of Rho-associated kinase, ROCK, which is known to be an 
effector of RhoA in the negative regulation of neurite outgrowth, was also 
investigated. To address these issues, effects of Rho inhibitor, exoenzyme C3 
transferase, and ROCK inhibitor, Y27632, on neurite outgrowth of GFRα2 isoforms 
co-expressing cells were studied. Neuro2A cells have previously been shown to 
respond to LPA, resulting in the inhibition of neurite outgrowths through the RhoA-
ROCK dependent mechanism (Sayas et al., 2002). Hence, LPA was used as a positive 
control for the effectiveness of Rho-ROCK inhibitors. 
 When stimulated with GDNF or NTN, Neuro2a co-expressing GFRα2a and 
GFRα2b (Fig. 5.6A) or GFRα2c and GFRα2b (Fig. 5.6B) did not extend neurite-like 
structures. However, a significant number of these cells extended neurite-like 
structures in the presence of the Rho antagonist, exoenzyme C3 transferase, 
suggesting the involvement of Rho family of GTPases in the inhibitory effects of 
GFRα2b (Fig. 5.6A, B). C3 transferase was also found to inhibit LPA effects on 
retinoic acid induced neurite outgrowth. At the concentration level of C3 transferase 
used in this study, no significant cell death was observed (data not shown). 
 Using the ROCK inhibitor, Y27632, the inhibitory activity of LPA on retinoic 
acid induced neurite outgrowth was significantly attenuated (Fig. 5.6). However, the 
same concentration of Y27632 (10 µM) did not attenuate the inhibitory activity of 
GFRα2b in co-expression with GFRα2a (Fig. 5.6A) or GFRα2c (Fig. 5.6B). Higher 
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concentrations of Y27632 (20 µM) resulted in significantly higher backgrounds of 





Figure 5.6. Effects of RhoA and ROCK inhibitors in ligand induced neurite 
outgrowth of GFRα2 isoforms co-expression models. A, B, Effects of RhoA 
inhibitor, exoenzyme C3 transferase (1 µg/ml) and ROCK inhibitor, Y27632 (10 µM), 
on ligand induced neurite outgrowth in co-expression models of GFRα2a and 
GFRα2b (GFRα2a+ GFRα2b) (A), or GFRα2c and GFRα2b (GFRα2c+ GFRα2b) (B). 
Lysophosphatidic acid (LPA) was used as a positive control in this study. LPA (10 
µM) antagonized neurite outgrowth induced by 5 µM retinoic acid (RA), such neurite 
inhibition of LPA was attenuated by C3 (1 µg/ml) and Y27632 (10 µM). Mean ± SD 
was calculated from results obtained in triplicates. The effects of RhoA and ROCK 
inhibitors were compared to the effects of the inhibitors alone.  With the 
concentrations of inhibitors used, no significant cell deaths were observed. Significant 
differences in percentage of cells bearing neurites were calculated between ligand 
stimulated and control samples, using paired Student’s t-test (*P≤0.01). 
 
 In order to investigate the possible involvement of RhoA in the inhibitory effects 
of GFRα2b, an attempt was made to pull down activated RhoA from cell lysates 
using GST-Rhotekin and subsequently immunoblotted for RhoA. Similar to the 
effects of LPA, when GFRα2b was stimulated with either NTN or GDNF, it was 
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found to activate RhoA significantly (Fig. 5.7). Neuro2A expressing GFRα2a, 
GFRα2c or pIRES vector control did not activate RhoA significantly when stimulated 
with these ligands. This observation is consistent with the suggestion that RhoA 
and/or other Rho GTPases may be involved in the inhibition of neurite outgrowth 
mediated through GFRα2b. 
 
 
Figure 5.7. Analyses of RhoA activation in Neuro2A cells transfected with 
GFRα2 isoforms or pIRES control. After a 10-minute treatment of LPA (10 µM), 
GDNF or NTN (50 ng/ml), GTP-bound RhoA was pulled down from cells lysates 
using GST-Rhotekin and immunoblotted for RhoA. LPA served as a positive control 
for RhoA activation. Blotting of total RhoA in cells lysate showed similar loading of 
cell lysates for pull down assays. 
 
The involvement of RhoA in the activation of GFRα2b was not restricted to 
inhibiting GFRα1a, GFRα2a or GFRα2c induced neurite outgrowths, but also to 
those induced by retinoic acid (Fig. 5.8A). Similar to the above observations, the 
inhibitory effects of GFRα2b on retinoic acid induced neurite outgrowth appear to be 
mediated in a Rho dependent manner (Fig 5.8A). Furthermore, the inhibition of 
ROCK may be sufficient to oppose the effects of LPA but not that of GFRα2b on 
retinoic acid induced neurite outgrowths (Fig. 5.8B).  
 










Figure 5.8. Effects of RhoA and ROCK inhibitors on GFRα2b inhibition of 
retinoic acid (RA) induced neurite outgrowth. A, RhoA inhibitor, exoenzyme C3 
transferase (1 µg/ml) inhibited the ligand activated GFRα2b attenuation of neurite 
extension induced by retinoic acid (RA) (5 µM). The same concentration of 
exoenzyme C3 transferase also attenuated Lysophosphatidic acid (LPA) (10 µM) 
inhibition of RA induced neurite extension. B, Lack of effect of ROCK inhibitor, 
Y27632, on the ligand activated GFRα2b inhibition of RA induced neurite extension. 
The same concentration of Y27632 (10 µM) significantly attenuated the neurite 
outgrowth inhibition induced by LPA. Mean ± SD was calculated from results 
obtained in triplicates. The effects of RhoA and ROCK inhibitors were compared with 
the effects of the inhibitors alone. With the concentrations of inhibitors used, no 
significant cell deaths were observed. Significant differences in percentage of cells 
bearing neurites were calculated between ligand stimulated and control samples, using 
paired Student’s t-test (*P≤0.01). 
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To further confirm the involvement of RhoA in GFRα2b inhibitory activities, 
the effect of RhoA dominant negative mutant (RhoA-DN) was investigated (Fig. 5.9). 
Expression of RhoA-DN in GFRα2b cells resulted in an increase in the percentage of 
cells bearing neurite, in ligand treated GFRα2b cells (Fig. 5.9B). It also abolished the 
GFRα2b inhibition on RA-induced neurite outgrowth. Neurite outgrowths were 
observed in cells stained positive for both HA-tagged RhoA-DN and beta III tubulin 
(Fig. 5.9A). These results further indicate the involvement and importance of RhoA in 
the inhibitory activities of GFRα2b.  
Actin reorganization is commonly observed in RhoA-ROCK mediated neurite 
retraction and growth cone collapse. The activation of RhoA-ROCK pathway by LPA 
leads to phosphorylation and hence deactivation of cofilin, an adaptor protein 
involved in actin depolymerization (Hsieh et al., 2006; Huang et al., 2006; Maekawa 
et al., 1999). Here, the possibility of cofilin deactivation by ligand induced GFRα2b 
was also investigated. Ligand activated GFRα2b induced rapid phosphorylation of 
cofilin (Fig. 5.10). Increased phosphorylation of cofilin was not observed in GFRα2a 
or GFRα2c (data not shown). It has also been noted that the cofilin phosphorylation 
induced by ligand activated GFRα2b was not as intense and sustainable as compared 
to that induced by LPA treatment. The differences in cofilin phosphorylation induced 
by ligand activated GFRα2b and LPA treatment may be indicative of differences in 












Figure 5.9 RhoA dominant negative mutant prevented inhibitory effects of 
GFRα2b. A, GFRα2b cells transfected with HA-tagged RhoA dominant negative 
mutant (RhoA DN), where differentiated with retinoic acid (RA) in presence of 
GDNF. Cells were stained with beta III tubulin (green) and anti-HA (red). Cells 
double-stained with beta III tubulin and HA-RhoA DN showed positive for neurite 
outgrowth (arrowhead). (maginification x200) B, Cells count for neurite outgrowth 
mediated by GFRα2b treated with or without RhoA DN. Significant differences in 
percentage of cells bearing neurites were calculated between ligand stimulated and 
control samples, using paired Students t-test (**P≤0.01). 
 








Figure 5.10. Ligand activated GFRα2b mediated phosphorylation of cofilin. 
Neuro2A cells stably expressing GFRα2b were treated with 50 ng/ml of GDNF or 
NTN, or 10 µM of Lysophosphatidic acid (LPA), for 5, 30 or 60 minutes. LPA served 
as a positive control for phosphorylation of cofilin. A, Western blots detection of 
phospho-cofilin in Neuro2A cells stably expressing GFRα2b were treated with GDNF, 
NTN or LPA. Blot was stripped and reprobed for pan-cofilin. B, Fold change of 
phosphorylated cofilin in GFRα2b cells treated with GDNF, NTN or LPA. Similar 
results were repeated in three independent experiments. Significant differences in fold 
change of phosphorylated cofilin between control and treated samples were calculated 
using paired Student’s t-test. A value of 0.05 was considered significant (*P<0.05, 
**P<0.01) 
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5.2.7 GFRα2b may prevent but not retract neurite outgrowth 
 
In the studies on the inhibition of retinoic acid induced neurite outgrowth by 
GFRα2b, GDNF or NTN was added simultaneously with retinoic acid.  It would be of 
interest to know if inhibition of neurite outgrowth is effective if cells were first treated 
with retinoic acid, prior to ligand activation of GFRα2b. As was shown previously 
(Fig. 5.5), minimal neurite outgrowths were observed when the GFRα2b transfectants 
were simultaneously exposed to retinoic acid and GDNF or NTN. However, when the 
ligands were added one, three, or six hours after the addition of retinoic acid, 
significant neurite outgrowths were observed (Fig. 5.11A). This was however less as 
compared to cells treated with retinoic acid alone (Fig. 5.11A). These data indicate 
that neurite inhibition of GFRα2b may be most effective when GFRα2b is activated 
by ligand prior to the exposure to retinoic acid. 
Besides inhibiting neurite outgrowth, LPA has also been shown to induce 
growth cone collapse and neurite retraction (Couvillon and Exton, 2006; Kranenburg 
et al., 1999). This raises the interesting question of whether GFRα2b may also induce 
neurite retraction. Retraction assays were performed by adding LPA, GDNF or NTN 
to 3-day retinoic acid differentiated GFRα2b cells. Three hours later, most cells 
treated with LPA rounded up in shape, indicating neurite retraction (Fig. 5.11B, C). 
GDNF or NTN did not have such an effect on retinoic acid differentiated GFRα2b 
cells, suggesting the neurite did not retract (Fig. 5.11B, C). 
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Figure 5.11.  Ligand activated GFRα2b may inhibit, but not retract neurite 
outgrowth mediated by Retinoid Acid. A, Effectiveness of ligand activated 
GFRα2b in attenuating neurite outgrowth of retinoic acid was investigated by adding 
GDNF or NTN (50 ng/ml), at zero hour, or one to six hours (1h, 3h, 6h) after cells 
treated with 5 µM of Retinoic Acid (RA). B, C, Studies of retraction effects of 
Lysophosphatidic acid (LPA) (10 µM), GDNF and NTN (50 ng/ml) in GFRα2b cells. 
Neuro2A cells stably expressing GFRα2b were differentiated with 5µM of Retinoic 
Acid (RA) for three days. By the third day, differentiation medium containing RA 
was removed, and replaced by media only, or media with LPA, GDNF or NTN. Cells 
were then incubated for three hours. Cells morphologies (magnification x200) (B) and 
percentage of cells bearing neurite (C) after removal of RA differentiation medium, 
and three-hour incubation of replacement media containing LPA, GDNF or NTN. 
Standard deviations are shown for triplicate wells. Significant differences in 
percentage of cells bearing neurites were calculated between stimulated and control 
























This study reveals a novel inhibitory activity of the GFRα2b isoform, where 
activation of the isoform antagonized neurite outgrowths induced by GFRα1a, 
GFRα2a and GFRα2b receptor isoforms. Ligand activated GFRα2b isoform also 
attenuated neurite outgrowth mediated by retinoic acid, a non-GFL stimuli. 
Furthermore, the ligand induced anti-neuritogenic activities of GFRα2b were RhoA 
dependent.   
Extending the observation where GFRα2b transfectants did not induce neurite 
outgrowth when activated by ligands (Chapter 4), the co-expression of GFRα2b was 
found to inhibit ligand induced neurite outgrowths by GFRα1a, GFRα2a and GFRα2c 
(Figure 5.1, 5.2). Similarly, in BE(2)-C cells endogenously expressing GFRα2b 
isoform, both GDNF and NTN did not significantly alter the morphology of the cells.  
However, the silencing of GFRα2b and subsequent treatment with either GDNF or 
NTN caused the cells to extend neurite-like structures (Figure 5.3). These results are 
consistent with GFRα2b serving a specific role in inhibiting neuritogenesis induced 
by some stimuli.  
It is well documented that GDNF and NTN are potent trophic factors which have 
potent effects on neuronal differentiation, promote survival and sprouting of ventral 
mesencephalic dopaminergic neurons in primary cultures and other neuronal cultures 
(Lin et al., 1993; Akerud et al., 1999; Baloh et al., 2000; Yan et al., 2003; 
Wanigasekara and Keast, 2005; Zihlmann et al., 2005). The finding in this study of a 
particular alternatively spliced variant of GFRα2 inhibiting neurite outgrowth was 
unexpected. 
The underlying GFRα2b inhibitory mechanism involves the Rho family of 
GTPases. RhoA is a member of Rho GTPases family, which includes RhoA, Rac and 
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Cdc42 (Luo, 2000; Van Aelst and Cline, 2004). While the involvement of Rac and 
Cdc42 in promoting neurite and axonal outgrowth has been shown, RhoA has been 
the focus in studies of molecular mechanisms for some glial-derived neurite 
outgrowth inhibitory factors such as Nogo-A, myelin-associated glycoprotein (MAG) 
(Niederost et al., 2002) and lysophosphatidic acid (LPA) (Sayas et al., 2002). More 
recent findings reveal that RhoA mediates neurite outgrowth inhibition by the 
reorganization of actin and microtubular network (Dickson, 2001; Leung et al., 2002). 
Consistent with these findings is that GDNF and NTN increase the active form of 
RhoA in GFRα2b but not in GFRα2a or GFRα2c transfectants. The Clostridium 
botulinum C3 exoenzyme specifically ADP-ribosylates and inactivates Rho, thus 
increasing neurite outgrowths in GFRα2a/GFRα2b and GFRα2c/GFRα2b co-
expression models. Furthermore, expression of RhoA dominant negative mutant 
abolished the inhibitory activity of ligand induced GFRα2b. It is interesting to note 
that GDNF induced RET mediated phosphorylation of focal adhesion kinase, paxillin 
and p130C through the activation of Rho family of GTPase and inhibited the 
outgrowth of neurites in TGW-I-nu cells (Murakami et al., 1999). It is however, 
unclear if this observation was due to the activation of GFRα2b or similar isoform/s 
(GFRα1b, see Chapter 6).  
The mechanism underlying the neurite outgrowth inhibitory activity of GFRα2b 
appears to differ in detail from that of LPA system. Both RhoA and ROCK are known 
to be involved in LPA induced inhibitory activities. Using these inhibitors, RhoA but 
not ROCK, was involved in the neurite inhibitory effect of GFRα2b. LPA but not the 
activation of GFRα2b, was capable of inducing neurite retraction in Neuro2A cells. 
Furthermore, the temporal profile and intensity of cofilin phosphorylation was also 
different between those activated by LPA, and those activated by GFRα2b. The 
Chapter 5                                                                    Part III: Inhbitory activities of GFRα2b isoforms 
 
 80
downstream effector(s) for RhoA underlying the mechanism of GFRα2b inhibition of 
neurite outgrowth remains unclear. 
When compared to GFRα2a, both GFRα2b and GFRα2c show deletion of eight 
cysteine residues and N-glycosylation sites at the N-terminus (Wong and Too, 1998). 
GFR is thought to be structurally organized into three distinct domains. The N-
terminal domain has previously been shown to be dispensable for ligands binding 
specificity and RET phosphorylation of GFRα receptors (Scott and Ibanez, 2001). 
Extending this observation, the N-terminal domain encoding the unique sequences of 
GFRα2a, GFRα2b and GFRα2c may serve to regulate distinct biochemical and 
cellular processes. It is tempting to speculate that the expression and interaction of 
specific GFRα2 receptor spliced isoforms may play an important role in neuronal 
differentiation involving GDNF and NTN. Recent observations where the expressions 
of GFRα2 isoforms are differentially regulated in Nurr1 induced dopaminergic 
differentiation of embryonic stem cells are consistent with this suggestion (Sonntag et 
al., 2004).  
In conclusion, the activation of RhoA and the deactivation of cofilin provide a 
consistent and convincing evidence for the existence of specific mechanisms 
underlying the ligand dependent inhibition of neurite outgrowth through GFRα2b. 
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6.1 Background and objectives 
 
GFRα1a and GFRα2a are closely related, with 48 % amino acid identity. Both 
receptors share nearly complete conservation of cysteine residues, suggesting similar 
three-dimensional structures and possibly similar biological functions (Jing et al., 
1997). GFRα1 is organized into 11 exons (1234 bp) and is alternatively spliced to 
produce at least two isoforms, namely the GFRα1a and GFRα1b (Dey et al., 1998; 
Shefelbine et al., 1998). These 2 isoforms are highly homologous, with a difference of 
only 5 amino acids (140DVFQQ144) in exon 5, which is not present in GFRα1b. 
Both isoforms are co-expressed at significant levels in the central and peripheral 
nervous system and have distinct biochemical activities (Charlet-Berguerand et al., 
2004; Yoong et al., 2005). However, it is unknown if the activation of these isoforms 
result in differential morphological changes. 
GDNF and NTN have previously been shown to regulate neurite outgrowths 
in various neuronal systems where GFRα1 and GFRα2 isoforms are often co-
expressed (Golden et al., 1998; Golden et al., 1999; Hishiki et al., 1998). GFRα1a has 
been shown to induce neurite outgrowths in PC12 cells (Chen et al., 2001; Wang et 
al., 2004). It is unclear if specific GFRα1 isoforms contributes to morphological 
changes similar to that found with the GFRα2 isoforms (Chapter 5, 6).  
In this section of the work, biochemical and morphological effects of ligand 
induced GFRα1 isoforms were investigated using Neuro2A cell model as described 
previously (Chapter 4, 5). Distinct neuritogenic activities between GFRα1 isoforms 
were observed.  GFRα1a but not GFRα1b mediated ligand induced neurite outgrowth. 
Furthermore, GFRα1b mediated attenuation of neurite outgrowth of GFRα1a in a 
RhoA-ROCK dependent manner.  
 




6.2.1 Ligand activated GFRα1 isoforms mediated different early 
response genes 
 
Neuro2A transfectants stably expressing GFRα1a or GFRα1b were generated 
similarly to that described in the GFRα2 studies (Chapter 5). In an effort to further 
understand the physiological functions of these isoforms, changes in the expression of 
the immediate early response genes (fos family (c-fos, fosB), jun family (c-jun, jun-b), 
egr family (egr-1 to egr-4) and GDNF inducible transcription factors mGIF and 
mGZF1) were investigated in response to GDNF and NTN. When stimulated with 
either ligand, GFRα1a and GFRα1b differentially regulated some of these early 
response genes over the period of 3 h of ligand stimulation (Fig. 6.1). The expressions 
of egr-1, egr-2, c-fos and fosB, were up-regulated when GFRα1a was stimulated with 
GDNF (Fig.6.1A). NTN was found to up-regulate egr-1 expression over a period of 
180 min, and transiently up-regulated the expression of egr-2 and fosB (Fig. 6.1B). 
Except for a low but significant up-regulation of egr-2 (2.5 fold), no obvious changes 
in the expression of the immediate early response genes were observed when GFRα1b 
was stimulated by GDNF (Fig. 6.1C). NTN was found to significantly up-regulate 
egr-2 gene expression over a period of 180 minutes, and transiently up-regulated egr-
1 (Fig. 6.1D). These results showed that the activation of GFRα1 isoforms results in 
the distinct transcription of specific sets of early response genes.  









Figure 6.1. GDNF and NTN regulated different early response genes in GFRα1a 
and GFRα1b expressing cells. Neuro2A cells stably expressing GFRα1a or GFRα1b 
were seeded sub-confluent on 10% FBS media overnight, and were then serum-
deprived with 0.5% FBS media for another night. Cells were then stimulated with 
GDNF (50 ng/ml) or NTN (50 ng/ml), for time period as indicated. Fold change of 
mRNA expressions of early response genes in Neuro2A cells expressing GFRα1a 
stimulated with GDNF (A) or NTN (B), or cells expressing GFRα1b stimulated with 
GDNF (C) or NTN (D) were measured by quantitative real time PCR. Similar results 
were repeated in four individual experiments. Error bars indicate standard deviations 
of triplicate measurements. Significant differences in expression of genes between 
ligand stimulated and control samples were calculated using paired Students t-test. A 
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6.2.2 GFRα1a but not GFRα1b induced MAPK dependent-neurite 
outgrowth upon ligand stimulations 
 
Using Neuro2A cells stably expressing GFRα1a or GFRα1b, neuritogenesis 
mediated by GDNF and NTN was investigated. Startling differences in neurite 
outgrowth mediated by GFRα1 isoforms were observed. GFRα1a but not GFRα1b 
induced neurite outgrowth when stimulated with ligand (Fig. 6.2). GDNF or NTN 
stimulated GFRα1a expressing cells to extend neurites with at least twice the body 
length and the number of cells bearing neurites was about 30%, comparable to that 
induced by retinoic acid (Fig. 6.2). In contrast, when stimulated with ligands, cells 
expressing GFRα1b remained round in shape and looked similar to naïve neuroblast 
in morphology (Fig. 6.2A). Retinoic acid was used as a positive control for inducing 
neurite extension and transfectants with either, GFRα1a or GFRα1b, showed similar 
extent of neurite outgrowths. This is indicative of the similar neurite outgrowth 
capabilities of these cells.   
The activation of ERK1/2 in both GFRα1 isoforms when treated with GDNF 
and NTN has previously been shown (Yoong et al., 2005). Here, it is further 
demonstrated that ligand induced neurite extension of GFRα1a cells is MAPK 
dependent, as this morphological change was sensitive to the MAPK inhibitor, U0126 
(Fig. 6.2B). The concentration of U0126 (5 µM) had no significant effect on the 
survival of Neuro2A transfectant (data not shown).   












Figure 6.2. GFRα1 isoforms mediated distinct neuritogenic activities. Neuro2A 
cells stably expressing GFRα1a or GFRα1b were treated in 0.5% serum media, with 
or without GDNF or NTN (50 ng/ml) for three days. Retinoic acid (RA) (5 µM) was 
used as a positive control to differentiate cells. A, Digital phase contrast images  
(magnification x200) of Neuro2A cells stably expressing GFRα1a or GFRα1b, 
treated for three days with RA, GDNF or NTN. B, Percentages of cells bearing 
neurite were counted for cells bearing neurite twice longer than cells bodies. Effects 
of MEK1/2 inhibitor, U0126 (5 µM) on GDNF and NTN induced neurite outgrowth 
were also investigated. Experiments have been repeated twice in three individual 
clones, with similar results. Significant differences in percentage of cells bearing 
neurite between ligand stimulated and control samples were calculated using paired 
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To further understand the morphological changes of ligand activated GFRα1 
isoforms, the distribution of two neuronal-cytoskeletal components in the 
differentiated Neuro2A transfectants were investigated. When treated with GDNF (or 
NTN), Neuro2A cells stably expressing GFRα1a extended long, axonal neurites, 
which were doubly-stained for NF-H and F-Actin (Fig. 6.3). At the extremities of the 
neurites are growth cones that were stained positive for F-Actin. Stimulation with 
either GDNF or NTN did not induce significant neurite extension in GFRα1 cells and 
F-Actin staining at the peripheral of cells was obvious (Fig. 6.3). These results further 













Figure 6.3. Confocal images for double staining of heavy chain neurofilament 
(NH-F) and F-Actin in GFRα1a or GFRα1b treated with GDNF. Neuro2A cells 
stably expressing GFRα1a or GFRα1b seeded on chamber slides were treated with 
GDNF (50 ng/ml) for three days. Cells were then fixed with paraformaldehyde and 
double-stained for NF-H (green) and F-actin (red). In GFRα1a cells, double 
immunostaining reveals the co-localization (yellow) of cytoskeletal components, NF-
H and F-Actin, along the neurites, while only F-Actin was stained at the growth cones 
(arrow). In GFRα1b cells, F-Actin stained the peripheral of cells, with no neurite 
extension observed. Scale bars, 20 µm.  
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6.2.3 GFRα1b inhibited ligand induced neuritogenic activities of 
GFRα1a in a RhoA-ROCK dependent mechanism 
 
The lack of morphological changes when GFRα1b was stimulated by ligands 
may have two possibilities. One is that ligand activated GFRα1b is NOT involved in 
the process of neurite extension, or, that GFRα1b may act similarly to GFRα2b, 
actively inhibiting some stimuli induced neurite outgrowths (Chapter 5).  
In order to test the hypothesis that GFRα1b may inhibit the process of neurite 
extension by ligand activated GFRα1a, both receptor isoforms were co-expressed in 
Neuro2A cells. Using pIRES bi-cistronic system, GFRα1b was expressed in the 5’ 
multiple cloning site (MCS) A while GFRα1a was expressed in 3’ cloning site (MCS-
B). Interestingly, no neurite extension was observed in the GFRα1b and GFRα1a co-
expressing cells upon ligand stimulations (Fig. 6.4A). As controls, clones with 
GFRα1a expressed in MCS-B alone or GFRα1b expressed in MCS-A alone were 
generated (Fig. 6.4B). When stimulated with ligands, these control clones showed 
morphological changes (Fig. 6.4) recapitulating the changes observed with the pIRES-
neo system (Fig. 6.2). With all the transfectants, retinoic acid induced neurite 
outgrowths, indicative of the capabilities of these cells to extend neurites (Fig. 6.4B).  
GDNF or NTN inhibited neurite extension in cells co-expressing GFRα1a and 
GFRα1b (Fig. 6.4). These observations are consistent with the idea that the activation 
of GFRα1b antagonizes ligands induced neuritogenic activities of GFRα1a.  
 







Figure 6.4. GFRα1b attenuated ligand induced neurite outgrowth in GFRα1a 
when co-expressed. A, Digital phase contrast images (magnification x200) of 
Neuro2A cells stably co-expressing GFRα1a with GFRα1b (GFRα1a + GFRα1b), 
treated with 0.5% FBS media with or without 5 µM retinoic acid (RA), GDNF or 
NTN (50 ng/ml). B, Differentiation profiles of cells stably expressing GFRα1a 
(expressed at 5’ multiple cloning site, MCS-A), GFRα1b (expressed at 3’ multiple 
cloning site, MCS-B), GFRα1a with GFRα1b, or bi-cistronic vector control (pIRES). 
Percentages of cells bearing neurite were counted for cells bearing neurite twice 
longer than cells bodies. Experiments were repeated twice in two individual clones, 
with similar results. Significant differences in percentage of cells bearing neurites 
between ligand stimulated and control samples were calculated using paired Students 
t-test (*P<0.002). 
 
In the previous study, GFRα2b was found to inhibit neurite extension by the 
RhoGTPase mechanism (Chapter 5). It is possible that GFRα1b may also regulate the 
process of neurite outgrowth inhibition by a similar mechanism. The role of 
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RhoGTPases in GFRα1b inhibitory activities was investigated using a Rho antagonist, 
exoenzyme C3 transferase. As shown in Fig. 6.5, significant neurite extension was 
observed in GFRα1b and GFRα1a co-expressing cells when exoenzyme C3 
transferase was added along with GDNF ligands. These results indicate that GFRα1b 
inhibition on ligand induced neurite outgrowths of GFRα1a is abolished in the 
presence of C3 transferase, suggesting that the inhibitory activity of GFRα1b is Rho 
dependent. Using a ROCK inhibitor, Y27632, the extent of neurite outgrowth in 
GFRα1 isoforms co-expressing cells was increased. These suggest that ROCK, a 
downstream effector of RhoA, may also be involved in the neurite outgrowth 
inhibitory effects of GFRα1b.  
 
 
Figure 6.5. GFRα1b attenuated ligand induced neurite outgrowth of GFRα1a, in 
a Rho-ROCK dependent mechanism. Effects of Rho antagonist, exoenzyme C3 
transferase (1 µg/ml) and ROCK inhibitor, Y27632 (10 µM) on GFRα1b attenuation 
of ligand induced neurite outgrowth of GFRα1a. Neuro2A cells stably co-expressing 
GFRα1a with GFRα1b were stimulated with retinoic acid (RA), GDNF, or NTN, with 
or without exoenzyme C3 transferase or Y27632. Percentages of cells bearing neurite 
were counted for cells bearing neurite twice longer than cells bodies. Experiments 
were repeated twice in two individual clones, with similar results. Significant 
differences in percentage of cells bearing neurites between ligand stimulated and 
control samples were calculated using paired Students t-test (*P<0.05, **P<0.002). 
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To further confirm the involvement of RhoA in GFRα1b inhibitory activities, 
the effect of RhoA dominant negative mutant (RhoA-DN) was investigated next (Fig. 









Figure 6.6. RhoA dominant negative mutant prevented inhibitory effects of 
GFRα1b. A, GFRα1a and GFRα1b co-expressing cells transfected with HA-tagged 
RhoA dominant negative mutant (RhoA-DN) were differentiated with RA in the 
presence of GDNF. Cells were stained with beta III tubulin (green) and anti-HA (red). 
Cells double-stained with beta III tubulin and HA-RhoA-DN showed positive for 
neurite outgrowth (arrow head). (magnification x200) B, Cells count for neurite 
outgrowth mediated by GFRα1a and GFRα1b co-expressing cells treated with or 
without RhoA DN. Significant differences in percentage of cells bearing neurites were 
calculated between ligand stimulated and control samples, using paired Students t-test 
(**P≤0.01). 
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Expression of RhoA-DN in GFRα1b cells resulted in the increase of the 
percentage of cells bearing neurite when stimulated with either GDNF or NTN (Fig. 
6.6B). Neurite outgrowths were observed in cells stained positive for HA-tagged 
RhoA-DN and for beta III tubulin (Fig. 6.6A). These results further indicate the 
involvement and importance of RhoA in the inhibitory activities of GFRα1b.  
The combinatory effects of GDNF or NTN and retinoic acid on neurite 
extension in GFRα1a or GFRα1b expressing cells was further examined. Extensive 
neurite extension was observed in retinoic acid treated GFRα1a and GFRα1b 
expressing cells even in the presence of either GDNF or NTN (Fig. 6.7A, B). Thus,  
GFRα1b did not inhibit retinoic acid induced neurite outgrowth.  
 





Figure 6.7. Combinatory effect of retinoic acid and GDNF ligands on 
neuritogenic activities of GFRα1 isoforms. Neuro2A cells stably expressing 
GFRα1a or GFRα1b were treated with 0.5% FBS media with or without 5 µM 
Retinoic Acid (RA), or a combination of RA with GDNF or NTN (50 ng/ml). A, 
Digital phase contrast images (magnification x200) of Neuro2A cells stably 
expressing GFRα1a or GFRα1b, treated with RA, or RA in combination with GDNF 
or NTN.  B, Percentages of cells bearing neurite were counted for cells bearing 
neurite twice longer than cells bodies. Experiments were repeated twice in three 
separate clones, with similar results. Significant differences in percentage of cells 
bearing neurite between ligand stimulated and control samples were calculated using 
paired Students t-test (*P<0.002). 
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6.2.4 Differential regulation of GFRα1 and Ret isoforms expression 
in retinoic acid differentiation of mouse embryonic stem cells 
 
As GFRα1b can regulate the neuritogenic activity of GFRα1a, the expressions 
of these isoforms may be differentially regulated in neurodevelopment. To gain an 
insight into this possibility, we examined the expression profiles of these GFRα1 and 
Ret isoforms in neuronal differentiation of mouse embryonic stem cells (mESC) using 
retinoic acid  (Bain et al., 1995; Bibel et al., 2004). Briefly, embryoid bodies, 
containing neural precursors, were generated by culturing mESC in serum reduced 
media supplemented with leukemia inducing factor (LIF) for four days, and exposure 
to retinoic acid for a further four days. Neuronal precursor cells obtained using this 
induction strategy have been characterized and some neurotrophic factor receptors, 
including the GFRα1 and Ret were shown to be up-regulated (Lee et al., 2005a). 
However, the expression profile of the receptor isoforms was not characterized. To 
extend the findings, the expression profiles of GFRα1, GFRα2 and Ret isoforms in the 
neuronal precursor cells were quantified, using 2 different mESC cell lines, the AB2.2 
and E14 cells. 
As shown in Fig. 6.8A, both expressions of GFRα1a and GFRα1b increased  
after retinoic acid induction (x-axis labeled as EB4-4+RA), with the expression level 
of GFRα1a higher than that of GFRα1b. Expression of GFRα1a increased by 
34.5±1.24 folds in AB2.2 cells, and 22.0±1.78 folds in E14 cells, after retinoic acid 
induction. On the other hand, expression of GFRα1b also increased by 24±1.03 folds 
and 30±2.13 folds in AB2.2 and E14 cells, respectively. However, the expression 
levels of GFRα1a were about six times higher than that of GFRα1b in these neuronal 
precursor cells derived from AB2.2 and E14 cells.  
Ret9 was the dominant isoform expressed in non-differentiated mESC cells. 
The expression of Ret 9 was about 17 and 5 times higher than Ret51 in non-
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differentiated AB2.2 and E14 mESC cells, respectively (Fig. 6.8B). However, the 
expression of Ret51 was significantly up-regulated in retinoic acid-induced neuronal 
precursor cells and was the dominant isoforms expressed (Fig. 6.8B). The expression 
of Ret 51 increased 34±2.31 fold in AB2.2, and 45±2.19 fold in E14 cells after 
retinoic acid induction. The expression of Ret9 isoform did not change significantly 
on induction of neuronal differentiation in both AB2.2 and E14 cells (Fig. 6.8B). On 
the other hand, expressions of the GFRα2 isoforms remained low before or after the 
retinoic acid induced neuronal differentiation of mESC (data not shown). These 
findings indicate that GFRα1 and Ret isoforms are differentially regulated in neuronal 
differentiation of mESC. GFRα1a and Ret51 are the major isoforms expressed in 
neuronal precursor cells induced from mESC, suggesting their potential role in the 
















Figure 6.8. Differential regulation of GFRα1 and Ret isoforms gene expression in 
retinoic acid induced neuronal differentiation of mouse embryonic stem cells. 
Neuronal precursors of AB2.2 and E14 cells were induced from embryoid bodies 
using the 4-4+ retinoic acid method. Briefly, embryoid bodies were induced by 
plating mouse embryonic stem cells, AB2.2 and E14 on non-adherent Petri dish in 
10% FBS media (without LIF) for four days and later supplemented with retinoic acid 
(5 µM) for subsequent four days. Expressions of GFRα1 (A) and Ret (B) isoforms in 
control and retinoic acid differentiated (EB4-4+RA) mouse embryonic stem cells 
were measured by quantitative real time PCR. Error bars indicate standard deviation 
of 3 measurements. Similar results were repeated in four experiments. Significant 
differences between expressions of isoforms were calculated using paired Students t-
test. A value of P<0.05 is considered significant (*P<0.05, **P<0.01).  





This study provides the first evidence of the distinct neuritogenic activities of 
GFRα1 isoforms and the novel inhibitory activity of GFRα1b isoform in antagonizing 
neurite outgrowth mediated by ligand activated GFRα1a.   
GFRα1 isoforms regulate the expression of distinct immediate early response 
genes when stimulated by either GDNF or NTN. This observation extends the 
previously  reported distinct biochemical activities and gene expression profiles of 
activated GFRα1 isoforms  (Charlet-Berguerand et al., 2004; Yoong et al., 2005). 
GFRα1a regulated egr-1, egr-2, c-fos and fosB when stimulated by GDNF, but egr-1 
is  only up-regulated when stimulated with NTN. In contrast, GFRα1b only regulated 
egr-2 when stimulated by either GDNF or NTN.  
The activation of egr-1 when neuronal cells are differentiated by NGF is well 
documented (Harada et al., 2001; Levkovitz et al., 2001; Milbrandt, 1987; Sukhatme 
et al., 1988). egr-1 is now thought to activate cdk5 and phosphorylate PP1, both are 
downstream effectors essential for neuronal differentiation (Li et al., 2007). The 
increase of egr-1 by ligand stimulated GFRα1a and the increase in neurite outgrowth 
are consistent with the above observations. Interestingly, egr-2 but not egr-1 is 
activated when GFRα1b is stimulated with either GDNF or NTN. The role of egr-2 in 
regulating neuronal morphologies is currently unknown. 
When co-expressed, GFRα1b inhibited ligands induced neurite outgrowth 
mediated by GFRα1a. The inhibitor studies suggest the involvement of Rho and 
ROCK pathway in the ligands mediated inhibitory activities of GFRα1b. The 
involvement of RhoA in the inhibitory activity of GFRα1b was further confirmed in 
this study by using a dominant negative mutant of RhoA. These findings are 
consistent with a neurite outgrowth inhibitory role of GFRα1b.  
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This study raised new insights into the existence of a common self-regulatory 
mechanism in the signaling and neuritogenic activities in GFRα1 and GFRα2.  With 
both receptors, particular splice variants can inhibit the others in inducing neurite 
outgrowths.  However, there are indications that the inhibitory activities and 
mechanisms of GFRα1b differ from that of GFRα2b. Firstly, ligand activated 
GFRα2b but not GFRα1b, can inhibit retinoic acid (a non-GFR stimuli) induced 
neurite outgrowth. Secondly, the data suggest that the inhibitory activities of GFRα2b 
may involve RhoA, but not its downstream kinase effector, ROCK. In contrast, the 
GFRα1b inhibitory activities appear to involve both RhoA and ROCK. Both GFRα1 
and GFRα2 transduce downstream signaling via recruitment and activation of the 
tyrosine kinase co-receptor, c-Ret. Understanding the specificity of GFRα1b and 
GFRα2b in activating different tyrosine residues of c-Ret (Plaza-Menacho et al., 2006) 
may provide clues to the downstream mechanisms involved in their inhibitory 
activities.  
 It has previously been shown that expressions of GFRα1 and Ret are up-
regulated during the neuronal differentiation of mESC (Lee et al., 2005a). However, 
the expression levels of the specific isoforms were unknown. In this study, the 
expression levels of the spliced variants of GFRα1 and Ret were accurately quantified 
by real-time PCR. The high expression of GFRα1a but not GFRα1b in retinoic acid 
differentiated mESC suggests a possible role of GFRα1a in regulating neuronal 
differentiation. The dominant isoform of Ret expressed in mESC changed from Ret9 
in naïve mESC to Ret51 in retinoic acid differentiated mESC. Mutagenesis study has 
shown that Ret9 but not Ret51 is vital for the development of kidney and enteric 
nervous system, and that the Ret51-deficient mouse is both viable and normal (de 
Graaff et al., 2001). While the functions of Ret in kidney formation and development 
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are just beginning to be elucidated, the mechanisms and role/s of Ret isoforms in 
neuronal development is presently unclear.  
 The existence of multiple isoforms is common in GDNF family receptors. 
Alternatively spliced isoforms have been reported in GFRα1, GFRα2, and GFRα4 
(see Literature Reviews, Chapter 2). These studies have shown that the truncated 
isoforms of GFRα1 (GFRα1b) and GFRα2 (GFRα2b) exert similar yet distinct 
inhibitory and anti-neuritogenic effects. The current results suggest that alternative 
splicing may be a common mechanism by which GFRα genes generate isoforms with 
opposing neuritogenic activities. Further studies are warranted to understand the 
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7.1 Background and objectives 
 
Neurite outgrowth is a complex differentiation process stimulated by many 
neuronal growth factors, transmitters, electrical activity and influenced by the 
extracellular cues. The outgrowth process is critically dependent on signaling which 
reorganizes the actin cytoskeleton by regulation of many actin-interacting proteins 
functioning downstream of Rho-family GTPases (Zhou and Cohan, 2004). In 
addition, de novo synthesis of numerous proteins is known to occur during neuronal 
differentiation  (da Silva and Dotti, 2002; Gallo and Letourneau, 2004; Tojima and 
Ito, 2004). Extending the search for biomolecules involved in neurite outgrowths, a 
large-scale RNAi screen identified  more than 100 genes to be involved in synapse 
structure and function (Sieburth et al., 2005) and a microscopy-based approach has 
identified  several novel proteins involved in the neurite outgrowth process (Laketa et 
al., 2007). Much is still to learn about the precise and tight control of genes and 
proteins involved in the temporal events in neurite outgrowths. 
Ligand activated GFRα2a and GFRα2c induce neurite outgrowths in Neuro2A 
cells (Chapter 4). GFRα2c lacks the exon 2 and 3, generating a protein with deletion 
of 132 amino acids, as compared to the full-length receptor isoforms, GFRα2a. 
Despite the vast differences in N-terminal structure, both GFRα2a and GFRα2c 
isoforms induced neurite outgrowths in a ligand dependent manner. However, there 
are significant differences in AKT signaling and the regulation of the expressions of 
some immediate early response genes, thus, indicating that GFRα2a and GFRα2c may 
utilize distinct mechanism/s in mediating ligand induced neurite outgrowths (Chapter 
4).  In this study, we examine the process of neurite outgrowths induced by these two 
receptor isoforms in greater detail.  
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  In this chapter, effects of kinase inhibitors on ligand activated neurite 
outgrowth in GFRα2a and GFRα2c transfected were investigated. We further compare 
the effects of ligands withdrawal in neurite outgrowth mediated by these two GFRα2 
isoforms. Expressions of various neuronal markers in ligand induced neurite 












7.2.1 Ligand activated GFRα2a and GFRα2c mediated neurite 
outgrowths via distinct signaling pathways  
 
 We first explored the involvements of various signaling kinases in neurite 
outgrowths in GFRα2a and GFRα2c cells by using selective inhibitors. The 
differential effects of kinase inhibitor on ligand induced neurite outgrowth in GFRα2a 
and GFRα2c cells are shown in Fig. 7.1. The Src inhibitor, PP2 (2 µM) attenuated 
ligand induced neurite outgrowths in both GFRα2a and GFRα2c cells (Fig. 7.1A). On 
the other hand, MEK1/2 inhibitor, U0126 (5 µM) attenuated ligand induced neurite 
outgrowths in GFRα2a cells, but not in GFRα2c cells (Fig. 7.1B). A PLCγ inhibitor, 
U73122 (0.1 µM) also exhibited similar effects, where it only attenuated ligand 
induced neurite outgrowth in GFRα2a cells, but not in GFRα2c cells (Fig. 7.1C). The 
concentrations of kinase inhibitors used in the studies have no significant effects on 
cells viability (data not shown). These results indicate that different signaling 
mechanisms are involved in ligand induced neurite outgrowth of GFRα2a and 
GFRα2c.  
Other inhibitors, SB 203580 (p38 inhibitor) and LY 294002 (PI3 kinase 
inhibitor) had no effect on ligand induced neurite outgrowth by GFRα2 isoforms (data 
not shown).  
Both GFRα2a and GFRα2c have been shown to mediate MAPK activations in 
Neuro2A cells (Fig. 4.5, Fig. 4.6). The effects of these kinase inhibitors on ligand 
induced MAPK activations in GFRα2a and GFRα2c cells were further elucidated. The 
dose effects of different kinase inhibitors on phosphorylations of ERK1/2 were shown 
in Fig. 7.2. Src kinase inhibitor, PP2 (1, 2, and 10 µM) prevented phosphorylation of 
ERK1/2 in both ligand induced GFRα2a and GFRα2c cells (Fig. 7.1A). PP3, an 
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inactive analog of PP2, showed no effect on ERK1/2 activations (Fig. 7.1A). These 
data suggest that Src is an upstream effector in ligand induced MAPK signaling of 
GFRα2a and GFRα2c receptor isoforms.  
 MEK1/2 inhibitor, U0126 (1, 5, and 10 µM), inhibited ligand induced ERK1/2 
phosphorylations in both GFRα2a and GFRα2c cells. It is worthy to note that while 
U0126 inhibited ERK1/2 activation in GFRα2c (Fig. 7.2B), it did not affect ligand 
induced neurite outgrowth of GFRα2c cells (Fig. 7.1B). These results indicated that 
Src, but not ERK1/2, is necessary for ligand induced neurite outgrowth in GFRα2c 
cells. 
 The PLCγ inhibitor, U73122 (0.05 to 1 µM), showed a dose dependent 
inhibitory effect on ERK1/2 phosphorylation. Low dose of U73122 (0.1 µM) was 
used in the neurite outgrowth studies (Fig. 7.1C), as the higher doses (0.5 and 1 µM) 
significantly affected cells viability. U73122 at 0.1 µM strongly inhibited the ligand 
induced neurite outgrowth in GFRα2a cells. The same concentration of U73122 did 
not completely abolish EKR1/2 phosphorylation. This is indicative of the involvement 
of PLCγ signaling in the outgrowth process and may not involve the activation of 
ERK1/2.  
 In conclusion, the results showed that the signaling mechanisms involved in 
the neurite outgrowths of ligand activated GFRα2a and GFRα2c are sufficiently 
different.  
 






Figure 7.1. Effects of kinase inhibitors on ligand induced neurite outgrowth in 
GFRα2a or GFRα2c transfected Neuro2A cells. Neuro2A cells expressing GFRα2a 
or GFRα2c were treated with GDNF or NTN, with or without Src inhibitor PP2 (2 
µM) (A), MEK1/2 inhibitor U0126 (5 µM) (B), or PLCγ inhibitor U73122 (0.1 µM) 
(C). After three days in culture, percentages of cells bearing neurite of at least twice 
the length of the cell bodies were scored. Similar results were obtained from two 
individual clones and the experiment was repeated at least twice. Significant 
differences between ligand stimulated and control samples were calculated using 
paired Students t-test. A value of P<0.05 was considered significant (*P<0.02). 
 





Figure 7.2. Effects of kinase inhibitors on ERK1/2 activation in GFRα2a and 
GFRα2c cells. Western blots of GFRα2a and GFRα2c cells treated with GDNF or 
NTN (50 ng/ml) for 10 minutes, with or without Src inhibitor PP2 (A), MEK1/2 
inhibitor U0126 (B), or PLCγ inhibitor U73122 (C), at concentrations as indicated. 
Cells were treated for respective inhibitors for 20 minutes prior to treatment of ligands. 
In Src inhibitor studies, effects of PP3, an inactive homolog of PP2, were also 
investigated. After immunoblotted for Phospho-ERK1/2 (pERK1/2), blots were 
stripped and reprobed for Actin as loading control. Similar results were obtained from 
two individual clones and the experiment was repeated at least twice. 
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7.2.2 Withdrawals of ligands produced different effects on neurite 
outgrowth mediated by GFRα2a and GFRα2c receptor isoforms 
 
 All previous neurite outgrowth experiments were studied by treating cells with 
stimuli for three continuous days in culture. To gain a further insight into the 
mechanism involved in ligand induced neurite outgrowth in GFRα2 isoforms, the 
effects of ligand withdrawal at the early time points were closely examined.  
 The effect of retinoic acid withdrawal in differentiation of naive or pIRES 
transfected Neuro2A cells was first investigated. Cells were either exposed to retinoic 
acid continuously for 48 h or for only 10, 30 or 60 min. Significant number of 
differentiated cells was observed when retinoic acid was present throughout the 48 h 
(Fig. 7.3). However, no differentiation was observed with cells exposed to retinoic 
acid for only 10, 30 or 60 min (Fig. 7.3). These observations indicate that exposure to 
retinoic acid for an hour or less is insufficient to induce significant differentiation.  
 The effect of time of exposure to GDNF and NTN on neurite outgrowths of 
GFRα2a and GFRα2c cells were examined next. Neurite outgrowth was observed in 
GFRα2a cells exposed to GDNF or NTN for 30 min, 1 h and 48 h, but not with cells 
exposed to the ligands for only 10 minutes (Fig. 7.4A). In contrast, neurite outgrowths 
were observed with GFRα2c cells exposure to the ligands for 48 h but not those 
exposed for an hour or less (Fig. 7.4B). 
 In conclusion, GFRα2a can mediate neurite outgrowth when exposed to the 
ligand for as short a period as 30 min, while GFRα2c cells required the presence of 
ligands for longer than 1 hour. It is important to note that the expression levels of the 
receptors were comparable (Chapter 4). Taken together, GFRα2a and GFRα2c 
isoforms have different kinetic responses in the process of ligand induced neurite 
outgrowth.  





Figure 7.3.  Time of exposure of cells to retinoic acid and differentiation. 
Neuro2A cells were treated with 5 µM of retinoic acid (RA) for the time indicated. 
The media containing retinoic acid were then removed and replaced with 0.5% serum 
containing media. The cells were then incubated for 48 h. Significant level of 
differentiation was observed with cells exposed to RA continuously for 48 h.  but not 
when the cells were exposed to RA for 10, 30 min or 1 h. Differences in percentage of 
cells bearing neurite were calculated between ligand stimulated and control samples, 
using paired Students t-test (**P≤0.01). Similar results were repeated in three 
individual experiments. 
 





Figure 7.4. Study of ligands withdrawal effects on neurite outgrowth mediated 
by GFRα2 isoforms in Neuro2A transfectants. Cells were treated with ligand for 
the time indicated. The differentiation media was then removed, and replaced with 
only 0.5% serum media.  Neurite outgrowths of GFRα2a (A) and GFRα2c (B) cells 
when exposed to GDNF and NTN for varying periods of time. GDNF or NTN were 
either present throughout all 48 hours or for only 10, 30 min or 1 h. Differences in 
percentage of cells bearing neurites were calculated between ligand stimulated and 
control samples, using paired Students t-test (*P≤0.01). Similar results were obtained 
in two individual clones with replication of at least three individual experiments. 
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7.2.3 GFRα2a and GFRα2c share some similar neuronal markers 
upon ligand induced neurite outgrowth 
 
Collapsin response mediator proteins (CRMP) family comprises five 
cytoplasmic proteins that have previously been shown to mediate neuronal 
morphogenesis (Nishimura et al., 2003; Yuasa-Kawada et al., 2003) and are 
expressed predominantly in developing neuronal systems  (Fukada et al., 2000; Wang 
and Strittmatter, 1996). Although little is known about their precise roles, regulation 
of CRMP2 by GDNF has been reported (Kodama et al., 2004). However, regulation 
of other CRMPs family members by GDNF or NTN via GFRα2 receptor is not known. 
Using quantitative real time PCR, the regulation of CRMP1B, CRMP2A, CRMP2B, 
CRMP3, CRMP4 and CRMP5 gene expressions in ligand activated GFRα2a and 
GFRα2c transfectants were investigated.  
Increases in gene expressions of CRMP3 were observed in GDNF and NTN 
treated GFRα2a and GFRα2c cells (Fig. 7.5). When GFRα2a was stimulated with 
ligand, CRMP3 expression was up-regulated only at 24 h or later but not at 6 h (Fig. 
7.5A).  Different kinetics of CRMP3 expressions were observed in GFRα2c cells, 
where up-regulation of CRMP3 was observed as early as 6 h and persisted up to 48 h, 
with slighter lower level of expression (Fig. 7.5B). No significant change in 
expression was observed with the other CRMPs examined, at 6, 24 or 48 h (data not 
shown). These results showed that both GFRα2a and GFRα2c when stimulated by 
ligands, up-regulated the expression of CRMP3 with different kinetics. 





Figure 7.5.  Regulation of CRMP3 gene expression by GFRα2a and GFRα2c, in 
Neuro2a cells stably expressing these receptor isoforms. Regulation of neuronal 
marker gene, CRMP3 (A, B) was measured by quantitative real time PCR. Fold 
change of CRMP3 gene in GFRα2a (A) and GFRα2c (B) was measured at 6, 24, and 
48 hours after induction of differentiation. Fold change or expression was normalized 
to expression of respective gene of control at the 6 hour. Significant differences in 
expression of gene between ligand stimulated and control sample at the 6 hour were 
calculated using paired Students t-test. A value of P<0.05 was considered significant 
(*P<0.02). 
 
 Neuro2A cells served as a model to study the selection of cholinergic and 
GABAnergic cell lineages during differentiation (Manabe et al., 2005). It has been 
shown that retinoic acid induces cholinergic markers, while dbCAMP induces 
GABAergic marker in Neuro2A cells, indicating the potential of Neuro2A to adopt 
cholinergic and GABAnergic characteristics  (Manabe et al., 2005). Little is known 
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cholinergic and GABAergic marker in ligand activated GFRα2a and GFRα2c cells 
were thus investigated. 
 Gene expression of a cholinergic marker ChAT was measured at 6, 24 and 48 
h of GDNF or NTN treatment in GFRα2a and GFRα2c cells. Expression of ChAT 
was barely detected in non-induced GFRα2a and GFRα2c transfectants, and no 
significant up-regulation of ChAT expression was observed after ligand stimulation 
(data not shown).  
 The biosynthesis of the inhibitory neurotransmitter, GABA, is catalyzed by 
two isoforms of glutamate decarboxylase (GAD) proteins, namely GAD67 and GAD65, 
which are encoded by two distinct genes, GAD1 and GAD2 respectively. GFRα2a was 
found to up-regulate the expression of GAD1 (Fig. 7.6A), but did not affect the 
expression of GAD2 (data not shown). On the other hand, GFRα2c showed a different 
profile in regulating the expressions of these genes. GFRα2c down-regulated the 
expression of GAD2 (Fig. 7.6B) and did not affect GAD1 expression (data not shown). 
  Interestingly, these results indicate that GFRα2 isoforms may be involved in 
regulating cell fate and may prefer GABAergic over cholinergic lineage in Neuro2A.  
 





Figure 7.6.  Regulation of GAD1 and GAD2 expressions by ligand stimulated 
GFRα2a and GFRα2c. The expression of neuronal markers, GAD1 and GAD2, were 
measured by quantitative real time PCR. Fold change of GAD1 gene expression in 
GFRα2a (A) and GAD2 expression in GFRα2c (B) were measured at 6, 24, and 48 h 
after induction of differentiation. Up-regulation of GAD1 was detected in GFRα2a 
cells (A) while GFRα2c showed down-regulation of GAD2 (B). Fold change was 
determined by normalizing the expression of the gene at the designated time points 
with the respective control sample (unstimulated) at 6 hour. Significant differences in 
expression of genes between ligand stimulated and control sample at 6 hour were 

















 In this study, the biochemical and signaling differences in ligand induced 
neuritogenic activities of GFRα2a and GFRα2c were studied. While both GFRα2a and 
GFRα2c induced neurite outgrowths when stimulated with either GDNF or NTN, the 
underlying neuritogenic mechanisms do not appear to be identical. Studies using 
various kinase inhibitors revealed different signaling mechanisms to be involved in 
ligand induced neurite outgrowth of GFRα2a and GFRα2c. Furthermore, the kinetics 
of exposure to ligands required for neurite outgrowths provide further evidence for 
different signaling mechanisms used by GFRα2a and GFRα2c. While both GFRα2a 
and GFRα2c up-regulated the expression of CRMP3, the kinetics however differed 
substantially.  Finally, it has also been shown that GFRα2a and GFRα2c up-regulated 
GABAergic markers in Neuro2A cells differently. 
 A schematic diagram of the effects of various kinase inhibitors on neurite 
outgrowths is shown (Fig. 7.7), GFRα2a and GFRα2c utilize distinct signaling 
pathways in mediating neurite outgrowths. Src, ERK1/2 and PLCγ are intimately 
involved in neurite outgrowth mediated by GFRα2a and are likely to act cooperatively 
in neuritogenesis. Neurite outgrowth of GFRα2c was sensitive only to PP2 inhibitor 
and the inhibitor attenuated ERK1/2 signaling in GFRα2c cells. These observations 
suggest that neurite outgrowth in GFRα2c cells may be attributed to yet another 
signaling pathway, which is downstream of Src.  
GFRα2a was able to induce neurite outgrowth when exposed to the ligands for 
as short as 30 minutes while GFRα2c required the presence of ligand for longer than 
an hour, indicating different kinetics in the signaling mechanisms of these two 
receptor isoforms. This difference in kinetics is unlikely to be due to the differences in 
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the expression levels of the GFRα2 isoforms or the co-receptors, NCAM and RET, as 




Figure 7.7. Schematic diagram of signaling mechanisms involved in ligand 
induced neurite outgrowth of GFRα2a and GFRα2c receptor isoforms. A, 
GFRα2a mediated neurite outgrowth was blocked by PP2 (Src inhibitor), U0126 
(MEK1/2 inhibitor) and U73122 (PLCγ inhibitor). Activation of ERK1/2 by GFRα2a 
was attenuated by PP2 and U0126. B, Neurite outgrowth in GFRα2c was prevented 
by PP2 but not by U0126. PP2 inhibited ERK1/2 activations, but the inhibition of 
ERK1/2 did not prevent neurite outgrowth, suggesting that an alternate pathway 
downstream of Src may be responsible for GFRα2c induced neurite outgrowth.  
 
 GDNF has previously been reported to enhance the expression of CRMP2 in 
neuroblastoma cells (Kodama et al., 2004). However, it is unclear if specific GFRα1 
and GFRα2 isoforms contribute to the observation. Using Neuro2A stably expressing 
GFRα2a or GFRα2c isoform, the up-regulation of CRMP3 but not other CRMPs, by 
GDNF and NTN was unexpected. GFRα2a and GFRα2c have different kinetics in the 
regulation of CRMP3 expression, suggesting a difference in the underlying 
mechanisms.  
A. B.
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The tissue-selective expression of various CRMP family members in the adult 
nervous system suggest the possibility of distinct functions of CRMPs in addition to 
growth cone collapse (Schweitzer et al., 2005; Wang and Strittmatter, 1996). Recently, 
CRMP-3 was shown to be a direct target of calpain and the cleavage product 
functioned as a positive injury signal to cause neuronal death after cerebral ischemia 
and excitotoxicity (Hou et al., 2006). The result of the enhanced expressions of 
CRMP-3 in GFRα2a and GFRα2c cells when stimulated with ligand may contribute 
to the sculpturing of the growth cones and possibly controlling the life span of the 
differentiated cells, this is but a speculation awaiting exploration. 
 Cholinergic and GABAergic neurons are two major types of nerve cells found 
in the cereberal cortex. Neuro2A has been used as a neuronal model in the studies of 
cholinergic and GABAergic cell fate selection (Manabe et al., 2005). Ligand activated 
GFRα2a and GFRα2c regulated GABAergic but not cholinergic markers. More 
specifically, the transcripts of the two GABAergic markers, GAD1 and GAD2, were 
differentially regulated by the GFRα2 isoforms. GAD1 and GAD2 code for two 
isoforms of glutamate decarboxylase (GAD) proteins, GAD67 and GAD65, 
respectively. While GAD67 is distributed throughout the cytoplasm and in the cell 
bodies, GAD65 is highly enriched in axon terminals and associated with synaptic 
vesicles (Kaufman et al., 1991; Mackie et al., 2003; Martin and Rimvall, 1993). 
Moreover, knocking out GAD1 gene but not GAD2 in mice produced a major 
decrease in whole brain GABA (Asada et al., 1996; Asada et al., 1997; Kaufman et 
al., 1991; Mackie et al., 2003; Martin and Rimvall, 1993), leading to proposal that 
GAD67 and GAD65 have distinct roles in the GABAergic neuron. In this study, 
GFRα2a and GFRα2c differently regulated the gene expression of the two GAD 
isoforms, suggesting possible roles of GFRα2a and GFRα2c isoforms in the 
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development of GABAergic neuron.  It is interesting to note that GFRα2 isoforms are 
highly expressed in the human cortex (Chapter 4, Figure 4.3) and may thus be 
involved in the development of GABAergic nerve cells in the cortex.  
The differences in neuritogenic mechanism of GFRα2a and GFRα2c further 
substantiate the concept that GFRα2 receptor isoforms have different biochemical 



































































In this thesis the biochemical and morphological functions of GFRα1 and 
GFRα2 isoforms were investigated. It was found that these isoforms share some 
common properties and yet have distinct biochemical and neuritogenic functions. 
While GDNF and NTN induced neurite outgrowth through GFRα2a and GFRα2c, 
ligand activated GFRα2b was found to inhibit neurite extension in a RhoA-dependent 
manner. Such neuritogenic inhibitory activities of GFRα2b were also observed in the 
alternatively spliced GFRα1 isoform, GFRα1b. Thus, depending on the presence of 
specific GFRα isoforms, GDNF and NTN may regulate pro- or anti-neuritogenic 
activities. The cross-talks of different GFLs (GDNF and NTN) with the same receptor 
complex (GFRα2, RET and NCAM) was found to result in the activation of different 
miRNAs. Thus, the observations reported herein suggest that the interaction of GFLs 
and the receptor complex is more intricate than initially anticipated.  
The emerging view is that the combinatorial interactions of the spliced 
isoforms of GFRα, RET and NCAM complexes with the GFLs may contribute to the 
complexity and accounts for the myriad of biological responses observed.  
 
8.2 Future studies 
8.2.1 Mechanism of ligand activated anti-neuritogenic activities of 
GFRα2b 
 
Although the activation and involvement of RhoA in GFRα2b inhibitory 
activity have been demonstrated, the downstream mechanism/s of GFRα2b inhibition 
of neuritogenesis remains unresolved. It has been shown that the activation of RhoA-
ROCK pathway by LPA leads to phosphorylation and hence deactivation of cofilin, 
an adaptor protein involved in actin depolymerization. Such phosphorylation of 
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cofilin is mediated by LIM-kinase, which is activated by ROCK and is responsible for 
the growth cone collapse induced by neuritogenic inhibitory factors, such as LPA  
(Tojima and Ito, 2004). Although the rapid phosphorylation of cofilin by ligand 
activated GFRα2b has been shown (Fig. 5.10), a more detail analysis of the 
mechanism is required. The involvement of LIM-kinase in the phosphorylation of 
cofilin and the contribution to the neurite outgrowth inhibitory will be of interest.  
How the phosphorylation of cofilin affects the reorganization of cytoskeleton when 
GFRα2b is activated will provide further insight into the mechanism/s underlying 
neuritogenesis.   
 
8.2.2 Hetero-oligomerization of isoforms 
 
It is currently unknown if the spliced variants interact physically to form 
complexes. It has been suggested that the pairs of GFRα bind to dimerized GDNF 
ligands and subsequently recruit dimers of the Ret co-receptor to transducer 
intracellular signaling (Airaksinen and Saarma, 2002). The endogenous co-
expressions of the three GFRα2 isoforms in the human cortex and in BE(2)-C cells 
suggests the possibility that GFRα2 isoforms may be able to form oligomers in vivo. It 
is unknown currently, whether GFRα isoforms prefer to form heterodimers or 
homodimers when more that one receptor isoforms are present. The use of epitope 
tags of individual receptor isoforms will enable the determination of the formation of 
homo/heterodimer in the same cell.  Understanding the mechanism of oligomerization 
may facilitate the understanding of physical interactions of the spliced isoforms and 
shed light on physiological relevance.  
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8.2.3 Relative ratios of GFRα isoforms expression may affect 
functions   
 
The co-expression of GFRα2 isoforms was performed using the bicistronic pIRES 
vector by expressing GFRα2b in the proximal 3’ multiple cloning site (Chapters 4 - 6). 
It has been suggested that the translation may be less efficient in the 3’ multiple 
cloning site compared to that of the 5’ multiple cloning site of a bicistronic pIRES 
system (Hennecke et al., 2001). Hence, it is possible that the protein expression of 
GFRα2b (expressed by 3’ multiple cloning site) may be lower than that of GFRα2a or 
2c, which were expressed by 5’ multiple cloning site in the co-expression model used. 
Nevertheless, GFRα2b inhibited the neuritogenic activities of the other GFRα2 
isoforms. As the IRES is not regulatable, the amount of transgene expressed cannot be 
controlled and does not allow a closer study on the relative expressions of the 
isoforms in the same cells. Currently, the laboratory has generated retroviral vectors 
which allow co-infections and the possibility of selecting predetermined levels of 
expression of multiple transgenes (Liu et al., 2000). By differentially expressing at 
various levels, it should be interesting to examine the possibility that the relative 
ratios of GFRα isoforms may have diverse functions. 
 
8.2.4 RET activations and RET isoforms 
 
Alternative mRNA splicing of RET generates at least two isoforms named RET9 and 
RET51, with cytoplasmic domains containing 12 and 14 tyrosine residues 
respectively. These tyrosine residues are potential targets for trans-phosphorylation by 
the tyrosine kinase enzyme upon binding and activation to GFR-GFL complex. Four 
of the tyrosine residues have been identified as docking sites for various cytoplasmic 
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adaptor proteins, including Grb7/10 (Tyr905), PLCγ (Tyr1015), Shc/ENIGMA 
(Tyr1062) and Grb (Tyr1096), activating several messenger pathways including PLCγ, 
Jun-N-terminal kinase (JNK), phosphotidylinositol-3-kinase (PI3K) and Ras-MAPK 
kinase pathways (Mason, 2000; Murakumo et al., 2006). The cadherin-like domains 
in the extra cellular region of RET is crucial for the binding of GFRα-GFL complex 
(Kjaer and Ibanez, 2003). However, the domains or regions on GFRα2 involved in 
binding to RET remain unclear. It is not known whether truncated GFRα isoforms 
may differ from full-length isoforms in recruiting and interacting with RET receptors. 
It is tempting to speculate that different GFRα isoforms may preferentially recruit 
specific RET isoforms and differentially phosphorylate one or more RET tyrosine 
residues to transduce distinct intracellular signaling. Further investigation of the 
interaction between specific GFRα and RET isoforms would be of future interest.  
 
8.2.5 Method development for simultaneous expressions detection of 
GFRα receptor isoforms 
 
As GFRα2b and GFRα1b exert antagonistic activity on other GFRα receptor isoforms, 
it is important to identify their expressions in vivo in order to understand their 
physiological functions. The quantitative real time PCR developed in the current 
study allows the specific detection of GFRα2 isoforms in total RNA isolated from 
tissues samples. It is currently unknown if these receptor isoforms are co-expressed in 
the same cell population. Detection and visualization of the co-expression of the 
GFRα2 isoforms in tissues or brain regions of interests will facilitate the 
understanding of the physiological relevance of the combinatorial actions of these 
GFRα2 isoforms. As GFRα2b and GFRα2c have no unique sequence as compared to 
GFRα2a, the conventional methods of in situ hybridization or immunochemistry 
Chapter 8                                                                                                   Conclusions and future studies 
 
 123
cannot differentiate the isoforms expressions from each other. The concept of 
designing probes at the specific cross-over exon boundary of GFRα2 isoforms 
(primers designed for quantitative real time PCR, Chapter 4) may be employed in 
developing specific probe for in situ hybridization. With the availability of narrow-
band width fluorescent quantum dots, it will be possible to discriminate as many as 5 
or more targets simultaneously (Tholouli et al., 2006).  Differential tagging of these 
isoforms-specific probes may then allow the simultaneous detection of expression of 
GFRα2 isoforms.  
 
 
8.2.6 In vivo studies of GFRα splice isoforms 
 
The current study revealed the complexity of interactions between GDNF ligands and 
GFRα splice isoforms, using in vitro model. Future studies should extend the 
understanding of GFRα splice isoforms using in vivo models. Using Neuro2A model, 
we have revealed the molecular and signaling mechanisms of GFRα splice isoforms 
in regulation of neuritogenic functions. For future studies, the use of primary neurons 
may better elucidate the phenotypical and neuritogenic funcations of GFRα splice 
isoforms. Lastly, the role(s) of GFRα splice isoforms in developing nervous systems 
and maintainances of neuronal functions needed to be further understood using 
specific transgenic or gene targeting mouse model. However, one must consider the 
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A. Cells culture 
Cells culture 
Mice neuroblastoma, Neuro2A (ATCC No. CCL-131), and the human neuroblastoma, 
BE(2)-C (ATCC No. CRL-2268) were purchased from ATCC (Manassas, VA, USA). 
Cells were grown in 10% fetal bovine serum (FBS, Hyclone, Logan, UT, USA) at 
37°C in 5% CO2, as previously described. 
 
Generation of Neuro2A cells expressing GFRα1 or GFRα2 isoforms.  
The murine neuroblastoma cell line Neuro2A which expresses endogenous RET and 
NCAM was stably transfected with either murine GFRα2a, GFRα2b, GFRα2c, 
GFRα1a, GFRα1b or vector control, pIRESneo (Clontech, Palo Alto, CA, USA) 
using Fugene-6 (Roche Lifescience, Germany) and selected with 0.8 mg/ml of G418 
(Promega, Madison, WI, USA) over a period of two months. Primers used for 
measuring GFR isoforms, RET and NCAM expression are listed in Table 9.1, as 
previously described (Too, 2003; Yoong et al., 2005). 
For co-expression studies of GFRα2b with other GFR isoforms, GFRα2a, 
GFRα2c or GFRα1a were cloned into the proximal 5’ multiple cloning site (MCS-A), 
while GFRα2b was cloned into distill 3’ multiple cloning site (MCS-B) of the 
bicistronic pIRES vector (Clontech, Palo Alto, CA, USA). All studies were carried 
out with three independent clones.  
For co-expression studies of GFRα1b and GFRα1a, GFRα1b was cloned into 
MCS-A, while GFRα1a was cloned into MCS-B of the bicistronic pIRES vector 
(Clontech, Palo Alto, CA USA). For control, cells with only GFRα1b expressed in 
MCS-A or cells with only GFRα1a expressed in MCS-B were generated. 
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Table 9.1. List of primers used for amplification of mouse GFRα2, GFRα1 
isoforms, Ret, NCAM and GAPDH. 
 

































Ret  mRet51-2891F/ 
mRet51-2975R 















B. Ligands stimulations for kinases studies  
Ligands stimulation of cells 
BE(2)-C or Neuro2A cells were seeded in DMEM with 10% FBS for 24 hours, 
followed by serum depletion (0.5% FBS) for 16 hours. The cells were then treated 
with 50 ng/ml of recombinant human GDNF (Biosource, Camarillo, CA, USA) or 
recombinant human NTN (ProSpec-Tany TechnoGene Ltd, Israel) in serum free 





Phosphorylation of MAPK (ERK1/2) or Akt was analyzed as follows. Cells were 
initially seeded in DMEM with 10% FBS for 24 hours and the serum was then 
depleted (0.5% FBS) for 16 hours. The cells were then treated with 50 ng/ml of 
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GDNF or NTN in serum free media for different time courses at 37 °C. For dose 
response studies, cells were stimulated with different concentrations of ligands for 10 
minutes at 37 °C. Control treatment with 1 M Sorbitol (Sigma, Saint Louis, Missouri, 
USA) was carried out simultaneously. The supernatants were then removed and cells 
were washed once with phosphate-buffered saline (PBS) and subsequently lysed in 
2% SDS. Protein concentrations were estimated using BCA assay (Pierce, Rockford, 
IL, USA). ERK1/2 or Akt phosphorylation was analyzed by Western blot using 
phospho-specific antibodies according to the manufacturer’s instructions (Cell 
Signaling Technology, Danvers, MA, USA). Blots were stripped with RestoreTM 
Western Stripping Buffer (Pierce, Rockford, IL, USA) and reprobed with pan 
antibodies to verify equal loading of protein. Western blots were detected using 
UltraSignal Chemiluminscent kit (Pierce, Rockford, IL, USA) according to the 
manufacturer’s instructions. Chemiluminescence was imaged and analyzed by 
Quantity One version 4.0 (Bio-Rad, Hercules, USA).  
For studies of kinetic and dose response of ligand induced ERK1/2 activations, 
dot blot analysis was performed using BIO DotTM Apparatus (Bio-Rad, Hercules, 
USA). Five micrograms of protein were loaded per well in triplicates. Densities of 
blots were imaged and measured by Quantity One 4.0 (Bio-Rad, Hercules, USA).  
To study the effects of kinases inhibitors, MEK inhibitor U0126 (Promega, 
Madison, WI, USA), Src inhibitor PP2 (Chemicon International, Temecula, CA, 
USA), or PLCγ inhibitor U73100 (Biosource, Camarillo, CA, USA) were added 20 
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Binding of [125I] GDNF to GFRα2 isoforms transfected Neuro2A cells. 
 [125I] GDNF (~1000 mCi/mmol) was prepared using Amersham Bolton and hunter 
reagent (Amersham Biosciences, Buckinghamshire, England). Briefly, 10 µg of 
recombinant human GDNF (Prospec-Tany Technogene, Israel) were labeled with 1 
mCi of Bolton and Hunter reagent for one hour at room temperature according to 
manufacturer’s instructions. The reaction was terminated by adding 10 µl 0.1% BSA. 
Radiolabeled GDNF was then purified through a Sephadex G-10 column.  
Binding studies were carried out as previously described (Jing et al., 1997). 
Briefly, 0.1 millions cells were seeded per well on 24-well Costar tissue culture plates 
for two days before the assay. Prior to the experiment, cells were placed on ice for 15-
20 minutes and then washed once with ice-cold DMEM buffer, 25 mM HEPES, pH 
7.0. Cells were then incubated at 4˚C for three hours with 0.2 ml of binding buffer 
(DMEM buffer, 25 mM HEPES, 2 mg/ml bovine albumin serum and Roche Complete 
Inhibitor Cocktail, pH 7.0) containing 50 pM [125I]GDNF and various concentrations 
of unlabeled GDNF. At the end of incubation, cells were washed three times with 0.3 
ml of ice-cold washing buffer, and lysed in 0.1% SDS containing 1 M NaOH. The 
radioactivity in lysates was measured in the Cobra II Auto Gamma Counter (Perkin 
Elmer Packard). 
 
C. Neurite outgrowth and differentiation experiments 
Assessment of neurite outgrowth in GFRα transfected Neuro2A cells. 
Twenty to fifty thousands cells per well were seeded on six well plates overnight, in 
DMEM supplemented with 10% FBS. Cells were then incubated with media 
containing 0.5% FBS, with or without 50 ng/ml of recombinant human GDNF 
(Biosource, Camarillo, CA, USA) or NTN (ProSpec-Tany TechnoGene Ltd, Israel). 
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Cells were incubated for three more days. All-trans retinoic acid (Sigma, Saint Louis, 
Missouri, USA) (5 µM) was used as a positive control for inducing neurite outgrowth. 
Cells bearing neurite twice the length of the cell bodies were scored. More than 600 
cells from three different fields were counted per well. The significance differences 
between ligands stimulated and control samples were calculated using paired Students 
t-test. A value of P<0.05 was considered significant.  
 
Immunocytochemistry and confocal microscopy.  
Cells were seeded on chamber slides and fixed with 4% paraformaldehyde in PBS for 
15 minutes at room temperature. After three washes with PBS, cells were 
permeabilized and blocked with serum (Dako, Glostrup, Denmark 1:10), 0.5% Triton-
X100 in 1 X PBS for 30 minutes at room temperature. Cells were then incubated with 
primary antibodies (diluted 1:200, in 0.1% Triton-X100, 0.1% BSA, 1 X PBS) for 1 h 
at 37 ˚C and then washed three times in 1 X PBS. Secondary antibody (Alexa Fluor 
488, Molecular Probes, USA) was then added at a dilution of 1:200 and incubated for 
one hour. The cells were then washed in 1 X PBS and mounted for visualization. 
Image acquisition was obtained using confocal microscope equipped with 
fluorescence detection (Zeiss, Thornwood, NY, USA).  
F-actin (Phalloidin conjugated with TRITC) and high-molecular-weight 
neurofilament protein (NF-200) antibody, anti-HA (conjugated with TRITC) were 
purchased from Sigma (Sigma, Saint Louis, Missouri, USA); monoclonal beta-III 
Tubulin antibody was purchased from R&D System (Minneapolis, MN, USA).  
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Silencing of GFRα2b in BE(2)-C.  
siRNA duplexes (Invitrogen, Carlsbad, CA, USA) were designed across the specific 
exon (exon 1 and 3) boundary of GFRα2b (as listed in Table 9.2). Sub-confluent cells 
(50-80%) were seeded on six well plates, in 10% FBS DMEM. Cells were transfected 
with siRNA duplexes (20pmol) using Transfectin (Bio-Rad, Hercules, USA) in 400µl 
of 0.5% FCS DMEM per well. Total RNA was isolated for six hours post-transfection, 
and gene expression was measured by real time PCR. For differentiation studies using 
BE(2)-C, six hours after silencing of GFRα2b, 2ml of differentiation medium 
containing retinoic acid (5µM), GDNF (50 ng/ml)  or NTN (50 ng/ml) in 0.5% FBS 
DMEM was added to the media. Morphological differences were observed three days 
later. 
 










Series of siRNA were designed across exon 1-3 of GFRα2b, underlined are sequences 
on exon 3 of GFRα2b.  
 
 
Rho activation assay 
Neuro2A cells were seeded in 10% FBS DMEM and incubated for 18-24 hours.  
Subsequently, the serum was reduced to 0.5% in DMEM and the cells were incubated 
for a further 18-24 hours. Cells were then treated with 10µM LPA (Sigma), GDNF 
(50 ng/ml) or NTN (50 ng/ml) in serum free DMEM for 10 minutes. Cells were lysed 
and used directly for the GTP-RhoA pull down assay according to the manufacturer’s 
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instructions (Pierce, Rockford, IL, USA).  RhoA inhibitor exoenzyme C3 transferase 
and ROCK inhibitor Y27632 were purchased from Calbiochem. Exoenzyme C3 
transferase was transfected into cells using lipotransfecting agent, Transfectin (Biorad, 
Hercules USA), at 1 µl of Transfectin/ 1 µg of C3 transferase per well of 6-well plate. 
This was done four hours prior to the start of the experiment. Cells were then treated 
with RhoA inhibitor exoenzyme C3 transferase (1 µg/ml) or ROCK inhibitor Y27632 
(10µM), with or without the presence of a differentiating medium. Lysophosphatidic 
acid (LPA, 10µM) (Sigma, Saint Louis, Missouri, USA) was used as a positive 
control for activities of Rho and ROCK inhibitor.  
 The plasmid of HA-tagged dominant negative RhoA (T19N) was a generous 
gift from Dr. Low Boon Chuan of Department of Biological Science, National 
University of Singapore. The dominant negative RhoA (RhoA-DN) was transfected to 
cells using Transfectin (Bio-Rad, Hercules, USA), 14-16 hours prior to the start of the 
experiment. Cells expressing RhoA-DN were then treated with differentiation media 
for three additional days, and were immunostained for beta-III Tubulin and 
monoclonal anti-HA TRITC conjugate (Sigma, Saint Louis, Missouri, USA), as 
described above.  
 
Neuronal differentiation of mice embryonic stem cells  
Two cell lines of mice embryonic stem cells (mESC) were used in this study, the 
AB2.2 and E14 cells. mESC was maintained on high-glucose DMEM (Gibco, CA 
USA) containing 15% FBS (Hyclone, Logan, UT, USA), 1x glutamine-pen-strep 
(Gibco, CA, USA), leukemia inhibitory factor (LIF) (1,000 U/ml) (Chemicon 
International, Temecula, CA, USA), and 143 µM β-mercaptoethanol (Merck, 
Germany), in a 5% CO2 humidified atmosphere at 37 ˚C.  Cells were passaged every 
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three days, with daily replacement of fresh media. Cells were cultured on flasks 
coated with 0.1% gelatin (Sigma, Saint Louis, Missouri, USA), for at least one hour at 
37 ºC.   Neuronal precursors were induced using retinoic acid and 4-4+ methods as 
previously described  (Bain et al., 1995; Bibel et al., 2004). Briefly, embryoid bodies 
were induced by plating 3 X106 mESC cells onto non-adherent 10 cm bacterial dishes 
in EB medium (mESC medium without LIF and only 10% FBS) and incubated for 
eight days. Medium was changed every two days, and 5 µM retinoic acid was added 
after four days of embryoid bodies induction. Total RNA and reverse transcription 
were carried out as described above. Gene expressions of GFRα1 and Ret isoforms 
were measured by quantitative real time PCR, using specific primers as listed in Table 
9.1. 
 
D. Quantitative real time PCR  
Isolation of RNA and reverse transcription 
Total RNA from cells were prepared and the integrity of the samples were validated 
by denaturing agarose gel electrophoresis as described previously (Too and Maggio, 
1995). One to five micrograms of total RNA were reverse-transcribed using 400U of 
ImpromII and 0.5 µg random hexamer (Promega, Madison, WI, USA) for 60 minutes 
at 42 °C according to the manufacturer’s instructions. The reaction was terminated by 
heating at 70 °C for 5 minutes and used directly for quantitative real time PCR. Six 
independent preparations of cDNA were used for the study. All measurements were 
carried out in triplicates. 
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Quantitative real time PCR  
Quantitative real time PCR was performed on the iCycler iQ (Bio-Rad, Hercules, 
USA) using Sybr Green I. The threshold cycles (Ct) were calculated automatically 
using the Optical interface v3.0B. Real time PCR was performed after an initial 
denaturation for 3 minutes at 95 oC followed by 40 to 50 cycles of 60 seconds 
denaturation at 95 oC, 30 seconds annealing at 60 oC and 60 seconds extension at 72 
oC. Fluorescent detection was carried out at the annealing phase. The reaction was 
carried out in a total volume of 50 µl in 1X XtensaMix-SGTM (BioWORKS, 
Singapore), containing 2.5 mM MgCl2, 10 pmol of primers and 1.25 U Platinum DNA 
polymerase (Invitrogen Carlsbad, CA, USA). Melt curve analyses and agarose gel 
electrophoresis were carried out at the end of PCR to verify the identity of the 
products.  
All real time PCR quantifications were carried out simultaneously with 
linearized plasmid standards and a non template control. The gene expression levels 
were interpolated from standard curves and normalized to the expressions of GAPDH 
in the same samples.  
 
Quantification of miRNAs precursors 
Total RNA was extracted from BE(2)-C cells using Trizol reagent (Invitrogen, 
Carlsbad, CA, USA) with linear acrylamide (20 µg/ml; Ambion Inc, Austin, TX, 
USA). The concentration of total RNA and the integrity of the RNA were quantified 
by absorbance (260 nm) and by 1% denaturing agarose gel electrophoresis. Further 
verifications were carried out using ExperionTM RNA StdSens analysis kit (Bio-Rad, 
Hercules, USA).  Total RNA samples were treated with RNase-free DNase I 
(Promega, Madison, WI, USA) and inactivated at 80 °C for 5 minutes, according to 
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manufacturer’s recommendations. The DNAse I treated RNA samples were initially 
heated at 80°C in the presence of 15 pmol of pre-validated gene specific reverse 
primers (listed in Table 9.3) (Schmittgen et al., 2004) for 5 minutes, snapped chilled 
on ice and reverse transcribed [1× buffer, dNTPs (10 mM), dithiothreitol (DTT), 
RNase inhibitor, Thermoscript (15 U)] as specified by the manufacturer (Invitrogen, 
Carlsbad, CA, USA). The reverse transcription was carried out at 60 °C for 45 
minutes and terminated by a further incubation at 85 °C for 5 minutes. The samples 
were then used for quantitative real time PCR as described above using gene specific 
primers (listed in Table 9.3) (Schmittgen et al., 2004). The real time PCR primers 
used here amplify both the short hair-pin structures of the miRNA precursors, primary 
(pri-miRNAs) and pre-miRNAs. The fold changes in the target miRNA, normalized 
to U6 RNA and relative to the expression in control sample, were calculated for each 
sample using the equation 2-∆∆Ct, where ∆∆Ct = (CtmiRNA – CtU6RNA)stimulated - (CtmiRNA 
– Ctu6RNA)control.  
 
Table 9.3 List of primers used for amplification and measurement of human pri-
miRNA. 
 
miRNA Name of primer 
(Forward/Reverse) 
Primer sequences (Forward/reverse) 
U6 U6F/ U6R CTCGCTTCGGCAGCACA/ 
AACGCTTCACGAATTTGCGT 
let-7d let-7dF/ let-7dR AACGCTTCACGAATTTGCGT/ 
AAGGCAGCAGGTCGTATAGT  
miR-15 miR-15aF/ miR-15aR GTAGCAGCACATAATGGTTTGTG/ 
GCAGCACAATATGGCCTG  
miR-16 miR-16F/ miR-16R GCAGCACGTAAATATTGGCGT/ 
CAGCAGCACAGTTAAATACTGGA
G  
miR-18 miR-18F/ miR-18R TAAGGTGCATCTAGTGCAGATAG 
GAAGGAGCACTTAGGGCAGT 
miR-20 miR-20F/ miR-20R GCACTAAAGTGCTTATAGTGCAG/ 
GTACTTTAAGTGCTCATAATGCA 
miR-21 miR-21F/ miR-21R GCTTATCAGACTGATGTTGACTG/ 
CAGCCCATCGACTGGTG 
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miR-24-2 miR-24-2F/ miR-24-2R CTCCCGTGCCTACTGAGCT/ 
CCCTGTTCCTGCTGAACTGAG  
miR-28 miR-28F/ miR-28R GGAGCTCACAGTCTATTAGTTACC
/ 
CCTCCAGGAGCTCACAATCT 
miR-29 miR-29F/ miR-29R ATGACTGATTTCTTTTGGTG/ 
ATAACCGATTTCAGATGGTG 
miR-30a miR-30aF/ miR-30aR GTAAACATCCTCGACTGGAAGCT/ 
GCTGCAAACATCCGACTGAA 
miR-30d miR-30dF/ miR-30dR GTTGTTGTAAACATCCCCGAC/ 
GCAGCAAACATCTGACTGAAAG 
miR-33 miR-33F/ miR-33R TGTGGTGCATTGTAGTTGCA/ 
CTGTGATGCACTGTGGAAAC 
miR-92-1 miR-92-1F/ miR-92-1R TCTACACAGGTTGGGATCGG/ 
CGGGACAAGTGCAATACCATA 
miR-93-1 miR-93-1F/ miR-93-1R AAGTGCTGTTCGTGCAGG/ 
CTCGGGAAGTGCTAGCTCA 
miR-101 miR-101F/ miR-101R GCCCTGGCTCAGTTATCACA/ 
GCCATCCTTCAGTTATCACAGTA 
miR-105-1 miR-105-1F/ miR-105-1R CAAATGCTCAGACTCCTGTGGT/ 
GCACATGCTCAAACATCCGT 






miR-147 miR-147F/ miR-147R CTAAAGACAACATTTCTGCACAC/ 
ATCTAGCAGAAGCATTTCCAC  
miR-216 miR-216F/ miR-216R TGGCTTAATCTCAGCTGGCA/  
TGAGGGCTAGGAAATTGCTCT 
miR-219 miR-219F/ miR-219R TCCTGATTGTCCAAACGCAA/ 
GGGACGTCCAGACTCAACTCTC 
miR-22 miR-220F/ miR-220R CCACACCGTATCTGACACTTT/ 
CAGACCGCATCATGAACAC 




 To prepare the plasmid standards for quantitative real time PCR, open reading frame 
of human GFRα2 isoforms and GAPDH were subcloned into p-GEMT (Promega, 
Madison, WI, USA). For early response genes and transcriptional factors, partial 
sequences were subcloned into p-GEMT. XbaI or XmnI (Promega, Madison, WI, 
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USA) was used to linearize plasmids to be used as templates for real time PCR 
amplifications.  
 
Quantitative real time PCR of human GFRα receptor, RET and NCAM in 
BE(2)-C  
Specific primers were designed to amplify the 3’ GPI (glycosylphosphatidylinositol) 
sequences of GFRα1 or GFRα2, and did not distinguish between various alternatively 
spliced isoforms. Primers used for amplifying GPI region of GFRα1 and GFRα2, the 
common tyrosine kinase domain of RET and the N-terminal domain of NCAM, are 
listed in Table 9.4. All real time PCR quantification was carried out as described 
above, simultaneously with linearized plasmid standards and no template controls. 
The concentrations of GFRα, RET and NCAM in BE(2)-C cells were interpolated 
from standard curves and normalized to the expressions of GAPDH. 
 
Table 9.4 List of primers used for amplification of human GFRα2, GFRα1, Ret, 
NCAM and GAPDH.  
 
Gene Name of primer 
(Forward/Reverse) 
Primer sequences (Forward/reverse) 
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Sequence independent real-time PCR for human GFRα2 isoforms. 
 Real time PCR was performed as described above. Specific exon overlapping 
forward primer used for amplification of human GFRα2a was designated as “2a 
15+9F”, for human GFRα2b as “2b 17+7F”, and for human GFRα2c as “2c 18+5F”. 
A common reverse primer, designated as “553R”, was used for all three isoforms 
(listed in Table 9.5). All real time PCR quantification was carried out simultaneously 
with linearized plasmid standards and a non template control. Gene expression levels 
were interpolated from standard curves and normalized to the expressions of GAPDH 
in the same samples. Differences in the expression levels of  GFRα2 isoforms were 
analyzed using paired Student’s t-test with a level of significance of P<0.05. 
 
Table 9.5 List of primers used for amplification of human GFRα2 isoforms and 
GAPDH. 
 
Gene Name of primer 
(Forward/Reverse) 
Primer sequences (Forward/reverse) Size of 
amplicon 
(bp) 
GFRα2a 2a 15+9F/  553R TCTTCTTCTTTCTAGACGAGACCC
/ GCAGATGGAGATGTAGGAGGAG 
545  
GFRα2b 2b 17+7F/ 553R CCTCTTCTTCTTTCTAGGTGAGGA
/ GCAGATGGAGATGTAGGAGGAG 
233 
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Measurement of early response genes and neuronal markers regulated by GDNF 
and NTN.  
Cells were seeded in DMEM with 10% FBS for 24 hours, followed by serum 
depletion (0.5% FBS) for 16 hours. The cells were then treated with GDNF (50 ng/ml) 
or NTN (50 ng/ml) in serum free media for varying periods of time at 37 °C. Total 
RNA was then isolated and reverse transcribed as described above. The gene 
expression levels were then quantified by real time PCR using gene specific primers 
designed for early response gene, (listed in Table 9.6) or neuronal marker genes 
(listed in Table 9.7). Expression of target genes and GAPDH were interpolated from 
standard curves. Fold changes of target genes were calculated as changes in 
normalized gene expressions of stimulated samples as compared to control.  
Table 9.6 List of primers used for amplification of mouse early response genes. 
 
Gene Name of primer 
(Forward/Reverse
) 
Primer sequences (Forward/reverse) Size of 
amplicon 
(bp) 





















Table 9.7 List of primers used for measurement of mouse neuronal markers. 
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Products of PCR amplification of GFRα1 (lane 1), GFRα2 (lane 2), Ret (lane 3), 
and NCAM (lane 4) from adult human brain. Primers were designed to recognize 
common C-terminal for GFRα1, GFRα2 or Ret, or to common N-terminal for NCAM 
(listed in Table 9.4), which were common to all isoforms. 100 bp marker (increment 

































Immunocytochemistry of cytoskeletal component in ligand treated Neuro2A cells 
expressing GFRα2 isofroms. Figures show immunocytochemistry of beta III tubulin  
(green) in Neuro2A cells stably expressing GFRα2 isoforms, treated three days with 























List of publications 
 
1. Li Foong Yoong, Zhong Ni Peng, Guoqiang Wan, Heng-Phon Too. Tissue 
expression of alternatively spliced GFRa1, NCAM and RET isoforms and the 
distinct functional consequence of ligand-induced activation of GFRa1 
isoforms, (Molecular Brain Research  2005, 139:1, 1-12).  
 
2. Li Foong Yoong, Guoqiang Wan, Heng-Phon Too. Glial cell-line derived 
neurotrophic factor and Neurturin regulate the expressions of distinct miRNA 
precursors through the activation of GFRα2. (Journal of Neurochemistry, 
2006, 98, 1149–1158) 
 
3. Li Foong Yoong and Heng-Phon Too. Glial Cell Line-Derived Neurotrophic 
Factor and Neurturin Inhibit Neurite Outgrowth and Activate RhoA through 
GFRα2b, an Alternatively Spliced Isoform of GFRα2 (Journal of 
Neuroscience, 2007, 27:21, 5603-5614) 
 
4. Li Foong Yoong, Zhong Ni Peng, Guoqiang Wan, Heng-Phon Too. GFRα1b 
inhibits GFRα1a neuritogenic activities in GDNF and NTN signaling. 
(Manuscript in preparation for Journal of Neurochemistry). 
 
5. Leong DT, Gupta A, Bai HF, Wan Q, Yoong LF, Too HP, Chew FT, 
Hutmacher DW. Absolute quantification of gene expression in biomaterials 



















1. YOONG Li Foong, PENG Zhong Ni, TOO Heng-Phon, Differential 
Expressions of GFRα1 and Ret Alternatively Spliced Isoforms In Murine 
Embryonic and Adult Tissues, 7th  National University of Singapore- National 
University Hospital Annual Scientific Meeting, Singapore, 2003 
2. YOONG Li Foong, Wan Guo Qiang, Peng Zhong Ni, Too Heng Phon. 
Expression and transcriptional profiles of GFR-Alpha1 alternatively spliced 
isoforms, 2nd International Congress of Neuroscience, Singapore, 2004 
 
3. YOONG Li Foong, Too Heng-Phon, Distinct signaling and functional 
differences between GDNF family receptor alpha-2 (GFRα2) isoforms , 20th 
Biennial Meeting of the International Society for Neurochemistry, Austria 
2005. 
 
4. YOONG Li Foong, Too Heng-Phon; Novel antineuritogenic activity of GDNF 
Family Receptor Alpha 2b (GFRα2b), 2006 ASBMB (American Society for 
Biochemistry and Molecular Biology) Annual Meeting, San Francisco 2006. 
 
5. YOONG Li Foong, Too Heng-Phon; GDNF Family Receptor Alpha 2b 
(GFRα2b) is an inhibitory receptor splice variant that antagonize GFRα2a and 
GFRα2c induced neurites extension, 20th IUBMB Congress and 11th 
FAOBMB Congress, Japan 2006.  
 
6. YOONG Li Foong, Too Heng-Phon; GDNF Family Receptor Alpha 2b 
(GFRα2b) is an inhibitory receptor splice variant that antagonize GFRα2a and 
GFRα2c induced neurites extension, 7th Bienniel Meeting of the Asian Pacific 




Invited seminars and presentations 
 
1. The novel anti-neuritogenic function of alternatively spliced glial cell line-
derived neurotrophic factor (GDNF) receptor isoforms, at Howard Florey 
Research Institute, Melbourne Australia, September 2006. 
 
2. The novel anti-neuritogenic function of alternatively spliced glial cell line-
derived neurotrophic factor (GDNF) receptor isoforms, at St. Jude Children’s 
Research Hospital, Memphis USA, October 2006. 
 
3. YOONG Li Foong; Studies of GDNF Family Receptor Alpha 2 (GFRα2) 
isoforms, Young Scientists & Students session, 8th Biennial Advanced School 
of Neurochemistry of ISN (International Society of Neurochemistry), 







Reprints of publications 
 
1. Li Foong Yoong, Zhong Ni Peng, Guoqiang Wan, Heng-Phon Too. Tissue 
expression of alternatively spliced GFRa1, NCAM and RET isoforms and the 
distinct functional consequence of ligand-induced activation of GFRa1 
isoforms, (Molecular Brain Research  2005, 139:1, 1-12).  
 
2. Li Foong Yoong, Guoqiang Wan, Heng-Phon Too. Glial cell-line derived 
neurotrophic factor and Neurturin regulate the expressions of distinct miRNA 
precursors through the activation of GFRα2. (Journal of Neurochemistry, 
2006, 98, 1149–1158) 
 
3. Li Foong Yoong and Heng-Phon Too. Glial Cell Line-Derived Neurotrophic 
Factor and Neurturin Inhibit Neurite Outgrowth and Activate RhoA through 
GFRα2b, an Alternatively Spliced Isoform of GFRα2 (Journal of 
Neuroscience, 2007, 27:21, 5603-5614) 
 
www.elsevier.com/locate/molbrainresMolecular Brain ResearcResearch Report
Tissue expression of alternatively spliced GFRa1, NCAM and
RET isoforms and the distinct functional consequence of
ligand-induced activation of GFRa1 isoforms
Li Foong Yoonga,1, Zhong Ni Penga,1, Guoqiang Wana,c, Heng-Phon Tooa,b,*
aDepartment of Biochemistry, National University of Singapore, Lower Kent Ridge Road, Singapore 119260, Singapore
bMEBCS, Singapore-Massachusetts Institute of Technology Alliance, Singapore
cJohns Hopkins Singapore, Biopolis, Singapore
Accepted 1 May 2005
Available online 24 June 2005Abstract
Glial-cell-line-derived neurotrophic factor (GDNF) exerts its effect through a multi-component receptor system consisting of GFRa1,
RET and NCAM. Two highly homologous alternatively spliced GFRa1 isoforms (GFRa1a and GFRa1b) have previously been identified. In
this study, isoform specific real-time PCR assays were used to quantify the expression levels of GFRa1, RET and NCAM isoforms in murine
embryonic and adult tissues. The expression levels of GFRa1b were found to be comparable to that of GFRa1a in peripheral tissues.
However, GFRa1a was the predominant isoform expressed in the whole brain. The co-expressions of GFRa1 and the co-receptors were
developmentally regulated and differentially expressed in some tissues. Microarray analyses of GFRa1 isoforms transfected cells stimulated
with NTN showed distinct and non-overlapping gene profiles. These observations are consistent with the emerging view that the
combinatorial interactions of the spliced isoforms of GFRa, RET and NCAM may contribute to the pleiotropic biological responses.
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Glial-cell-line-derived neurotrophic factor (GDNF) is a
cysteine-knot protein and belongs to a structurally related
family of neurotrophic factors which includes Neurturin
(NTN), Artemin and Persephin [1]. These GDNF family
ligands (GFLs) have been shown to support the growth,
maintenance and differentiation of a wide variety of neuronal
and extraneuronal systems. GFLs exert their effects through a
multi-component receptor system consisting of the GFRa,0169-328X/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.molbrainres.2005.05.016
* Corresponding author. Department of Biochemistry, National University
of Singapore, Lower Kent Ridge Road, Singapore 119260, Singapore. Fax:
+65 779 1453.
E-mail address: bchtoohp@nus.edu.sg (H.-P. Too).
1 Equal contribution.RET and NCAM [38,42]. Presently, the genes encoding four
GFRa-related proteins, GFRa1 (GDNF-Ra), GFRa2
(NTNR-a, TrnR2), GFRa3 and GFRa4 have been isolated
[3,6,16,17,19,29,44,47,54]. The ligand selectivity of GFRa1
has been a subject of controversy. Some studies have shown
that GDNF but not NTN binds specifically to GFRa1 [6,19].
However, these findings have not been confirmed by others,
and more recent results showed that both GDNF and NTN
bind and activate GFRa1 in transfected cells as well as
midbrain dopaminergic, parasympathetic and submandibular
gland neurons [17,34,51].
Alternative RNA splicing occurs in nearly all metazoan
organisms as a means of producing functionally diverse
polypeptides from a single gene. In a recent genome-wide
microarray analyses, it is estimated that greater than
74% of the human multi-exon genes are alternatively splicedh 139 (2005) 1 – 12
L.F. Yoong et al. / Molecular Brain Research 139 (2005) 1–122[18]. We and others have previously identified two highly
homologous alternatively spliced GFRa1 isoforms [11,37,
40], and these were named GDNFR-a (GFRa1a) and
GDNFR-h (GFRa1b) [8,11,16]. Both isoforms are ex-
pressed at unknown quantities in various human and rodent
tissues. In addition to the existence of spliced isoforms of
GFRa1, multiple isoforms of GFRa2 [12,52] and GFRa4
[22,23,26] have also been reported. The alternatively spliced
variants of RET [10,20,25] and NCAM [7,35,36] have been
shown to have distinct biochemical and physiological
functions. These observations are consistent with the
emerging view that the combinatorial interactions of
the spliced isoforms of GFRa RET and NCAM may
contribute to the multi-component signaling system to
produce the myriad of observed biological responses.
In an effort to understand the possible physiological
contributions of the GFRa1 isoforms, it is essential to
determine the quantitative expression levels of the receptor
and the multi-component receptor system. Currently, the
quantitative expression levels of these isoforms are
unknown. This is due to the lack of a method to quantify
these highly homologous sequences. Concurrent with this
study, an attempt to quantify the relative ratio of GFRa1
isoforms in tissues has been reported [8]. In this study, we
report the development of specific, sensitive and high
throughput real-time PCR assays to quantify the expression
levels of GFRa1, RETand NCAM isoforms in murine whole
embryos and adult tissues. These isoforms were shown to be
expressed at significant levels during development, more at
later stages. In addition, we tested the hypothesis that the
spliced GFRa1 isoforms have distinct functions by micro-
array analyses of NTN stimulated GFRa1 isoform trans-
fected cells which showed no overlap of gene profiles,
indicative of distinctive functional roles of these isoforms.2. Materials and methods
2.1. Reverse transcription (RT) reaction
Total RNA was prepared as described previously [46].
Total RNA from different tissues and from whole embryo
were isolated from murine (Balb c). Further purification to
remove genomic DNA was carried out using Nucleospin
RNA II (Macherey-Nagel, Germany) according to manufac-
turer’s instructions. The integrity of total RNAwas validated
by denaturing agarose gel electrophoresis. Five micrograms
of total RNA from each tissue was reverse-transcribed using
400 U of ImpromII and 0.5 Ag random hexamer (Promega,
Madison, WI, USA) for 60 min at 42 -C according to the
manufacturer’s instructions. The reaction was terminated by
heating at 70 -C for 5 min and used directly for quantitative
real-time PCR. Six independent batches of cDNAwere used
for the study. All measurements were carried out in triplicate.
All experiments involving animals were carried out in
accordance to the Institutional Animal Care and UseCommittee of the National University of Singapore and were
in accordance with the US Public Health Service Guide for
the Care and Use of Laboratory Animals.
2.2. Sequence independent real-time PCR using SYBR
Green I Plasmids construction
Unless stated otherwise, all templates were generated by
reverse transcription (RT)-PCR using murine brain cDNA
(Balb c), subcloned into pGEM-T (Promega), and all clones
were verified by DNA sequencing. The complete open
reading frame (ORF) of murine GFRa1a (GenBank
accession number: AF014117) and GFRa1b (GenBank
accession number: AF015172) were generated by PCR
and subcloned into pIRESneo (Clontech). The complete
ORF of GAPDH was generated using the GenBank
sequence (accession number NM_008084).
Murine RET51 (GenBank accession number AF209436)
and RET9 (GenBank accession number AY326397)
templates were generated using the pairs of primers
RET51 – 3251R (TCTTGGGAACCCAGTGCTAG)/
RET51–3168F (ATGGATTGAAA ACAAACTCTATGG-
CAT) and RET9–3243R (GTTACAGAGAGTTGGGATG)/
RET9–3168F (ATGGATTGAAAACAAACTCTATGGTA),
respectively. RET tyrosine kinase domain (TK2) template
was generated using the primers mRET51 – 2890F
(TTCTGAAGACAGGCCACAGGA)/mRET51–2974R
(CACTGGCCTCTTGTCTGGCT).
NCAM (N-terminal) template encoding the 5V ORF
sequences was generated with primers mNCAM-N-F282
(TGTCAAGTGGCAGGAGATGC)/mNCAM-N-R419
(GGCGTTGTAGATGGTGAGGGT). A common forward
primer (mNCAM-14-F1, CTCGCCTCTGAGTGGAA-
ACCG) was used to generate NCAM120, NCAM140 and
NCAM180 with the respective specific reverse primers
mNCAM-15-R77 (TCAGAGCAGAAGAAGAGTCA-
CCGC), mNCAM-17-R+12 (CTACAGGGCCCTTTTCG-
GGTTCTGTC) and mNCAM-18-R+12 (CTACAGGQ
GCCCTTTTCGGTCTTTGCT). XbaI (Promega) and XmnI
(Promega) were used to linearize pGEM-T and pIRESneo
plasmids, respectively.
2.3. Sequence independent real-time PCR
Real-time PCR was performed on the iCycler iQ
(Biorad, Hercules, USA) using Sybr Green I. The thresh-
old cycles (Ct) were calculated using the Optical interface
v3.0B. Real-time PCR was performed after an initial
denaturation for 3 min at 95 -C followed by 40 to 60
cycles of 60 s denaturation at 95 -C, 30 s annealing at 60
-C and 60 s extension at 72 -C. Fluorescent detection was
carried out at the annealing phase. The reaction was
carried out in a total volume of 50 Al in 1 XtensaMix-
SGi (BioWORKS), containing 2.5 mM MgCl2, 10 pmol
of primers and 1.25 U Platinum DNA polymerase
(Invitrogen). Melt curve analyses were carried out at the
L.F. Yoong et al. / Molecular Brain Research 139 (2005) 1–12 3end of PCR to verify the identity of the products. All real-
time PCR quantification was carried out simultaneously
with linearized plasmid standards and a negative water
control. The concentrations of GFRa1, RET and NCAM in
all of the tissues were interpolated from standard curves
and then normalized to the expressions of GAPDH in the
same tissues. Differences in the expression levels of
isoforms were analyzed using paired Student’s t test with
a level of significance of 0.05 > P > 0.02. The specificity
of an assay (DCt/E) is determined by the difference in the
Ct values of the defined target and test templates
normalized to the efficiency of target amplification (E) as
described previously [45].
NCAM120, NCAM140 and NCAM180 were ampli-







amplifying the common N-terminal sequences of
NCAM, the same primers used to generate the template
NCAM (N-terminal) were used (mNCAM-N-F282 and
mNCAM-N-R419).
GFRa1a and GFRa1b were amplified using a com-
mon reverse primer mGFRa1a-550R (TGGTACAGG-
GGGTGATGTAGG) and the corresponding specific
forward primers mGFRa1a-421F (CATATCAGATGTT-
TTCCAGCA) and mGFRa1b-409F (CAGTCCCGTTC-
ATATCAGTGGA), respectively. For amplifying the
common glycosylphosphatidylinositol (GPI) sequences




RET9 and RET51 were amplified with the same primers
used to generate the plasmid templates as mentioned above.
To amplify the common tyrosine kinase region (TK2)
shared by RET9 and RET51, TK2 template was amplified
with primers RET51–2890F (TTCTGAAGACAGGCCA-
CAGGA) and RET51–2974R (CACTGGCCTCTTGTCTG
GCT). GAPDH was amplified using primers mhGAPDH-
R599 (GATGGCATGGACTG TGGTCA) and mGAPDH-
F456 (GATGGGTGTGAACCACGAGAA).
2.4. Stable transfection of Neuro2A cells
Neuro2A cells were stably transfected with either
GFRa1a, GFRa1b or pIRESneo (Clontech) vector control
using Fugene-6 (Roche Lifescience) and selected with 0.8
mg/ml of G418 over a period of 6 months. The cell lines
were grown in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% heat-inactivated fetal
bovine serum (FBS, Hyclone USA) in a 37 -C humidified
incubator with 5% CO2.2.5. Analysis of MAP Kinase (Erk/12) phosphorylation
Cells were seeded in DMEM with 10% FBS for 24 h
followed by serum depletion (0.5% FBS) for 16 h. The cells
were then treated with 50 ng/ml of GDNF, NTN, Artemin or
Persephin (PreproTech, England) in serum free media for 15
min at 37 -C. Control treatment with 1 M sorbitol (Sigma)
was carried out simultaneously. The supernatants were
removed, and cells were washed once with phosphate-
buffered saline (PBS) and subsequently lysed in 2% SDS.
Protein concentrations were determined using BCA (Pierce,
Rockland USA). MEK inhibitor U0126 (Promega) was
added 15 min prior to the addition of either GDNF or NTN,
and ERK1/2 phosphorylation was analyzed by Western blot
using phospho-specific antibodies according to the manu-
facturer’s instructions (Cell Signaling Technologies). Immu-
noblots of transfected cells with GFRa1 (R&D), NCAM
(Chemicon) and RET (Santa Cruz) were carried out
according to the manufacturer’s instructions. Immunoblots
were visualized with chemiluminescence detection using
horseradish peroxidase (Pierce, Rockland, USA). Blots were
stripped and reprobed with actin (Dako) or pan Erk1/2 (Cell
Signaling Technology) antibodies to verify equal loading of
protein.
2.6. Immunocytochemistry
Cells were seeded on cover slips and fixed with 4%
paraformaldehyde in PBS for 15 min at room temperature.
After three washes with PBS, cells were permeabilized
with 0.5% Triton-X100 in 1 PBS for 30 min at room
temperature and blocked with normal rabbit serum
(DAKO, 1:10) in 0.1% Triton X-100 in PBS for another
30 min. The cells were then incubated with antiphospho-
Erk1/2 antibody (Sigma, MO, USA) in 0.1% Triton X-
100, 0.1% BSA, 1 PBS for 1 h at 37 -C and then
washed three times in 1 PBS. Secondary antibody
(Alexa Fluor 488, Molecular Probes, USA) was then
added at a dilution of 1:1000 and incubated for 1 h. The
cells were then washed in 1 PBS and visualized. Image
acquisition was obtained using microscope equipped with
fluorescence and phase contrast microscopy (Zeiss). For
quantification of phospho-ERK1/2 time course activations,
intensities of fluorescence were measured with Fluostar
Optima (BMG Labtech) at excitation of 485 nm and
emission of 520 nm.
2.7. Microarray analyses and verification with real-time
PCR
For microarray analyses, cells were seeded in DMEM
with 10% FBS for 24 h, and the serum was reduced (0.5%
FBS) for a further 16 h. The cells were treated with 50 ng/ml
of NTN (PreproTech, England) in serum free media for 10
min at 37 -C. Two independent clones of GFRa1a and
GFRa1b stably transfected cell lines were studied. Total
L.F. Yoong et al. / Molecular Brain Research 139 (2005) 1–124RNA was isolated as described above. Total RNA (2 Ag)
was reverse transcribed and biotinylated cRNA (20–30 Ag)
produced according to the manufacturer’s instructions
(CodeLink Expression Bioarray System, Amersham Bio-
science). The biotinylated cRNA was fragmented and then
hybridized to CodeLink Uniset Mouse I Bioarray (Amer-
sham Bioscience) gene chips, washed and detected with
Cy5–Streptavidin dye conjugate. Bioarrays were scanned
with GenePix 3000B Array Scanner (Axon Instruments) and
analyzed using CodeLink Expression Analysis Software Ver
2.0 (Amersham Bioscience). Initial studies with murine
brain total RNA in three independent studies showed that
the coefficient of variation of signal reproducibility was
about 15%, and the sensitivity of detecting two-fold
detectable change was about 98% confidence based on
unpaired t test analyses. Differential expression was
calculated as the increase between ligand stimulated and
control samples. A gene was considered differentially
expressed when the mean probe intensity is higher than
background control, increase or decrease of at least two-fold
and showed reproducible changes in the two independent
clones studied. Some of these genes were then selected to be
analyzed by comparative real-time PCR analyses [24].
Primer pairs were designed to yield a short amplicon
(100–200 bp) and with Tm of 60 -C. Total RNA (5 Ag)
was converted to cDNA and analyzed by real-time PCR, asFig. 1. Schematic diagram of the exon organizations of GFRa1[A], RET [B]
amplification. (A) A common reverse primer, mGFRa1a-550R (open arrows), wa
mGFRa1b-409F (solid arrow) to amplify GFRa1b. (B) A specific primer spannin
used to amplify RET9. RET51 was amplified with the exon spanning primer
amplified using exon overlapping primers. Forward primer for NCAM120 (mNCA
(mNCAM-17-R+8) and NCAM180 (mNCAM-18-R+8) were designed across exodescribed above. All amplifications were run in triplicate,
and each experiment was replicated at least twice. GAPDH
was used as a reference gene for comparative analysis.
2.8. Data analyses
The fold change in the target gene, normalized to GAPDH
and relative to the expression in control sample, was calculated
for each sample using the equation 2DDCt, where DDCt =
(Cttarget  CtGAPDH)stimulated  (Cttarget  CtGAPDH)control.3. Results
3.1. Development of a highly specific and sensitive
quantitative real-time PCR assay
The exon organizations of the murine spliced variants of
GFRa1, RET and NCAM are shown in Fig. 1. GFRa1a
contains an extra 15 nucleotides encoded by exon 5, which
is absent in GFRa1b isoform. With the RET isoforms,
RET9 contains a unique intronic sequence of 27 nucleotides
(intron 9), and RET51 contains exon 20. NCAM140 does
not possess any unique sequences. Exon 15 is present in
NCAM120 but is absent both in NCAM140 and
NCAM180. Based on the limited availability of uniqueand NCAM [C] alternatively spliced isoforms and the primers used for
s used with mGFRa1a-421F (dashed arrow) to amplify GFRa1a, and with
g exon/intron 19 (Ret9–3168F) and a 3V UTR primer (Ret9–3243R) were
Ret51–3168F and Ret51–3251R. (C) NCAM isoforms were specifically
M-14F179) was designed across exon 14/15; reverse primers for NCAM140
ns 17/19 and 18/19, respectively.
Fig. 2. Quantification of GFRa1 isoforms. Amplifications of five log10 dilutions of GFRa1a (A), GFRa1b (C), plasmid standards. Negative controls with no
templates (Water) were carried out simultaneously. The slopes of the plots of Ct versus log10 mol of GFRa1a and GFRa1b standards were 3.96 T 0.38 (r2 =
0.98) and 3.61 T 0.21 (r2 = 0.98), respectively. Equal quantities (6 attomol) of GFR isoforms were amplified separately using GFRa1a (B) and GFRa1b (D)
exon specific primers. The experiments were repeated at least 5 separate times with similar results.
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primers were designed and used for amplification (Fig. 1).
Initial studies were carried out to optimize the amplifi-
cation conditions. A dwell time of 30 s for annealing, 60 s
for denaturation at 95 -C and 60 s for extension at 72 -C
were found to be optimal for the amplifications of the
isoforms. There was no difference in the efficiencies of
amplifying short amplicons of the exact size to the targets or
those subcloned into plasmids. The use of hot-start
polymerase increased the sensitivities of these assays
significantly, allowing the detection of sub-zeptomoles of
templates (Fig. 2). The slopes of the plots of Ct versus
log10 mol of all the standards were between 3.39 T 0.30
(r2 = 0.98) to 4.12 T 0.44 (r2 = 0.99). The specificities (r) of
the assays with hot-start polymerase were greater thanFig. 3. Gel electrophoresis analysis of products after real-time PCR quantification
(lane 1), GFRa1b (lane 2), RET9 (lane 3), RET51 (lane 4), GFRa1 glycosylphosp
(lane 6) and GAPDH (lane 7). (B) Amplification products with primers design
NCAM140 (lane 3) and NCAM180 (lane 4). Only bands corresponding to predic105 folds. For instance, amplifications of GFRa1b using
GFRa1a exon overlapping primers were at least 105 fold
less efficient than amplifying GFRa1a (Figs. 2B and D).
Initial optimizations of the number of base pairs (bp)
overlapping two adjacent exons were carried out (data not
shown). The optimal number of bp overlaps was found to be
dependent on the spliced variant examined. Hence, the use
of 5 bp exon overlapping primer was the optimal length
required to achieve high specificity of amplifications of the
two GFRa1 isoforms. However, 8 bp exon overlapping
primers were required to achieve high specificity of
amplification for NCAM isoforms (Fig. 1C). Thus, the use
of such exon overlapping primers under optimal conditions
allowed the development of highly specific assays for the
isoforms.s of adult murine brain transcripts. (A) Amplification products of GFRa1a
hatidylinositol sequence (lane 5), RET encoding the tyrosine kinase region
ed to the N-terminal sequence of NCAM (lane 1), NCAM120 (lane 2),
ted sizes were observed. M, 100 bp DNA marker.
Fig. 4. Expression levels of GFRa1 and co-receptor isoforms in murine
brain, heart, ileum, kidney, liver, testis and whole embryo of days 7, 11, 15
and 17. (A) Except for the brain, most tissues expressed comparable levels
of GFRa1a and GFRa1b. (B) RET9 was significantly higher in expression
than RET51 in most tissues. In the liver, the expression of RET9 and
RET51 was below the detection limit of the assays. (C) Expression levels of
NCAM120, NCAM140 and NCAM180. Expression of NCAM isoforms
was undetectable in the liver. Expression levels of GFRa1 and co-receptors
were determined using primers designed to the glycosylphosphatidylino-
sitol sequence of GFRa1 (GPI), N-terminal sequence of NCAM (N-
terminal) and tyrosine kinase sequence of RET (TK2). The expression
levels were normalized to the levels of GAPDH in the same tissue. The
results were expressed as mean T SEM of at least 5 independent
experiments. Significant differences in expression levels of GFRa1 (A)
and RET (B) isoforms were calculated using paired Student’s t test. A value
of P < 0.05 were considered significant (*P = 0.02, **P < 0.01).
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levels of GFRa1, RET and NCAM isoforms transcripts in
adult tissues and whole embryos at different stages of
development. With all the assays, the efficiencies of
amplifying isoforms from cDNA prepared from various
tissues at different concentrations of RNA were identical to
the respective standards used. Single products of the
predicted sizes corresponding to the isoforms were observed
by gel electrophoresis (Fig. 3). Melt curve analyses showed
the predicted melting profiles. All amplified products were
then subcloned and the sequences validated by DNA
sequencing.
3.2. GFRa1b is expressed significantly in mouse tissues
The expression levels of GFRa1 in various murine adult
tissues and whole embryo were shown in Fig. 4A. The sum
of expression levels of GFRa1a and GFRa1b (Fig. 4A)
quantified using specific isoform assays was similar to the
levels determined using the assay designed to the common
sequences (Fig. 4A). Both GFRa1a and GFRa1b were
expressed at equivalent levels in all the tissues examined,
except in the brain, where GFRa1a is the predominant
isoform. Expressions of GFRa1 isoforms were very low at
early stage of development (E7) but increased significantly
in later stages. In the liver, both GFRa1 isoforms were
expressed at similar levels but significantly higher than in
other tissues. The expression of GAPDH in both brain and
liver were equivalent when normalized to the amount of
total RNA (data not shown).
3.3. RET9 is predominantly expressed in mouse tissues
Initial Northern blot analyses of murine tissues showed
the existence of multiple hybridization bands (data not
shown). As the probe used for Northern blot analyses do not
discriminate between RET9 and RET51, we next employed
specific real-time PCR assays to quantify these isoforms.
The highest expression of RET was found in the brain
and testis (Fig. 4B). Similar to the results from Northern
blot, the expressions of both RET isoforms in the kidney
were found to be low. Although Northern blot analyses
showed distinct hybridization signals in the liver, the
expression of both isoforms was not detected either by the
specific isoform assays (Fig. 4B) or the assays designed to
the tyrosine kinase sequences (Fig. 4B). The expression
levels of RET9 were significantly higher than that of RET51
in brain, heart, ileum, testis and the whole embryo samples.
Both RET9 and 51 isoforms were expressed at low levels in
the early (E7) as compared to the later stages of develop-
ment. However, the third isoform of RET, RET 43, was not
detected in any of the mouse tissues examined (data not
shown). The sum of expression levels of RET9 and RET51
(Fig. 4B) quantified using specific isoform assays was
similar to the levels determined using the assay designed to
the common tyrosine kinase sequences (Fig. 4B).
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levels in the brain
All three NCAM transcripts were highly expressed in
the brain but at low levels in most adult peripheral tissues
(Fig. 4C). Differential expressions of NCAM isoforms
were observed during development. The expression of
NCAM120 increased at later stages of development (E15,
E17), while NCAM140 and 180 were expressed at
significant levels early in development (E11). The sum of
expression levels of NCAM isoforms (Fig. 4C) quantified
using specific isoform assays was similar to the levels
determined using the assay designed to the common N-
terminal sequences (Fig. 4C).
3.5. Neuro2A cells express NCAM and RET isoforms
endogenously
To test the hypothesis that the spliced GFRa1 isoforms
may have different functions, we used Neuro2A as a model
as it expressed both NCAM and RET endogenously. At leastFig. 5. Quantification of GFRa1, RET and NCAM expressions in stably transfecte
expressed in cells transfected with the respective vectors and not in the pIRES v
(NCAM) and tyrosine kinase sequences of RET (RET) showed no significant cha
GFRa1 transfected cells. The results were expressed as mean T SEM of at least
GFRa1 isoforms were calculated using paired Student’s t test. A value of P < 0
GFRa1, RET and NCAM. GFRa1b (1b) was expressed at similar levels to GFRa
transfected cells showed no specific expression of GFRa1. NCAM isoforms (120,
were expressed at similar levels in GFRa1a (1a), GFRa1b (1b) and vector control
actin to verify equal loading of samples.5 independent clones of stably transfected Neuro2A cells
were analyzed for the expressions of GFRa1, NCAM and
RET isoforms using real-time PCR and Western blot
analyses (Fig. 5). Neuro2A cells express both RET (RET9
and RET51) and NCAM (NCAM120, 140 and 180)
isoforms endogenously. The expression levels of RET and
NCAM isoforms were similar in GFRa1a, GFRa1b or
pIRES transfected Neuro2A cells. Initial studies using
various commercially available antibodies to detect the
expression of GFRa1 showed significant differences in the
specificity and sensitivity of the Western blots. Specific
GFRa1 isoforms expressions were only detected using
antibody raised against the extracellular domain (R&D
System) but not with antibodies directed at the C-terminal
peptide GFRa1 (Santa Cruz and BD Pharmingen), both by
immunocytochemistry and Western blot analysis (data not
shown). Using the antibody directed at the extracellular
domain, the expression levels of GFRa1a and GFRa1b
were similar in transfected cells (Fig. 5B). Consistent with
this observation, the expression levels of GFRa1 isoforms
were similar at the transcript level (Fig. 5A).d Neuro2A cells. (A) Real-time PCR analyses. GFRa1a and GFRa1b were
ector control cells. Quantifications of the N-terminal sequences of NCAM
nge in the expression levels of endogenously expressed NCAM or RET in
3 independent experiments. Significant differences in expression levels of
.05 was considered significant (**P < 0.01). (B) Western blot analyses of
1a (1a) when detected using anti-GFRa1 antibody. Vector control (pIRES)
140 and 180 kDa), RET9 (150 and 170 kDa) and RET51 (155 and 175 kDa)
(pIRES) transfected cells. Blots were stripped and reprobed with antibody to
Fig. 6. Western blot analyses of ERK1/2 activation for GFRa1a and GFRa1b
stably transfected Neuro2A cells stimulated with GFLS. (A) Cells were
treated 10 min with 50 ng/ml of GDNF (G), NTN (N), Artemin (A), Persephin
(P) or 1 M sorbitol (S). The blots were probed with antibody to phospho-ERK
1/2, stripped and reprobed with pan antibody to Erk1/2 (lower panel).
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transfected cells
When stimulated with either GDNF or NTN, both GFRa1a
and GFRa1b induced the phosphorylation of ERK1/2 potently
(Fig. 6). At the concentration (50 ng/ml) and time (10 min)Fig. 7. Immunocytochemical staining of phosphorylated ERK1/2 in GFRa1a and G
NTN for the specified time. Nuclear localization of phosphorylated ERK1/2 was ra
inhibitor U0126 (10 AM). (B, C) Quantification of phosphorylated ERK1/2 in GDN
30 min. The results were expressed as mean T SD of triplicate readings. The expstudied, Artemin and Persephin did not significantly activate
ERK1/2 when compared to sorbitol as a stimulus. GDNF or
NTN stimulated ERK1/2 phosphorylation was rapid and
transient (Figs. 7A and B). Phosphorylated ERK1/2 was
localized to the nucleus rapidly and was inhibited by U0126
(Fig. 7A). ERK1/2 phosphorylation was specific to the MEK
pathway as inhibitors of the p38 (SB 230580) and PI3 kinases
(LY 294002) pathways did not inhibit ERK1/2 phosphoryla-
tion (data not shown). As a control, transfected cells with either
GFRa1a or GFRa1b were stimulated with phorbol ester. No
significant difference in the kinetics of ERK1/2 phosphoryla-
tion was observed (data not shown).
3.7. Profiles of ligand-induced gene expression in GFRa1
isoform transfected cells
To compare the gene expression profiles of NTN
stimulated GFRa1 isoforms, microarray analyses of twoFRa1b transfected cells. (A) Cells were treated with 50 ng/ml of GDNF or
pid (5 min), and the phosphorylation of ERK1/2 was inhibited by the MEK
F (B) and NTN (C) stimulated GFRa1a and GFRa1b cells over a period of
eriment was repeated at least 3 separate times with similar results.
Table 1
NTN induced gene expression in GFRa1a and GFRa1b transfected cells at







NM023048 0.36 Ankyrin repeat and SOCS box-containing
protein 4 (Asb4)
AK004405 0.54 Similar to KU70-Binding protein
AK005902 0.56 Hypothetical Trp–Asp repeat (WD-repeat)
structure containing protein
AK009937 0.58 Hypothetical Cysteinyl-tRNA synthetase
containing protein
AK010065 0.6 Unclassifiable
AK007332 0.68 Hypothetical 8.5 kDa Protein homolog
AK003917 1.33 Similar to BBP-like protein 2
AK016949 1.47 SWI/SNF related, matrix associated, actin
dependent regulator of chromatin
AK016716 1.62 Similar to polymerase (RNA) III
GFRa1b
NM022891 0.44 Ribosomal protein L23 (Rpl23)
NM023200 0.56 Protein phosphatase 1, regulatory (inhibitor)
subunit 7 (Ppp1r7)
AF233643 0.65 Cytochrome P450 CYP4F13 mRNA
AK017628 0.7 Hypothetical mitochondrial energy transfer
proteins (carrier protein)
NM080452 0.77 Mitochondrial ribosomal protein S2 (Mrps2)
AK009218 1.22 Nuclear protein skip
NM008206 1.34 Histocompatibility 2, O region alpha locus
(H2-Oa)
AF360543 1.59 HNK-1 sulfotransferase
NM010375 3.16 Granzyme G (Gzmg)
The changes in gene expression were confirmed by real-time PCR using the
comparative method (2DDCt) and were statistically significant ( P < 0.05).
GenBank sequence accession number and gene annotations were assessed
based on information supplied in the databases and from the literature.
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Focusing on the early changes in gene expression, a total
of 10,000 genes were analyzed at 10 min of stimulation by
NTN in duplicates. Approximately 0.4% and 0.2% of the
total number of genes were stimulated in GFRa1a and
GFRa1b, respectively. When stimulated by NTN, no
overlap in the activated gene profiles between the two
GFRa1 isoforms was observed. To validate the results,
selected NTN stimulated samples were further analyzed for
changes in expression levels by real-time PCR using
comparative 2DDCt method. It was found that the profile
of changes in gene expression is consistent with the
microarray analyses. No overlap in the gene expression
profiles was observed between GFRa1a and GFRa1b cells
when stimulated with NTN for 10 min, indicative of
distinct functional differences between the two isoforms
(Table 1).4. Discussions
This is the first report using real-time PCR to quantify
and compare the expression levels of GFRa1, RET andNCAM isoforms in tissues. To date, two distinct protein-
coding alternatively spliced GFRa1 isoforms have been
identified [11,37,40]. GFRa1b is identical to GFRa1a except
that for the absence of 5 amino acids (140DVFQQ144),
encoded by exon 5. Hence, GFRa1b do not have unique
sequences for the design of amplification primers by PCR.
Due to the lack of significant differences in nucleotide
sequences, the detection and quantification of these isoforms
often pose a challenge. We have previously shown that it is
not possible to accurately quantify a homologous sequence
using common amplification primers and specific fluoro-
genic probes [53]. By designing exon overlapping primers, it
is however possible to discriminate and quantify highly
homologous alternatively spliced sequences [45,53]. Con-
current with this study, an attempt to quantify the relative
ratio of GFRa1 isoforms in tissues has been reported [8].
GFRa1a is expressed at significantly higher levels than
GFRa1b in the central nervous system. Liver expresses high
levels of both GFRa1a and GFRa1b, higher than that found
in the brain. Consistent with this observation, we have
previously detected high expression level of GFRa1 in the
liver by Northern blot analyses, and the isoforms were
subsequently isolated [11]. Both isoforms were detected only
at later stages of development (E11–E17), unlike NCAM or
RET expression [15].
The RET gene is alternatively spliced to yield two
major isoforms, RET9 and RET51 [41]. RET is widely
expressed in mammalian embryos and plays diverse roles
in development [4,31,39,43]. During embryogenesis, the
main sites of RET expression are in the nervous and
excretory systems [30,50]. RET9 is critically important in
kidney morphogenesis and enteric nervous system deve-
lopment, whereas RET51 appears dispensable [10]. It has
been suggested that RET51 may be involved in differ-
entiation events in later kidney organogenesis [20]. The
two spliced variants recruit signal transducers in differ-
entiation pathways differently and have dramatic bio-
chemical differences on activation of GFRa1a [5,9,49]. In
this study, significant level of RET was detected early in
development (E7), similar to NCAM 140 but not NCAM
120/180 or GFRa1a. In most of the tissues examined,
RET9 is the predominant isoform expressed. It is not
known if the spliced GFRa1 isoforms may preferentially
activate specific isoforms of RET.
GFRa are expressed more widely than RET in many
regions of the nervous system in vivo [48,55], raising the
possibility that RET-independent GFRa may act to capture
and concentrate diffusible GFLs and subsequently present-
ing them in trans to RET-expressing cells to stimulate RET
signaling [27,32]. Other evidence suggests that GFRa can
mediate GFL signaling in a RET-independent manner
through the neural cell adhesion molecule (NCAM) [33].
The physiological importance of trans-signaling and
GFRa1-dependent NCAM signaling in the development
of the nervous system or the kidney has recently been
challenged [14]. However, the study could not rule out the
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Interestingly, neither RET nor NCAM isoforms were
detectable in the liver where high levels of GFRa1 isoforms
were found, raising the possibility of the existence of yet to
be identified co-receptor/s or signaling through RET/
NCAM-independent pathway/s. Another possibility is that
other alternatively spliced RET isoform not detected by the
highly specific real-time PCR assay developed herein may
exist. This is consistent with the Northern blot analyses with
a probe encoding the tyrosine kinase sequence of RET
showing bands smaller than 4 kb in certain tissues (liver,
heart and testis). The identity of these bands is currently
investigated.
GFRa1a appears to be structurally organized into distinct
domains [13]. Domain 3 has been crystallized and has been
used to model domain 2 [21]. Interestingly, the predicted
domain 2 helices [2] showed the same positions of cysteine
residues which are thought to form disulfide bridges as
observed in the helices in domain 3. Both domains 2 and 3
are involved in the binding of GDNF. Domains 1 and 2 are
thought to be linked by an extended loop (residues 114–
144). The absence of the 5 amino acids (140DVFQQ144) in
GFRa1b isoform may confer significant structural differ-
ences between the spliced isoforms which may have
different functional consequences. To test the hypothesis
that the spliced GFRa1 isoforms have distinct functions, we
used DNA microarray to analyze NTN stimulation of
GFRa1 isoforms in transfected cells. Both GFRa1 isoforms
when stimulated by GDNF or NTN resulted in the rapid
phosphorylation and nuclear localization of ERK1/2,
specifically through the MEK pathway. An early time point
was then chosen to examine the gene profile of NTN
stimulation of GFRa1 isoforms. Stimulation with NTN
resulted in specific gene changes which are not shared by
the isoforms, indicative of distinctive functional roles.
Consistent with this finding, a recent report showed
biochemical differences in the activation of the spliced
variants [8].
It is now believed that a substantial fraction of the human
genes (¨74%) produce alternatively spliced transcripts [18].
A significant proportion of these alternative-splicing events
are thought to alter the resulting protein products, which
may result in altered functions [28]. The differential
expression and distinct functional response of spliced
isoforms of GFRa1 are consistent with the emerging view
that the combinatorial interactions of these spliced isoforms
and the co-receptors may contribute to the multi-component
signaling system to produce the myriad of observed
biological responses.References
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Abstract
Glial cell line-derived neurotrophic factor (GDNF) and neur-
turin (NTN) are structurally related neurotrophic factors that
have both been shown to prevent the degeneration of dop-
aminergic neurons in vitro and in vivo. NTN and GDNF are
thought to bind with different affinities to the GDNF family
receptor alpha-2 (GFRa2), and can activate the same multi-
component receptor system consisting of GFRa2, receptor
tyrosine kinase Ret (RET) and NCAM. MicroRNAs (miRNAs)
are a class of short, non-coding RNAs that regulate gene
expression through translational repression or RNA degrada-
tion. miRNAs have diverse functions, including regulating
differentiation, proliferation and apoptosis in several organ-
isms. It is currently unknown whether GDNF and NTN regu-
late the expression of miRNAs through activation of the same
multi-component receptor system. Using quantitative real-time
PCR, we measured the expression of some miRNA precur-
sors in human BE(2)-C cells that express GFRa2 but not
GFRa1. GDNF and NTN differentially regulate the expression
of distinct miRNA precursors through the activation of mito-
gen-activated protein kinase (extracellular signal-regulated
kinase 1/2). This study showed that the expression of distinct
miRNA precursors is differentially regulated by specific lig-
ands through the activation of GFRa2.
Keywords: GDNF family receptor alpha-2, glial cell line-de-
rived neurotrophic factor, microRNA, neurturin, receptor tyr-
osine kinase Ret.
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Glial cell line-derived neurotrophic factor (GDNF), neurturin
(NTN), artemin and persephin are cysteine-knot proteins and
are structurally related neurotrophic factors (Airaksinen and
Saarma 2002). These GDNF family ligands (GFLs) have been
shown to support the growth, maintenance and differentiation
of a wide variety of neuronal and extraneuronal systems
(Saarma and Sariola 1999; Airaksinen and Saarma 2002).
GFLs exert their effects through a multi-component receptor
system consisting of GDNF family receptor alpha (GFRa),
receptor tyrosine kinase Ret and neural cell adhesion
molecule (NCAM) (Airaksinen et al. 1999; Paratcha et al.
2003). Each GFL is known to bind preferentially to one GFR
(in vitro), and the activation of the multi-component receptor
system shows some degree of promiscuity in ligand specif-
icity (Horger et al. 1998; Airaksinen et al. 1999; Cik et al.
2000; Wang et al. 2000; Scott and Ibanez 2001). Mice
lacking GDNF, GFRa1 or RETshare common phenotypes for
kidney agenesis and the absence of many parasympathetic
and enteric neurons (Enomoto et al. 1998, 2001; Cullen-
McEwen et al. 2001). NTN or GFRa2 knock-out mice show
similar deﬁcits in parasympathetic and enteric innervations,
but notable differences have been reported (Heuckeroth et al.
1999; Rosenthal 1999; Rossi et al. 1999). These phenotypic
differences may be due to a different genetic background of
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the mice used or, more interestingly, may suggest the
possibility of GDNF crosstalk through GFRa2 in vivo.
GDNF has been used in clinical trials and the results were
favorable in some reports (Gill et al. 2003; Slevin et al. 2005)
but not in others (Nutt et al. 2003; Peggy 2005). Although
crosstalk in development may be of limited signiﬁcance
(Airaksinen and Saarma 2002), it may be highly relevant
when exogenous GFLs are applied in vivo.
MicroRNAs (miRNAs) are small, non-coding RNAs that
serve as important post-transcriptional regulators of gene
expression in metazoans. To date, a large number of
miRNAs have been identiﬁed in diverse organisms, inclu-
ding vertebrates and plants (Dugas and Bartel 2004; Harfe
2005). The number of miRNA genes appeared to be greater
than 1% of the predicted genes in humans (Lim et al. 2003;
Bentwich et al. 2005). In many respects, miRNA genes
resemble protein coding genes in that they may possess
introns (Rodriguez et al. 2004) and are transcribed by RNA
polymerase II (Lee et al. 2004). In addition, the transcripts
from miRNA genes are capped, spliced and polyadenylated
(Cai et al. 2004). Pre-miRNA sequences are predicted based
on the folded structures and are derived from primary
transcript, pri-miRNA (Bartel 2004). The mature miRNA
(21–24 nucleotides) is located in the hairpin structure of pre-
miRNA and is produced through at least two RNAse III-
mediated steps (Lee et al. 2002; Du and Zamore 2005). It is
now clear that miRNAs exert their functions by binding to
complementary sequences on target mRNAs, inducing
cleavage of mRNAs or repression of protein translation
(Ke et al. 2003; Nelson et al. 2003; Bartel 2004; Pillai
2005). miRNAs have extensive regulatory roles, including
involvement in development, cell proliferation, cell death
and morphogenesis (Ambros 2003; Miska 2005; Pillai
2005).
It is currently unknown whether GDNF and NTN can
regulate the expression of miRNAs in various cellular
processes. In this study, the human BE(2)-C cell line, which
express GFRa2 but not GFRa1, was used to examine the
regulation of some miRNA precursors (pre-miRNAs and pri-
miRNAs) by GDNF and NTN. Interestingly, the results
showed that despite the promiscuity of ligand–receptor
interaction, GDNF and NTN regulate the expression of
distinct miRNA precursors through the activation of the
mitogen-activated protein kinase (MAPK) [extracellular
signal-regulated kinase (ERK1/2)] signaling pathways.
Materials and methods
Cell culture
Neuroblastoma BE(2)-C (CRL-2268) cells were purchased from
ATCC (Manassas, VA, USA). Cells were grown in 10% fetal bovine
serum (FBS; HyClone, Logan, UT, USA) at 37C in 5% CO2, as
previously described (Kobori et al. 2004).
Isolation of RNA and reverse transcription
Total RNA from BE(2)-C cells was prepared and the integrity of the
samples was validated by denaturing agarose gel electrophoresis, as
described previously (Too and Maggio 1995). A 1–5 lg aliquot of
total RNA was reverse-transcribed using 400 U ImpromII and
0.5 lg random hexamer (Promega, Madison, WI, USA) for 60 min
at 42C, according to the manufacturer’s instructions. The reaction
was terminated by heating at 70C for 5 min and was used directly
for quantitative real-time PCR. Six independent preparations of
cDNA were used for the quantiﬁcation of GFRa, NCAM and RET
levels in BE(2)-C cells. All measurements were made in triplicate.
Quantitative real-time PCR of GFRa, NCAM and RET
Quantitative real-time PCR was performed on the iCycler iQ (Bio-
Rad, Hercules, CA, USA) using Sybr Green I. The threshold cycles
(Ct) were calculated automatically using OPTICAL INTERFACE v3.0B
(Bio-Rad, Hercules, CA, USA). Real-time PCR was performed after
an initial denaturation for 3 min at 95C, followed by 40–50 cycles
of 60 s denaturation at 95C, 30 s annealing at 60C and 60 s
extension at 72C. Fluorescent detection was done at the annealing
phase. The reaction was carried out, in a total volume of 50 lL, in
1· XtensaMix-SG (BioWORKS, Singapore) containing 2.5 mM
MgCl2, 10 pmol of primers and 1.25 U platinum DNA polymerase
(Invitrogen Carlsbad, CA, USA). Melt-curve analyses and agarose
gel electrophoresis were carried out at the end of PCR to verify the
identity of the products. Speciﬁc primers were designed to amplify
the 3¢ GPI (glycosylphosphatidylinositol) sequences of GFRa1 or
GFRa2, and do not distinguish between various alternatively-
spliced isoforms. Primers used for amplifying GFRa1 were
HuGFRa1-GPI 1220F (TGTCGGGCAATACACACCTC) and
HuGFRa1-GPI 1364R (AGAGCGGTTACCACCAGGA). GFRa2
was ampliﬁed using HuGFRa-2a-1263F (CTTCACAGAGCTCAC-
GACAAA) and HuGFRa-2a-1381R (TCAGCATCAGGACAGA-
CAGC). A pair of primers (TTCATCGGGACTTG GCAGC/
ACCATACATCACTTTGCGTG) was designed to amplify the
common tyrosine kinase domain of RET and does not distinguish
between the isoforms (RET9 and RET51). The N-terminal domain
of NCAM was ampliﬁed using primers hNCAMC-F341 (CAG-
CAGCGGATCTCAGTGGT) and hNCAMC-R547 (CATCACA-
CACAATCACGGCA). GAPDH transcript was ampliﬁed using
primers huGAPDH-435F (GATCATCAGCAATGCCTCCT) and
huGAPDH-597R (GCCATCACGCCACAGTTT). All real-time
PCR quantiﬁcations were carried out simultaneously with linearized
plasmid standards and no template controls. The concentrations of
GFRa, RET and NCAM in BE(2)-C cells were interpolated from
standard curves and normalized to the expressions of glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH).
Quantification of miRNAs precursors
Total RNA was extracted from BE(2)-C cells using Trizol reagent
(Invitrogen) with linear acrylamide (20 lg/mL; Ambion Inc., Austin,
TX, USA). The concentration of total RNA and the integrity of the
RNAwere quantiﬁed by absorbance (260 nm) and by 1% denaturing
agarose gel electrophoresis. Further veriﬁcations were carried out
using the Experion RNA StdSens analysis kit according to the
manufacturer’s instructions (Bio-Rad). Total RNA samples were
treated with RNase-free DNase I (Promega) and inactivated at 80C
for 5 min, according to manufacturer’s recommendation. The DNAse
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I-treated RNA samples were initially heated at 80C in the presence
of 15 pmol of pre-validated, gene-speciﬁc reverse primers (Schmitt-
gen et al. 2004) for 5 min, snap-chilled on ice and reverse transcribed
[1 · buffer, dNTPs (10 mM), dithiothreitol (DTT), RNase inhibitor,
Thermoscript (15 U)] as speciﬁed by the manufacturer (Invitrogen).
The reverse transcription was carried out at 60C for 45 min and
terminated by a further incubation at 85C for 5 min. The samples
were then used for quantitative real-time PCR, as described above,
using gene-speciﬁc primers (Schmittgen et al. 2004). The real-time
PCR primers used here amplify both the short hairpin structures of
the miRNA precursors, primary (pri-miRNAs) and pre-miRNAs. The
fold changes in the target miRNA, normalized to U6 RNA and
relative to the expression in control sample, was calculated for
each sample using the equation: 2–DDCt, where DDCt ¼ (CtmiRNA )
CtU6RNA)stimulated ) (CtmiRNA ) CtU6RNA)control.
Ligand stimulation of cells
BE(2)-C cells were seeded in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) with 10% FBS for 24 h, followed by serum depletion
(0.5% FBS) for 16 h. The cells were then treated with 50 ng/mL
GDNF or NTN (PreproTech, London, UK) in serum-free medium
for the designated length of time at 37C. Control treatment with
1 M sorbitol (Sigma, St. Louis, MO, USA) was carried out
simultaneously for the analyses of MAPK activation. To control
for variability, two identical plates of cells were stimulated
simultaneously. One of the two plates of cells was used for direct
RNA isolation and the other was used for western blot analysis. For
inhibitor studies, MEK1/2 inhibitor, U0126 (Promega), was added
simultaneously with the ligands or, alternatively, cells were pre-
treated with the inhibitor for 20 min prior to the addition of ligands.
Western blot analysis of MAPK (ERK1/2) phosphorylation
Ligand stimulations were terminated by removing the supernatant
ﬂuids, then the cells were washed once with phosphate-buffered
saline (PBS). The cells were lysed in 2% sodium dodecyl sulfate
(SDS) and protein concentrations were determined using bicinch-
oninic acid (BCA; Pierce, Rockford, IL, USA). ERK1/2 phos-
phorylation was analyzed by the SuperSignal western blotting kit
(Pierce) using phospho-speciﬁc antibody (p-Thr202/204) according
to the manufacturer’s instructions (Cell Signaling Technology,
Danvers, MA, USA). Blots were stripped and either re-probed with
actin (Dako, Glostrup, Denmark) or pan ERK1/2 antibodies
(Promega) to verify equal loading of proteins. For kinetic studies,
total cell extracts (5 lg) were blotted onto Hybond-N (Amersham
Biosciences, Little Chalfont, UK) using the BIO Dot Apparatus
(Bio-Rad). Western blots were detected with ERK1/2 phospho-
speciﬁc antibody (p-Thr202/204) using the UltraSignal Chemilu-
minscent kit (Pierce) according to the manufacturer’s instructions.
Chemiluminescence was imaged and analyzed by QUANTITY ONE
version 4.0 (Bio-Rad).
Results
Neuroblastoma BE(2)-C cells express GFRa2, NCAM
and RET
The quantitative real-time PCR assays designed for GFRa1
and GFRa2, NCAM and RET were highly sensitive (detec-
tion limit of 10 copies per reaction) and speciﬁc, showing
only single products of the predicted sizes corresponding to
the amplicons as observed by gel electrophoresis (data not
shown). The ampliﬁcation efﬁciencies of cDNA at different
concentrations of RNA were greater than 95% and were
identical to the respective standards used. Melt-curve analy-
ses showed the predicted melting proﬁles, and all ampliﬁed
products were validated by DNA sequencing. Using these
assays, NCAM, RET and GFRa2, but not GFRa1, were
detected in BE(2)-C cells (Fig. 1a). In BE(2)-C cells, the
GFRa1 transcript level was below the detection limit of the
assay and estimated to be less than 1 : 106 when expressed as
the ratio of GFRa1 to GAPDH. The absence of GFRa1
expression in BE(2)-C cells was not due to failure of
detection by the real-time PCR assay as the same assay, when
used to quantify the expression level of the transcript in adult
human brain, showed signiﬁcant levels of GFRa1 (a ratio of
GFRa1 to GAPDH of 0.08 ± 0.002). Ampliﬁcations of
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Fig. 1 Expression levels of GFRa, RET and NCAM transcripts in
human neuroblastoma BE(2)-C cells by quantitative real-time PCR. (a)
GFRa2, RET and NCAM were expressed at significant levels com-
pared with GFRa1. The expression of GFRa1 was below the detection
limit of the assay (< 1 : 106, when expressed as the ratio of GFRa1 to
GAPDH). The results are expressed as mean ± SEM of at least three
independent experiments. (b) Amplification of GFRa1 (lane 1), GFRa2
(lane 2), RET (lane 3) and NCAM (lane 4) from BE(2)-C cells using
primers as described in the Material and methods. Amplifications with
primers designed to exons 1–4 of the GFRa2 gene using cDNA from
human adult brain (lane 5) and BE(2)-C (lane 6) were carried out using
primers (huGFRa2-1F: ATGATCTTGGCAAACGTCTT and huGFRa2-
526R: TCTTGCAGTTGTCATTCAGGT). The amplified products and
the 100 bp DNA marker (M) were resolved in a 2% agarose gel.
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human brain, using GFRa2 primers designed to amplify
exons 1–4 (Wong and Too 1998), showed multiple products.
Three distinct products (about 500, 200 and 100 bp) were
observed in human brain and only two of these (about 500
and 200 bp) were observed in BE(2)-C cells (Fig. 1b). These
products were subsequently veriﬁed by sequencing to
correspond to the exon organizations of previously known
alternatively-spliced isoforms GFRa2a (526 bp), GFRa2b
(211 bp) and GFRa2c (127 bp). The signiﬁcant expressions
of GFRa2, NCAM and RET in BE(2)-C cells thus provided a
suitable model for further studies.
Regulation of MAPK (ERK1/2) phosphorylation by
GDNF and NTN
Both GDNF and NTN activated MAPK (ERK1/2) rapidly in
BE(2)-C cells (Fig. 2a). The responses to GDNF and NTN
were similar in kinetics and sustainable over a period of 6 h
(Fig. 2b). The MEK1/2 inhibitor, U0126, inhibited GDNF-
and NTN-induced phosphorylation of MAPK (ERK1/2) in a
dose-dependent manner (Fig. 2c). At the concentrations
used, there was no evidence of cell death as measured
by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) conversion assay (data not shown). This result
suggests that GDNF and NTN activate MAPK signaling by
phosphorylation on Thr202/204 of ERK1/2 through GFRa2.
Regulation of miRNA precursor expression by GDNF
and NTN
In total, 23 pairs of pre-validated primers designed to anneal
to the hairpin of miRNA precursors (Schmittgen et al. 2004)
were used to quantify cDNA samples prepared from BE(2)-C
cells. Initial attempts to co-reverse transcribe and accurately
quantify both U6 and the miRNA precursors simultaneously
were unsuccessful. The ampliﬁcation of U6 from cDNA
samples prepared from 1 lg RNA consistently showed Ct
values of about 16 cycles (Fig. 3a). This is equivalent to the
ampliﬁcation of 107 copies of GFRa2, which has a similar
amplicon size and PCR efﬁciency (3.5 cycles per log
dilution). The failure to detect amplicon after 40 cycles
(detection limit equivalent to one copy per reaction) deﬁned
the expression level of the miRNA precursors as undetect-
able. BE(2)-C cells were found to express eight of the 23
distinct miRNA precursors (miR-16, miR-18, miR-21, miR-
24-2, miR-92-1, miR-93-1, miR-107 and miR-124a-2). All
amplicons showed distinct melt curves (Fig. 3b) and the sizes
were veriﬁed by gel electrophoresis (Fig. 3c). GDNF was
found to transiently up-regulate the expressions of miR-21
and miR-24-2 precursors signiﬁcantly (Fig. 4a). Interestingly,
NTN was found only to down-regulate the expression of miR-
92-1 precursor (Fig. 4b). No signiﬁcant changes in the
expression of the other miRNA precursors were observed.
To determine the contribution of the MAPK pathway in
the regulation of the expression of miRNA precursors,
U0126 was used to inhibit MEK1/2 activation (Fig. 5).
At the submaximal dose (2.5 lM), U0126 inhibited the
up-regulation of miR-21 (Fig. 5a) and miR-24-2 precursor
expressions induced by GDNF (Fig. 5b), and the down-
regulation of miR-92-1 precursor expression by NTN
(Fig. 5c).
Differentiation of BE(2)-C cells with GDNF and NTN
Both miR-21 and miR-24-2 have previously been shown to
be up-regulated in 12-O-tetradecanoylphorbol-13-acetate
(TPA) differentiated HL-60 (Kasashima et al. 2004) and














































































GDNF: - +     +     +       +       +           - - - - - -
NTN: - - - - - - - +    +     +      +      +
U0126 1.0µM: - -     +      - - - - -     +      - - -
U0126 2.5µM: - - -     +       - - - - -     +     - -
U0126 3.5µM:   - - - -      + - - - - -      +     -







Fig. 2 GDNF and NTN induce MAPK (ERK1/2) phosphorylation in
BE(2)-C cells. (a) Cells were stimulated with either GDNF or NTN and
phosphorylated ERK1/2 was detected by western Blot. (b) Kinetic
analyses of GDNF- and NTN-induced ERK1/2 phosphorylation. The
blots were stripped and re-probed with anti-pan ERK1/2 antibody for
the verification of protein loading (lower panels). (c) Concentration-
dependent inhibition of MAPK activation by U0126 in GDNF- and
NTN-stimulated BE(2)-C cells. The cells were pre-treated for 20 min
with different concentrations of U0126 inhibitor before exposure to
GDNF or NTN for a further 10 min. The results are expressed as
standard deviations of triplicate measurements, and similar results
were observed with three independent experiments.
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(Houbaviy et al. 2003). As these miRNA precursors were
similarly up-regulated by GDNF in BE(2)-C cells (Fig. 4a),
we examined the morphology of BE(2)-C cells when
induced by GDNF and NTN over a period of 5 days.
Differentiation of BE(2)-C cells was induced by retinoic
acid but not GDNF or NTN (Fig. 6). The expression levels
of miR-21 and miR-24-2 precursors in BE(2)-C cells were
signiﬁcantly increased by retinoic acid (Fig. 7). Interest-
ingly, miR-92-1, which was down-regulated by NTN, was
up-regulated by retinoic acid instead (Fig. 7).
Discussion
The results from this study reveal a novel function of GFRa2
in the regulation of miRNA precursors. This function is
mediated by MAPK (ERK1/2), and the downstream regula-
tion of distinct miRNA precursors is dependent on the ligand
used.
GFRa2 and GFRa1 share about 48% amino acid identity
and nearly complete conservation of cysteine residues,
suggesting that these two receptors have similar three-
dimensional structures and possibly share similar functions
(Jing et al. 1997; Scott and Ibanez 2001). This is consistent










Fig. 3 Real-time PCR amplifications of miRNA precursors. Gene-
specific primers designed to the hairpin of miR-107 and miR-147
precursors were used for amplification using cDNA samples prepared
from BE(2)-C cells. (a) Real-time PCR quantification plot showing
amplifications of U6 and miR-107. miR-147 amplicon was not detec-
ted, even after 40 cycles of amplification. No template controls showed
background fluorescence, even after 40 cycles of amplification. (b)
Melt-curve analysis after 40 cycles of amplification. Melt-curve ana-
lysis after amplifications showed distinct peaks of miR-107 and U6
products. (c) Gel electrophoresis of short hairpin products after
amplification by real-time PCR. Amplifications were carried out using
primers for the precursors of miR-107 (lane 1), miR-124a-2 (lane 2),
miR-92-1 (lane 3), miR-93-1 (lane 4), miR-21 (lane 5), miR-24-2 (lane
6), miR-16 (lane 7), miR-18 (lane 8) and U6 (lane 9). The amplified
products and the 25 bp DNA marker (M) were resolved in a 4%




































































Fig. 4 Regulation of miRNA precursor expression by GDNF and NTN.
miRNA precursor expression levels in BE(2)-C cells were expressed
as fold change on stimulation with GDNF (a) and NTN (b) over a
period of 6 h. Eight distinct miRNA precursors were detected in BE(2)-
C cells, as shown in the inserts. Similar results were obtained from at
least three independent experiments. Error bars indicate standard
deviations of triplicate measurements. Significant differences in gene
expression between ligand-stimulated and control cells were calcula-
ted using Student’s paired t-test. A value of p < 0.05 was considered
significant (**p < 0.001, *p < 0.05).
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with evidence from transfected cells and primary cultures,
where GDNF and NTN have similar properties in activating
the multi-component receptor complex (Baloh et al. 1997;
Airaksinen et al. 1999; Wang et al. 2000; Scott and Ibanez
2001; Coulpier et al. 2002; Charlet-Berguerand et al. 2004).
Furthermore, midbrain dopaminergic neurons, which only
express GFRa1, appear to survive equally well with both
GDNF and NTN in vitro and in vivo (Horger et al. 1998),
and respond to neither ligand in the absence of GFRa1
(Cacalano et al. 1998). However, there are observations of
distinct functional differences with the use of speciﬁc
ligands. Although GDNF and NTN promote the survival of
dopaminergic neurons through GFRa1 (Cacalano et al.
1998; Akerud et al. 1999), only GDNF possesses neurito-
genic and hypertrophic effects (Akerud et al. 1999). In
cultured sympathetic neurons, GDNF was able to promote
the survival of cultured sympathetic neurons through
GFRa2, but NTN could not promote survival through
GFRa1 (Buj-Bello et al. 1997). Furthermore, GDNF, but
not NTN, could promote the axonal growth of dorsal root
ganglion (DRG) neurons through GFRa1 (Paveliev et al.
2004). Recently, GDNF and NTN have been shown to



















































































Fig. 5 Inhibition of miRNA precursor expression by U1026 in ligand-
stimulated cells. Cells were pre-treated for 20 min with 2.5 lM U0126
before exposure to GDNF or NTN. The up-regulation of miR-21 (a)
and miR-24-2 precursor (b) expression by GDNF was abolished in the
presence of U0126. Similarly, the down-regulation of miR-92-1 by NTN
(c) was abolished by U0126. The results were reproduced in at least
three independent experiments. Error bars indicate standard devia-
tions of triplicate measurements. Significant differences in the
expression of the genes between ligand-stimulated and control sam-
ples were calculated using Student’s paired t-test. A value of p < 0.05
was considered significant (**p < 0.001, *p < 0.05).
Control (0.5% media) + Retinoic Acid (5 uM) 
+ GDNF + NTN 
Fig. 6 Treatment of BE(2)-C cells with retinoic acid, GDNF and NTN.
Cells (20 000) were seeded on 6-well plates overnight in DMEM
supplemented with 10% FBS. Cells were then incubated in 0.5% FBS-
supplemented medium, with or without all-trans retinoic acid (5 lM),
GDNF (50 ng/mL) or NTN (50 ng/mL). The cells were then incubated
for 3 days. Retinoic acid-treated cells, but not GDNF- or NTN-treated
cells, showed neurite extension. The experiment was repeated at least
three times with similar results.
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expressing GFRa1 (Lee et al. 2006). The emerging view is
that the crosstalk of exogenously applied GDNF and NTN
with the non-preferred receptors may result in distinct
functions.
In order to address the signiﬁcance of GDNF and NTN
crosstalk in regulating the expression of miRNA in a deﬁned
system, a cell that expresses the multi-component receptor
complex with only one particular GFRa is required. The
distinct advantage of using quantitative real-time PCR is that
it allowed the reliable quantitative deﬁnitions of speciﬁcity,
sensitivity and efﬁciency of an assay compared with the
conventional end-point PCR-based assays (Wong and Medr-
ano 2005). Using the highly speciﬁc, efﬁcient and sensitive
quantitative real-time PCR assays developed in this study,
BE(2)-C cells were found to express NCAM, RET and
GFRa2, but not GFRa1. These cells express GFRa2a and
GFR2b, but not GFRa2c isoforms. The presence of GFRa2,
but not GFRa1, in BE(2)-C cells agrees with the previous
observation of Kobori et al. (2004) but not with a recent
report using semi-quantitative PCR (Hansford and Marshall
2005). Consistent with the suggestion that both GDNF and
NTN can activate the same multi-component receptor system,
GDNF has been shown to induce the enhancement of
phosphorylation and enzymatic activity of tyrosine hydroxy-
lase through the activation of GFRa2 (Kobori et al. 2004).
GDNF and NTN are known to activate, in a similar
manner, a number of signaling pathways, including ERK,
phosphatidylinositol-3-kinase (PI3K)/AKT, p38 mitogen-
activated protein kinase (MAPK) and c-Jun N-terminal
kinase (JNK) (Trupp et al. 1999; Takahashi 2001; Pezeshki
et al. 2003; Ichihara et al. 2004), and regulate the expres-
sions of various immediate early response genes (Fukuda
et al. 2003; Pezeshki et al. 2003). Intriguingly, stimulation
with GDNF and NTN resulted in similar kinetics of
activation of ERK1/2 but regulated the expressions of distinct
miRNAs. The rapid changes in gene expression of miR-21,
miR-24-2 and miR-92-1 parallel the rapid induction of early
response genes (Murphy et al. 2004; Sng et al. 2004).
Interestingly, miR-92-1, which was rapidly down-regulated
by NTN, was unaffected by GDNF stimulation but was
found instead to be up-regulated by retinoic acid stimulation.
Recently, neurotrophins have been shown to regulate the
expression of a miRNA (miR-132) through a cAMP-
dependent pathway, resulting in changes in neuronal mor-
phology (Vo et al. 2005). The stimulation of GFRa2 by
either GDNF or NTN did not result in neurite outgrowth in
BE(2)-C cells. However, when stimulated by retinoic acid,
these cells showed extensive neurite outgrowth and the
up-regulation of miR-21, miR-24-2 and miR-92-1.
Analysis of the proximal sequences of miR-21, miR-24-2
and miR-92-1 by computational prediction of eukaryotic
promoters (Scherf et al. 2000) revealed the existence of
multiple regulatory elements, suggesting that the expression
of these miRNAs may be regulated by multiple pathways,
similar to other RNA polymerase II-mediated transcripts (Lee
et al. 2004; Sng et al. 2004). The binding of NGF to TrkA
receptor is known to activate two or more distinct signaling
pathways, and the inhibition of a single pathway can inhibit
the expression of the transcription of some genes (Marek
et al. 2004). It is likely that the differential regulation of
distinct miRNA expression by GDNF and NTN in BE(2)-C
cells may similarly require the concerted signaling of multiple
signaling pathways. The integration of signaling pathways
regulating the expression of these miRNAs may provide a
means for a more precise transcriptional control, depending
on whether one or more pathways are activated. With the
innumerable distinct signaling pathways induced by activated
c-RET (Takahashi 2001; Ichihara et al. 2004), GDNF and
NTN, acting through the same receptor complex, appear to
activate two or more signaling mechanisms. The integration
of these pathways is a subject for further investigation.
miRNAs are now thought to be involved in a number of
physiological and developmental processes (Croce and Calin
2005; Harfe 2005; Miska 2005). Both miR-21 and miR-24-2
have been shown to be involved in cell proliferation and
differentiation, and are overexpressed in various human
cancers (Houbaviy et al. 2003; Kasashima et al. 2004; Chan
et al. 2005; Iorio et al. 2005). These two miRNAs were
up-regulated by GDNF and retinoic acid, but not NTN, in
BE(2)-C cells. NTN, but not GDNF, rapidly down-regulate
miR-92 expression in BE(2)-C cells. Interestingly, retinoic




























Fig. 7 Regulation of miRNA precursor expression in BE(2)-C by reti-
noic acid. The expression of miR-21, miR-24-2 and miR-92-1 pre-
cursors was up-regulated by retinoic acid over a period of 6 h. Similar
results were obtained from at least three independent experiments.
Error bars indicate standard deviations of triplicate measurements.
Significant differences in expression of miRNA precursors between
ligand-stimulated and control cells were calculated using Student’s
paired t-test. A value of p < 0.05 was considered significant
(**p < 0.001, *p < 0.05).
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miR-92 has previously been shown to be ampliﬁed, overex-
pressed as a polycistronic miRNA cluster (Ota et al. 2004)
and up-regulated in expression in some cancers (Calin et al.
2004). However, the function of miR-92 has yet to be
determined.
The speciﬁc regulation of the expression of these miRNAs
by GDNF and NTN suggests distinct functions associated
with the activation of GFRa2. It is likely that many more
miRNAs may be involved in various cellular processes, and
that the expression of speciﬁc clusters of these miRNAs may
be cell-type speciﬁc.
The search for miRNA targets by various algorithms
(Lewis et al. 2003; John et al. 2004; Krek et al. 2005) has
met with some success, and a recent study showed that some
of the targets escape prediction (Nakamoto et al. 2005). To
date, the speciﬁc targets of miR-21, miR-24-2 and miR-92-1
remain unknown, and predictions by various algorithms
suggest more than a hundred putative targets for each of
these microRNAs. In a continuing effort to further our
understanding of the biochemical events underlying GLF and
GFRa interactions, the quantitative changes in expression of
other miRNA precursors (Jiang et al. 2005) and mature
forms of miRNA (Chen et al. 2005; Raymond et al. 2005;
Shi and Chiang 2005) are currently under investigation.
In summary, we have shown that GDNF and NTN
speciﬁcally regulate the expression of distinct miRNAs
through the same GFRa2 and multi-component receptor
system. We have also provided the ﬁrst evidence that the
upstream regulation of the expression of some of these
miRNAs by GDNF and NTN involves the same MAPK
(ERK1/2) signaling pathway.
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Glial Cell Line-Derived Neurotrophic Factor and Neurturin
Inhibit Neurite Outgrowth and Activate RhoA through
GFR2b, an Alternatively Spliced Isoform of GFR2
Li Foong Yoong1 and Heng-Phon Too1,2
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The glial cell line-derived neurotrophic factor (GDNF) and neurturin (NTN) belong to a structurally related family of neurotrophic
factors. NTN exerts its effect through a multicomponent receptor system consisting of the GDNF family receptor 2 (GFR2), RET,
and/or NCAM (neural cell adhesion molecule). GFR2 is alternatively spliced into at least three isoforms (GFR2a, GFR2b, and
GFR2c). It is currently unknownwhether these isoforms share similar functional and biochemical properties. Using highly specific and
sensitive quantitative real-time PCR, these isoforms were found to be expressed at comparable levels in various regions of the human
brain. When stimulated with GDNF and NTN, both GFR2a and GFR2c, but not GFR2b, promoted neurite outgrowth in transfected
Neuro2A cells. These isoforms showed ligand selectivity in MAPK (mitogen-activated protein kinase) [ERK1/2 (extracellular signal-
regulated kinase 1/2)] andAkt signaling. In addition, theGFR2 isoforms regulated different early-response geneswhen stimulatedwith
GDNF or NTN. In coexpression studies, GFR2b was found to inhibit ligand-induced neurite outgrowth by GFR2a and GFR2c.
Stimulation of GFR2b also inhibited the neurite outgrowth induced byGFR1a, anothermember of the GFR. Furthermore, activation
of GFR2b inhibited neurite outgrowth induced by retinoic acid and activated RhoA. Together, these data suggest a novel paradigm for
the regulation of growth factor signaling and neurite outgrowth via an inhibitory splice variant of the receptor. Thus, depending on the
expressions of specific GFR2 receptor spliced isoforms, GDNF and NTNmay promote or inhibit neurite outgrowth through the multi-
component receptor complex.
Key words: GDNF; NTN; GFR2; RhoA; inhibitory splice isoforms; neuroblastoma
Introduction
Neurturin (NTN), glial cell line-derived neurotrophic factor
(GDNF), Artemin, and Persephin are cysteine knot proteins and
are members of the GDNF family ligands (GFLs) (Kotzbauer et
al., 1996; Airaksinen and Saarma, 2002). These GFLs have been
shown to support the growth, maintenance, and differentiation
of a wide variety of neuronal and extraneuronal systems (Saarma
and Sariola, 1999). Each GFL is known to bind preferentially to
one GDNF family receptor  (GFR) in vitro, and the activation
of the multicomponent receptor system shows some degree of
promiscuity in their ligand specificities (Horger et al., 1998;
Airaksinen et al., 1999; Cik et al., 2000; Wang et al., 2000; Scott
and Ibanez, 2001). NTN is thought to signal through its preferred
receptor complex consisting of GFR2, RET, and/or neural cell
adhesion molecule (NCAM) (Baloh et al., 1997; Buj-Bello et al.,
1997; Widenfalk et al., 1997; Paratcha et al., 2003).
Alternative splicing is prevalent in many mammalian ge-
nomes, as a means of producing functionally diverse polypep-
tides from a single gene (Blencowe, 2006). It has been estimated
that 50% of human multi-exon genes are alternatively spliced
(Modrek andLee, 2002).Multiple alternatively spliced variants of
GFR1 (Sanicola et al., 1997; Dey et al., 1998; Shefelbine et al.,
1998), GFR2 (Wong and Too, 1998; Dolatshad et al., 2002), and
GFR4 (Lindahl et al., 2000, 2001;Masure et al., 2000) have been
reported. Similarly, alternative spliced isoforms of the corecep-
tors RET (Lorenzo et al., 1997; de Graaff et al., 2001; Lee et al.,
2002) and NCAM (Povlsen et al., 2003; Buttner et al., 2004) have
been reported. The alternatively spliced isoforms of GFR1 have
recently been shown to exhibit distinct biochemical functions
(Charlet-Berguerand et al., 2004; Yoong et al., 2005). These ob-
servations are consistent with the emerging view that the combi-
natorial interactions of the spliced isoforms of GFR, RET, and
NCAMmay contribute to the multicomponent signaling system
to produce the myriad of observed biological responses.
We have previously shown that all three isoforms of GFR2
are expressed at significant levels in the murine whole brain and
embryo (Too, 2003). It is, however, unknown whether these iso-
forms serve distinct or redundant functions. To gain a better
insight into their biological relevance in the CNS, the expression
levels of the isoforms in different regions of the humanbrainwere
quantified by highly specific real-time PCR assays. The biological
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functions of the isoforms were then examined in a neuronal dif-
ferentiation model using Neuro2A cells and in BE(2)-C cells,
which express the spliced isoforms endogenously.
Here, we showed that ligand activation of the isoforms differ-
entially activated mitogen-activated protein kinase (MAPK) [ex-
tracellular signal-regulated kinase 1/2 (ERK1/2)] and AKT sig-
naling and regulated distinct early-response genes. Furthermore,
both GDNF and NTN induced neurite outgrowth through
GFR2a and GFR2c, but not GFR2b. Activation of GFR2b
inhibited neurite outgrowth induced by the other two GFR2
isoforms as well as GFR1a and retinoic acid. RhoA was also
found to be activated by GDNF andNTN through GFR2b. This
study thus provides the first piece of evidence of a dominant
inhibitory activity of GFR2b on neurite outgrowth and distinct
signaling mechanisms underlying the activation of spliced
isoforms.
Materials andMethods
Cell culture. Neuro2A (catalog #CCL-131; American Type Culture Col-
lection, Manassas, VA) and BE(2)-C (catalog #CRL-2268; American
TypeCulture Collection) cells were grown inDMEMsupplementedwith
10% heat-inactivated fetal bovine serum (FBS; Hyclone, Logan, UT). All
cultures were maintained in a 5% CO2 humidified atmosphere at 37°C.
Reverse transcription reaction. Total RNA for different human brain
regions was purchased from Clontech (Palo Alto, CA). Total RNA from
Neuro2A cells was prepared as described previously (Too and Maggio,
1995). The integrity of isolated total RNA was validated by denaturing
agarose gel electrophoresis. Five micrograms of total RNA were reverse
transcribed using 400 U of ImpromII and 0.5 g of random hexamer
(Promega, Madison, WI) for 60 min at 42°C according to the manufac-
turer’s instructions. The reaction was terminated by heating at 70°C for 5
min, and the cDNA was used directly for quantitative real-time PCR.
Three independent preparations of cDNA were used for the study. All
measurements were performed in triplicate.
Plasmids constructions. To prepare plasmid standards for quantitative
real-time PCR, open reading frames of human GFR2 isoforms and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were subcloned
into p-GEMT (Promega). For early-response genes and transcriptional
factors, partial sequences were subcloned using the same primers used
for real-time PCR quantification. XbaI or XmnI (Promega) was used to
linearize plasmids to be used as templates for real-time PCR
amplifications.
Sequence-independent real-time PCR. Real-time PCR was performed
on the iCycler iQ (Bio-Rad, Hercules, CA) using SYBR Green I. The
threshold cycles (Ct) were calculated using the Optical interface version
3.0B. Real-time PCR was performed after an initial denaturation for 3
min at 95°C, followed by 40–60 cycles of 60 s denaturation at 95°C, 30 s
annealing at 60°C, and 60 s extension at 72°C. Fluorescent detection was
performed at the annealing phase. The reaction was performed in a total
volume of 50l in 1XtensaMix-SG (BioWORKS, Singapore), contain-
ing 2.5 mM MgCl2, 10 pmol of primer, and 1.25 U of Platinum DNA
polymerase (Invitrogen, Carlsbad, CA). Melt-curve analyses were per-
formed at the end of PCR to verify the identity of the products. A specific
exon-overlapping forward primer used for amplification of human
GFR2a was designated as “2a 15  9F” (5-TCTTCTTCTT-
TCTAGACGAGACCC-3), for human GFR2b as “2b 17  7F” (5-
CCTCTTCTTCTTTCTAGGTGAGGA-3), and for human GFR2c as
“2c 18  5F” (5-GCCTCTTCTTCTTTCTAGGGACA-3). A common
reverse primer, designated as “553R” (5-GCAGATGGAGATG-
TAGGAGGAG-3), was used for all three isoforms. The primer pair
5-GATCATCAGCAATGCCTCCT-3 and 5-GCCATCACGCCAC-
AGTTT-3 was used to amplify human GAPDH. All real-time PCR
quantification was performed simultaneously with linearized plasmid
standards and a nontemplate control. The gene expression levels were
interpolated from standard curves and normalized to the expressions of
GAPDH in the same samples. Differences in the expression levels of
GFR2 isoforms were analyzed using the paired Student’s t test with a
level of significance of p 0.05.
Generation of Neuro2A cells expressing GFR2 isoforms. The murine
neuroblastoma cell line Neuro2A, which express endogenous RET and
NCAM, was stably transfected with murine GFR2a, GFR2b, GFR2c,
or vector control pIRESneo (Clontech) using Fugene-6 (Roche, Mann-
heim, Germany) and selected with 0.8 mg/ml G418 (Promega), over a
period of 2 months. Primers used for measuring GFR2 isoforms, RET,
and NCAM expression were as described previously (Too, 2003; Yoong
et al., 2005). For coexpression studies, GFR2a, GFR2c, or GFR1awas
cloned into the proximal 5multiple cloning site, whereas GFR2b was
cloned into a distal 3multiple cloning site of the bicistronic pIRES vector
(Clontech). All studies were performed with three independent clones.
Assessment of neurite outgrowth in GFR2-transfected Neuro2A cells.
Twenty thousand to 50,000 cells per well were seeded on six-well plates
overnight, in DMEM supplemented with 10% FBS. Cells were then in-
cubated with medium containing 0.5% FBS, with or without 50 ng/ml
recombinant human GDNF (Biosource, Camarillo, CA) or NTN
(ProSpec-Tany TechnoGene, Rehovot, Israel). Cells were incubated for 3
more days. All-trans retinoic acid (5M; Sigma, St. Louis, MO) was used
as a positive control for inducing neurite outgrowth. Cells bearing at least
one neurite twice the length of the cell bodies were scored.More than 600
cells from three different fields were counted per well. Statistical signifi-
cance between ligand-stimulated and control samples was calculated us-
ing the paired Student’s t test. A value of p  0.05 was considered
significant.
Immunocytochemistry and confocal microscopy. Cells were seeded on
chamber slides, fixedwith 4%paraformaldehyde in 1PBS for 15min at
37°C, and subsequently fixed in methanol at20°C for an additional 15
min. After three washes with 1 PBS, cells were permeabilized and
blocked with serum (1:10; Dako, Glostrup, Denmark) and 0.5% Triton
X-100 in 1 PBS for 30 min at room temperature. The cells were then
incubated with F-actin (phalloidin-conjugated tetramethylrhodamine
isothiocyanate) and high-molecular-weight neurofilament protein (NF-
200) antibody (Sigma) in 0.1% Triton X-100, 0.1% BSA, and 1 PBS for
1 h at 37°C and washed three times in 1 PBS. A secondary antibody
(Alexa Fluor 488; Invitrogen, Eugene,OR)was then added at a dilution of
1:200 and incubated for 1 h. The cells were then washed in 1 PBS and
mounted for visualization. Image acquisition was obtained using a Zeiss
(Oberkochen, Germany) 510 meta confocal microscope equipped with
fluorescence detection.
Immunoblotting. Phosphorylation of MAPK (ERK1/2) or Akt was an-
alyzed as follows. Cells were initially seeded in DMEMwith 10% FBS for
24 h, and serum was depleted (0.5% FBS) for 16 h. The cells were then
treated with 50 ng/ml GDNF,NTN, Artemin, or Persephin (PreproTech,
London, UK) in serum-free medium for different periods of time at
37°C. For dose–response studies, cells were stimulated with different
concentrations of ligands for 10min at 37°C. Control treatment with 1 M
Sorbitol (Sigma) was performed simultaneously. The supernatants were
then removed, and cells were washed once with 1 PBS and subse-
quently lysed in 2% SDS. Protein concentrations were estimated using
the BCA assay (Pierce, Rockford, IL). ERK1/2 or Akt phosphorylation
was analyzed byWestern blot using phospho-specific antibodies accord-
ing to the manufacturer’s instructions (Cell Signaling Technology, Dan-
vers, MA). Blots were stripped with Restore Western Stripping Buffer
(Pierce) and reprobed with pan antibodies to verify equal loading of
protein.
For studying kinetics and dose–response of ligand-induced ERK1/2
activation, dot blot analysis was performed using the BIODot Apparatus
(Bio-Rad). Fivemicrograms of proteinwere loaded perwell in triplicates.
Blots were then detected by anti-phospho ERK1/2 antibodies (Cell Sig-
naling Technology) according to the manufacturer’s instructions. Den-
sities of blots were imaged andmeasured byQuantity One 4.0 (Bio-Rad).
Binding of [125I]GDNF to GFR2 isoforms transfected Neuro2A cells.
[ 125I] GDNF (1000 mCi/mmol) was prepared using Bolton and
Hunter reagent (Amersham Biosciences, Piscataway, NJ). Briefly, 10 g
of recombinant human GDNF (Biosource) was labeled with 1 mCi of
Bolton and Hunter reagent for 1 h at room temperature according to the
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manufacturer’s instructions. The reaction was then terminated by add-
ing 10 l of 0.1% tyrosine. Radiolabeled GDNF was then purified on a
Sephadex G-10 column.
Binding studies were performed as described previously (Jing et al.,
1997). Briefly, 0.1 million cells were seeded per well on 24-well Costar
(Cambridge,MA) tissue culture plates for 2 d before the assay. Before the
experiment, cells were placed on ice for 15–20min andwashed once with
ice-cold DMEM buffer and 25mMHEPES, pH 7.0. Cells were then incu-
bated at 4°C for 3 hwith 0.2ml of binding buffer [DMEM, 25mMHEPES,
2 mg/ml bovine albumin serum, and Complete Inhibitor Cocktail
(Roche), pH 7.0] containing 50 pM [125I]GDNF and various concentra-
tions of unlabeled GDNF. At the end of incubation, cells were washed
three times with 0.3 ml of ice-cold washing buffer and lysed in 0.1% SDS
containing 1 M NaOH. The radioactivity in lysates was measured using
the auto gamma counter (PerkinElmer Packard, Wellesley, MA).
Measurements of early-response genes regulated by GDNF and NTN.
Cells were seeded in DMEM with 10% FBS for 24 h, followed by serum
depletion (0.5% FBS) for 18–24 h. The cells were then treated with
GDNF (50 ng/ml) or NTN (50 ng/ml) in serum-freemedium for varying
periods of time at 37°C. Total RNA was then isolated and reverse tran-
scribed as described above. The gene expression levels were then quanti-
fied by real-time PCR using gene-specific primers. Primers used for am-
plification of early response genes were as follows: EGR-1-328F/EGR-1-
459R (5-GAGAAGGCGATGGTGGAGACGA-3/5-GCTGAAAAGG-
GGTTCAGGCCA-3) for egr-I; EGR-2-1F/EGR-2-179R (5-AT-
GAACGGAGTGGCGGGAGAT-3/5-TCTGGATAGCAGCTGGCAC-
CAG-3) for egr-2; mcfos(B)651F/mcfos(B)901R (5-TGTGGCCTC-
CCTGGATTT-3/5-CTGCATAGAAGGAACCGGAC-3) for c-fos; and
mFosB(A)1926F/mFosB(A)2107R (5-CAGGGTCAACATCCGCTAA-
3/5-GGAAGTGTACGAAGGGCTAACA-3) for fosB. Expression of
target genes and GAPDH was interpolated from standard curves. The
fold change of each target gene was calculated as a change in gene
expression of the stimulated sample normalized to GAPDH com-
pared with gene expression of the control sample normalized to
GAPDH.
Silencing of GFR2b in BE(2)-C. Small interfering RNA (siRNA) du-
plexes (Invitrogen) were designed across specific exon (exons 1 and 3)
boundaries of GFR2b (siGFR2b-155: TCTTCTTCTTTCTAGGT-
GAG; siGFR2b-137: TCTTCTTCTTTCTAGGTGAGGA; siGFR2b-
1010: TTCTTTCTAGGTGAGGAGTT; siGFR2b-713: TTTCTAG-
GTGAGGAGTTCTA; siGFR2b-515: TCTAGGTGAGGAGTTCTACG).
Subconfluent cells (50–80%) were seeded on six-well plates, in 10% FBS
DMEM. Cells were transfected with siRNA duplexes (20 pmol) using
Transfectin (Bio-Rad) in 400l of 0.5%FBSDMEMperwell. Total RNA
was isolated 6 h after transfection, and gene expression was measured by
real-time PCR. For differentiation studies using BE(2)-C, 6 h after silenc-
ing of GFR2b, 2 ml of differentiation medium containing retinoic acid
(5 M), GDNF (50 ng/ml), or NTN (50 ng/ml) in 0.5% FBS DMEMwas
added to the medium. Analyses of morphological differences were per-
formed after 3 d.
RhoA assay.Neuro2A cells were seeded in 10% FBS DMEM and incu-
bated for 18–24 h. Subsequently, the serum was reduced to 0.5% in
DMEM, and the cells were incubated for an additional 18–24 h. Cells
were then treatedwith 10M lysophosphatidic acid (LPA; Sigma),GDNF
(50 ng/ml), or NTN (50 ng/ml) in serum-free DMEM for 10 min. Cells
were lysed and used directly for the GTP-RhoA pull-down assay accord-
ing to the manufacturer’s instructions (Pierce). RhoA inhibitor exoen-
zyme C3 transferase and Rho kinase (ROCK) inhibitor Y27632 were
purchased from Calbiochem (La Jolla, CA). Exoenzyme C3 transferase
was transfected into cells using the lipotransfecting agent Transfectin
(Bio-Rad), at 1 l of Transfectin/1 g of C3 transferase per well of a
six-well plate, 4 h before start of the experiment. Cells were then treated
with RhoA inhibitor exoenzyme C3 transferase (1 g/ml) or ROCK in-
hibitor Y27632 (10 M), in the presence or absence of differentiating
stimuli. LPA (10M; Sigma)was used as a positive control for activities of
Rho and ROCK inhibitor.
Results
Differential expression profiles of GFR2 spliced variants
Currently, the expression levels of GFR2 spliced variants in spe-
cific regions of the brain are unknown. To address this issue, we
have developed sequence-independent real-time PCR assays to
quantify each of the spliced variants with high specificity and
sensitivity.
To discriminate between the three spliced variants of human
GFR2, overlapping exon primers were designed across exons 1
and 2, 1 and 3, or 1 and 4 to enable the specific detection and
quantification of GFR2a, GFR2b, and GFR2c, respectively
(Fig. 1A). Because the amplification products of GFR2a (545
bp), GFR2b (233 bp), and GFR2c (172 bp) were different in
sizes, it was critical to determine the optimal cycling parameters
for the selective amplification of each of the transcripts. A dwell
time of 30 s for annealing, 60 s for denaturation at 95°C, and 60 s
for extension at 72°C were found to be optimal for the amplifica-
tions of all three isoforms. The slopes of the plots of Ct versus
log10 mole of the human GFR2a, GFR2b, and GFR2c stan-
dards were 3.37 0.30 (r2	 0.98), 4.12 0.41 (r2	 0.99), and
3.82  0.54 (r2 	 0.99), respectively. The samples diluted in
parallel with the standards (data not shown). The specificity of
amplifying a particular isoform comparedwith the other variants
was 106-fold (data not shown). Hence, the amplifications of
GFR2b and GFR2c were at least 106-fold less efficient than
amplifying GFR2a, when using GFR2a exon-overlapping
Figure 1. Real-time PCR quantification of the expressions of GFR2 isoforms in the human
brain. A, A schematic diagram showing the protein coding exons and the positions of the
primers used for quantitative real-timePCR. Exons 1–9encode the full-lengthprotein sequence
of GFR2a. Specific forward primers (2a 15 9F for GFR2a, 2b 17 7F for GFR2b, and 2c
18 5F for GFR2c) were designed across exon junctions, whereas a common reverse primer
(553R) was used for the amplification of all the three isoforms. B, The expression levels of
GFR2 isoforms in a different human brain region normalized to the levels of GAPDH in the
same tissue. The results were expressed as mean  SEM (n 	 3). Significant differences
between theexpressions of the isoformswere calculatedusingpaired Student’s t test. A valueof
p 0.05 was considered significant (**p	 0.001).
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primers. The detection limits of the assays
were estimated to be100 copies of tran-
scripts per reaction.
Using these highly sensitive and spe-
cific assays, the expression levels of the
GFR2 alternatively spliced isoformswere
quantified in caudate nucleus, cortex, pu-
tamen, substantia nigra, subthalamic nu-
cleus, and thalamus of the human brain
(Fig. 1B). The three GFR2 isoforms were
detected at significant levels (104 copies
per reaction) in all areas of the brain, with
expression levels highest in the cortex. In
cortex, all three isoformswere expressed at
comparable levels, with GFR2b expres-
sion significantly lower than GFR2c
( p 0.01).
GFR2 isoforms differentially activated
ERK1/2 and Akt
To investigate the biological significance
of alternatively spliced GFR2 isoforms,
stable transfectants were generated in
Neuro2a cells. We have shown previously
that Neuro2a cells express RET and
NCAM, but not GFR2 receptors, endog-
enously (Yoong et al., 2005). The expres-
sion levels of GFR2 isoforms in stably
transfected Neuro2a cells (supplemental
Fig. 1, available at www.jneurosci.org as
supplemental material) were compara-
ble to that expressed in the human cor-
tex (Fig. 1B).
When stimulated with NTN, all the
three isoforms induced the rapid phos-
phorylation of ERK1/2 (Fig. 2A). How-
ever, when stimulated with GDNF,
GFR2a (Fig. 2A,C) and GFR2c (Fig.
2A,E), but not GFR2b (Fig. 2A,D), in-
duced significant ERK1/2 phosphoryla-
tion (more than twofold). The extent of
ERK1/2 phosphorylation was similar
whenGFR2a (Fig. 2C) andGFR2c (Fig.
2E) activated with either GDNF or NTN.
However, GFR2b showed rapid and sig-
nificant phosphorylation of ERK1/2 only
with NTN stimulation but not by GDNF
(Fig. 2A,D). Both GDNF and NTN in-
duced ERK1/2 phosphorylation in a dose–
responsemanner inGFR2a (Fig. 2F) and
GFR2c (Fig. 2H) transfectants. GDNF
appeared to be slightly more potent than
NTN in inducing ERK1/2 phosphoryla-
tion in both transfectants (Fig. 2F,H).
Compared with the stimulation with
NTN, GFR2b when stimulated with
GDNF showed no significant increase in
ERK1/2 phosphorylation even at the highest dose (Fig. 2G). No
significant increase in the phosphorylation of ERK1/2 was ob-
served in vector (pIRESneo) control transfected Neuro2A cells
when stimulated with either GDNF or NTN (data not shown).
We next investigated the ligand-regulated phosphorylation
of Akt using GDNF or NTN (Fig. 2B). NTN induced rapid and
significant phosphorylations of Akt in all three isoform trans-
fectants. However, GDNF induced the rapid and significant
phosphorylations of Akt in cells expressing GFR2b and
GFR2c.
The other GFLs, Artemin and Persephin, did not induce sig-
nificant phosphorylation of ERK1/2 or Akt in any of the GFR2
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Figure 2. Activations of ERK1/2 and Akt in GFR2 isoforms transfected Neuro2A cells when stimulated by either GDNF or NTN.
Cells were stimulated in serum-freemedium, with or without GDNF or NTN (50 ng/ml), for the period of time indicated. A,B, Five
micrograms of protein were loaded and separated by SDS electrophoresis, and phosphorylated ERK1/2 (pERK1/2; A) or Akt (pAkt;
B) was then detected by Western blot. Blots were stripped and reprobed with pan antibody as loading controls. C–E, Kinetics of
GDNF andNTN induced ERK1/2 activations in GFR2a (C), GFR2b (D), and GFR2c (E). Cellswere treatedwith 50 ng/ml GDNF or
NTN for 5, 15, and 30 min. F–H, Dose responses of the activation of ERK1/2 when stimulated with GDNF or NTN in GFR2a (F ),
GFR2b (G), and GFR2c (H ) isoforms. Cells were stimulated for 10 min with ligand at various doses. For kinetic and dose–
response studies, 5g of proteinwas loaded per well for dot blot quantification of phospho-ERK1/2 (pERK1/2). Themeans SD
were calculated from results obtained in triplicates. Significant differences in fold change of pERK1/2 between ligand stimulated
and control were calculated using the paired Student’s t test. A value of p 0.05was considered significant (**p 0.001; *p
0.05). Experiments were repeated three times with two independent clones with similar results.
5606 • J. Neurosci., May 23, 2007 • 27(21):5603–5614 Yoong and Too • Inhibitory Activity of GFR2b in GDNF Signaling
isoform transfectants (data not shown). In addition, neither
GDNF nor NTNwas found to activate p38 and c-Jun N-terminal
kinase (JNK) in any of the GFR2 isoform transfectants, even at
concentrations as high as 100 ng/ml and over a period of 1 h of
ligand stimulation (data not shown).
[125I]GDNF bound equally well to all three GFR2 isoforms
NTNhas been shown to bind with similar affinities to the GFR2
isoforms (Scott and Ibanez, 2001). Because GDNF failed to in-
duce a significant increase in the phosphorylation of ERK1/2 in
GFR2b transfectants (Fig. 2A,D,G), it is possible that GDNF
may not bind to this isoform. To address this possibility, we next
performed a ligand displacement study using [125I]GDNF (sup-
plemental Fig. 2, available at www.jneurosci.org as supplemental
material). GDNF displaced the binding of [125I]GDNF to the
three GFR2 isoforms with similar potencies. The IC50 for the
displacements of cells transfected with GFR2a, GFR2b, and
GFR2c were 3.27  0.02, 2.79  0.16, and 2.31  0.09 nM
(mean SD), respectively. Parental Neuro2A or cells transfected
with pIRESneo showed no significant binding to [125I]GDNF.
This result indicates that GDNF binds to all three isoforms with
similar affinities.
GFR2 isoforms activated different transcriptional genes
The differential activation of ERK1/2 andAkt (Fig. 2) suggests the
possibility that downstreambiochemicalmechanismsmay differ.
To explore this issue, we measured the
changes in gene expression of the fos fam-
ily (c-fos, fosB), jun family (c-jun, jun-b),
egr family (egr1–4), and GDNF-inducible
transcription factorsmGIF andmGZF1 in
response to GDNF andNTN (supplemen-
tal Table 1, available at www.jneurosci.org
as supplemental material). These factors
have previously been shown to be acti-
vated with GDNF or NTN (Yajima et al.,
1997; Trupp et al., 1999; Kozlowski et al.,
2000; Fukuda et al., 2003; Pezeshki et al.,
2003). The kinetics of gene activations
over a period of 6 h was quantified by real-
time PCR (Fig. 3). Distinct ligand-
induced early-response gene expressions
were observed with the activation of the
different GFR2 isoforms. GFR2a, when
stimulated by GDNF (Fig. 3A) or NTN
(Fig. 3B), upregulated egr-1 by as much as
fourfold to fivefold. GFR2b, when stim-
ulated by GDNF (Fig. 3C) or NTN (Fig.
3D), upregulated fosB by 10-fold com-
pared with control. When stimulated with
GDNF (Fig. 3E) or NTN (Fig. 3F),
GFR2c upregulated the expressions of
egr-1 and egr-2. With the other genes, no
significant changes were observed with
GDNForNTN stimulations. These results
showed that the activation of GFR2b iso-
form regulates the transcription of specific
sets of early-response genes.
Neurite outgrowths were induced by
GFR2a and GFR2c, but not GFR2b
Neuro2a cells serve as an excellent in vitro
model system for studying signaling path-
waysmediating neurite outgrowth. Under normal growth condi-
tions, most Neuro2a cells spontaneously sprout a basal level of
neurites. However, treatment with a variety of stimuli cause these
cells to develop extensive neurites similar to changes observed in
hippocampal and cortical cultures (Ahmari et al., 2000; Wash-
bourne et al., 2002).
To investigate possiblemorphological changes induced by the
activation of the GFR2 isoforms, the transfectants were stimu-
lated with either GDNF or NTN. Both GFR2a and GFR2c
transfectants showed extensive neurite outgrowths when stimu-
lated with either ligand, comparable to the effects of retinoic acid
(Fig. 4). Unexpectedly, neither NTN nor GDNF induced neurite
outgrowth in cells expressing GFR2b (Fig. 4). Immunocyto-
chemical staining for-III tubulin confirmed these observations.
(supplemental Fig. 3, available at www.jneurosci.org as supple-
mentalmaterial). Cells expressingGFR2b extended neurite-like
structures when treated with retinoic acid, indicative of the po-
tential for neurite outgrowth (Fig. 4A). GDNF andNTN have no
neuritogenic effect on control vector-transfected Neuro2A cells
(Fig. 4).
To further examine the morphological changes in these cells,
twomajor cytoskeletal components, F-actin andhigh-molecular-
weight neurofilament protein (NF-H), which are involved in
neurite outgrowth dynamics, were visualized by fluorescent
staining (Myers et al., 2006). With ligand (GDNF or NTN)-
stimulated GFR2a and GFR2c transfectants, NF-H-positive
















































































Figure 3. Kinetic analyses of the regulations of early-response genes by GDNF and NTN in GFR2 isoform transfectants. The
fold change of mRNA expressions of early-response genes in cells expressing GFR2a (A), GFR2b (C), and GFR2c (E) when
stimulatedwith GDNF andGFR2a (B), GFR2b (D), and GFR2c (F ) when stimulatedwith NTN at the designated period of time
is shown. The expression levelsweremeasured by quantitative real-time PCR. Similar resultswere obtained frommore than three
separate experiments. Error bars indicate SDs of triplicate measurements from one study. Significant differences in expression of
genesbetween ligand stimulated and controlwere calculatedusing thepaired Student’s t test. A valueofp0.05was considered
significant (**p 0.001; *p 0.05).
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filopodia (axon-like processes) were rela-
tively long and formed thick threads. Pro-
trusions with F-actin staining were ob-
served at the edges of the thick NF-H-
positive axon-like elements and cell bodies
(supplemental Fig. 4C, arrowheads, avail-
able at www.jneurosci.org as supplemen-
tal material). Engorgements were seen at
some terminal structures that were both
NF-H and F-actin positive (supplemental
Fig. 4C, arrow, available at www.jneurosci.
org as supplemental material). Long exten-
sions were not obvious with cells expressing
GFR2b when stimulated with either li-
gand. Instead, F-actin-positive staining was
found at the periphery of these cells where
NF-H was not found to colocalize exten-
sively (supplemental Fig. 4F, available at
www.jneurosci.org as supplemental mate-
rial). These observations provide additional
evidence of the lack of neurite outgrowth in
ligand-stimulated cells expressing GFR2b
and the neuritogenic activities of the other
two isoforms.
GFR2b inhibited neurite outgrowth
mediated by GFR2a, GFR2c, and
GFR1a isoform
Because GFR2b transfectants did not in-
duce neurite outgrowth when stimulated
with ligands, we explored the possibility
that this isoformmay affect themorpholog-
ical changes in cells coexpressing GFR2b
and GFR2a or GFR2c. We first estab-
lished stably transfectedNeuro2Acells coex-
pressing GFR2a and GFR2b (GFR2a
GFR2b) using a bicistronic vector. Expres-
sion and membrane targeting of GFR2a
were not affected when coexpressed with
GFR2b (supplemental Fig. 5, available at
www.jneurosci.org as supplemental mate-
rial). As shown previously, ligand-induced
stimulation of GFR2a but not GFR2b in-
duced neurite outgrowth (Fig. 4B). Ligand-
induced stimulation of cells coexpressing
GFR2a  GFR2b showed significantly
less neurite outgrowth (Fig. 5A). However,
these cells extended neurite when treated
with retinoic acid. Similarly, ligand stimula-
tion of cells coexpressing GFR2c and
GFR2b (GFR2cGFR2b) showed sig-
nificantly less neurite outgrowth (Fig. 5A).
Extending this finding, we next ex-
plored the possible inhibitory effect of the
activation of GFR2b on the neurite out-
growth induced by ligands in cells coex-
pressing GFR1a. Cells expressing only
GFR1a showed significant neurite outgrowth when stimulated
by GDNF, NTN, or retinoic acid (Fig. 5B). Interestingly, when
stimulated by either GDNF or NTN, cells coexpressing GFR1a
and GFR2b (GFR1a  GFR2b) showed significantly less
neurite outgrowth. These observations indicate that the activa-
tion of GFR2b inhibits neurite outgrowth induced by the acti-
vation of GFR2a, GFR2c, and even the structurally related
GFR1a.
Knock-down of GFR2b resulted in an increase in
neurite outgrowth
Wenext extended the above observation of the GFR2b-induced
inhibition of neurite outgrowth by investigating BE(2)-C cells








































Figure 4. Differential neuritogenic activities of ligand-activated GFR2 isoforms. Cells were seeded on six-well plates and
incubated for 16–18 h inmedium containing 10% serum. The cells were then exposed to GDNF or NTN (50 ng/ml) for 3more days
in 0.5% serum-containing medium. Retinoic acid (5M) was used as a positive control for cell differentiation. A, Digital phase-
contrast images of Neuro2A cells stably expressing GFR2a, GFR2b, GFR2c, or pIRES vector control when treatedwith retinoic
acid, GDNF, or NTN. B, Percentages of cells bearing neurites that were at least twice the length of the cells bodies. More than 600
cells were counted per well, on at least three different fields. Experiments were repeated twice with three individual clones, with
similar results. Significant differences in the percentage of cells bearing neurites between ligand stimulated and control were
calculated using the paired Student’s t test (*p 0.002). Error bars indicatemean SDof triplicatemeasurements. RA, Retinoic acid.
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that have previously been shown to endogenously expressGFR2
receptors (Kobori et al., 2004). These cells express a comparable
level of GFR2a andGFR2b (Fig. 6A). GFR2c was found to be
expressed at a level close to the detection limit of the assay (data
not shown). The presence of GFR2 but not GFR1 in BE(2)-C
cells agrees with previous observations (Kobori et al., 2004;
Yoong et al., 2006) but not with a recent report using semiquan-
titative PCR (Hansford and Marshall, 2005).
Similar to the above observations with the coexpression of
GFR2b with GFR2a, GFR2c, or GFR1a, both GDNF and
NTN failed to induce neurite outgrowth inBE(2)-C cells (Fig. 6C,
control). Neurite outgrowth was, however, observed when these
cells were treated with retinoic acid, an indication that BE(2)-C
cells have the capability of forming neurite-like structures. To test
the hypothesis that the activation of GFR2bmay inhibit neurite
outgrowth induced by GFR2a or GFR2c in BE(2)-C cells, we
attempted to silence the expression of GFR2b using siRNA.
Because GFR2b has no unique sequences compared with
GFR2a, the design of a GFR2b isoform-specific siRNA poses a
significant challenge. A series of siRNA duplexes were then de-
signedwith sequences overlapping exons 1 and 3 ofGFR2b (Fig.
6B). Of the five designs tested, only the siGFR2b-137 showed
significant discrimination in silencing GFR2a and GFR2b
(Fig. 6B). This particular siRNA design, siGFR2b-137, inhib-
ited the expression of GFR2b to10% of the control, with no
significant reduction in the expression of GFR2a.
When GFR2b expression was silenced, the BE(2)-C cells ex-
tended neurite-like structures when stimulated with either
GDNF and NTN (Fig. 6C). This observation supports the notion
that the activation of GFR2b inhibits neurite outgrowth in-
duced by ligand stimulation of GFR2a.
Signaling and biochemical activities of GFR2 isoforms in the
co-expression model
To further investigate the signaling and biochemical events un-
derlying ligand activation of GFR2b in the coexpression model,
we first examined the stimulation of MAPK (ERK1/2). GDNF
stimulated ERK1/2 phosphorylation in GFR2a or GFR2c, but
notGFR2b, transfectants (Fig. 2A). In the coexpressionmodels,
both GDNF and NTN induced rapid and transient phosphoryla-
tion of ERK1/2 (Fig. 7A).
Interestingly, when stimulated with ei-
ther GDNF or NTN, no change in the ex-
pression of either egr-1 or egr-2 was ob-
served (Fig. 7B–E). However, significant
upregulation of the expression of fosB was
observed in the coexpression of GFR2b
with GFR2a (GFR2a  GFR2b) or
with GFR2c (GFR2b GFR2c). This
observation showed that the activation of
coexpressed GFR2b with either GFR2a
orGFR2c results in the activation of fosB,
an early-response gene, reminiscent of
that observed in GFR2b transfected
alone (Fig. 3).
GFR2b also inhibited retinoic acid-
induced neurite outgrowth and
activated RhoA
We next addressed the possibility that
GFR2b may affect neurite outgrowth in-
duced by retinoic acid, a non-GFL stimu-
lus. Using Neuro2A-expressing GFR2b,
retinoic acid treatment resulted in extensive neurite outgrowth.
Both GDNF and NTN dramatically reduced the number of cells
bearing neurite-like structures in retinoic acid-treated GFR2b
transfectant (Fig. 8).
TheRho family of smallGTPases and the associated regulators
have been implicated in the modulation of neurite formation,
axonal pathfinding, and dendritic arborization (Mackay et al.,
1997; Van Aelst and Cline, 2004). Thus, it was of interest to
examine the possibility that GFR2bmay activate the Rho family
of GTPases. When stimulated with either GDNF or NTN,
Neuro2a coexpressing GFR2a and GFR2b (GFR2a 
GFR2b) or GFR2c andGFR2b (GFR2cGFR2b) did not
extend neurite-like structures (Fig. 5A). However, a significant
number of these cells extended neurite-like structures in the pres-
ence of C3 transferase, suggesting the involvement of the Rho
family of GTPases in the inhibitory effects of GFR2b (Fig.
9A,B). Because Neuro2A cells have previously been shown to
respond to LPA, resulting in the inhibition of neurite outgrowths
through the RhoA-dependent mechanism (Sayas et al., 2002), it
was not surprising that C3 transferase was found to inhibit LPA
effects on retinoic acid-induced neurite outgrowth. At the con-
centration of C3 transferase used in this study, no significant cell
death was observed (data not shown).
To gain a better understanding of themechanisms underlying
the inhibitory effects of GFR2b, we next examined the possible
involvement of ROCK, which is known to be an effector of RhoA
in the negative regulation of neurite outgrowth (Dickson, 2001;
Sayas et al., 2002). Using the ROCK inhibitor Y27632, the inhib-
itory activity of LPA on retinoic acid-induced neurite outgrowth
was significantly attenuated (Fig. 9A,B). However, the same con-
centration of Y27632 (10 M) did not attenuate the inhibitory
activity ofGFR2b (Fig. 9A,B).Higher concentrations of Y27632
(20 M) resulted in significantly higher background neurite out-
growth and therefore complicated the interpretation of the study.
To investigate the possible involvement of RhoA in the inhib-
itory effects of GFR2b, an attempt was made to pull down acti-
vated RhoA from cells lysates using glutathione S-transferase
(GST)–Rhotekin and subsequently immunoblotted for RhoA.
Similar to the effects of LPA, GFR2b, when stimulated with
either NTN or GDNF, was found to activate RhoA significantly
(Fig. 9C). However, Neuro2A expressing GFR2a, GFR2c, or
GFR 2a + 
GFR 2b
GFR 2c + 
GFR 2b
























































Figure5. Ligand-induced neurite outgrowth inNeuro2A coexpressingGFR2bwith other GFR isoforms. GFR2bwas stably
coexpressedwith GFR2a (GFR2aGFR2b) or GFR2c (GFR2cGFR2b) (A) or GFR1a (GFR1aGFR2b) (B). Cells
were treated with or without GDNF or NTN (50 ng/ml) for 3 d in 0.5% serum-containing medium. Retinoic acid (RA; 5 M)
differentiated all the transfectants efficiently. Experiments have been repeated twicewith three independent clones, with similar
results. Significant differences in the percentage of cells bearing neurites between ligand stimulated and control were calculated
using the paired Student’s t test (**p 0.002; *p	 0.05). Error bars indicate mean SD of triplicate measurements.
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pIRES vector control did not activate
RhoA significantly when stimulated with
these ligands. This observation is consis-
tent with the suggestion that RhoA and/or
other RhoGTPasesmay be involved in the
inhibition of neurite outgrowth mediated
through GFR2b.
The involvement of Rho in the activa-
tion of GFR2b is not restricted to inhib-
iting GFR1a-, GFR2a-, or GFR2c-
induced neurite outgrowth but also to that
induced by retinoic acid (Fig. 10A). Simi-
lar to the above observations, the inhibi-
tory effects of GFR2b on retinoic acid-
induced neurite outgrowth appeared to be
mediated through a Rho-dependent man-
ner. Furthermore, the inhibition of ROCK
may be sufficient to oppose the effects of
LPA but not that of GFR2b on retinoic
acid-induced neurite outgrowth (Fig. 10B).
Discussion
This study demonstrates a novel function
of GFR2b, an alternatively spliced iso-
form of GFR2. When activated by li-
gands (GDNF or NTN), GFR2b inhib-
ited neurite outgrowth induced byGFR1a,
GFR2a, and GFR2c isoforms. Further-
more, GFR2b was found to inhibit a non-
GFR stimulus, retinoic acid-induced neu-
rite outgrowth, and to activate RhoA.
Alternative splicing is prevalent in
many mammalian genomes and is a
means of producing functionally diverse
polypeptides from a single gene (Blen-
cowe, 2006). Recently, genome-wide mi-
croarray and large-scale computational
analyses of expressed-sequence tag and
cDNA sequences have estimated that
50% of human multi-exon genes are al-
ternatively spliced (Modrek and Lee,
2002). Comparative genomic analyses also
demonstrated that the greatest amount of
conserved alternative splicing occurs in
the CNS (Kan et al., 2005). In many sys-
tems, alternative splicing events have been
shown to produce isoforms with distinct
activities and biochemical properties, as a
means for diverse biological functions
(Lee and Irizarry, 2003).
In the cortex of human, mouse, and rat
brain, the expression of GFR2 mRNA
has been reported (Sanicola et al., 1997;
Widenfalk et al., 1997; Golden et al., 1998,
1999; Trupp et al., 1998). However, the
probes used in these studies cannot distin-
guish the expressions of the isoforms. In the present study, we
were able to specifically amplify all three isoforms in the human
brain regions using exon-overlapping primers (Too, 2003). In the
human brain, all three GFR2 isoforms are expressed at compa-
rable levels, with GFR2c significantly higher than the other two
isoforms. Compared with the other regions of the human brain,
the cortex expressed the highest levels of the isoforms. The func-
tional significance of these isoforms in the cortex has yet to be
defined. Interestingly, the high expressions of the GFR2 iso-
forms in the cortex, a region of the brain involved in learning
complex tasks, and the observation that GFR2 knock-out mice
show significant impairment in several memory tasks (Voikar et
al., 2004) may suggest a possible role of GFR2 signaling in the
development and/or maintenance of cognitive abilities that help
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Figure 6. Silencing of GFR2b expression in human BE(2)-C cells. A, The expression levels of GFR2a and GFR2b in BE(2)-C
cells were determined using quantitative real-time PCR. B, Effects of various designs of siRNA sequences on the expressions of
GFR2a and GFR2b in BE(2)-C. siRNA duplex (20 pmol) was transfected into cells, and total RNA was harvested 6 h later. The
expressions of GFR2a and GFR2b were then measured by quantitative real-time PCR. Significant differences between the
expression of the two isoforms after silencing with each of the siRNA designs were calculated using the paired Student’s t test
(**p	 0.001). C,D, Neurite outgrowth of BE(2)-C cells after silencing of GFR2b. C, Top row, Cells were stimulatedwith retinoic
acid (5M), GDNF, or NTN (50 ng/ml) in the absence of siRNA. Bottom row, Cells were transfected with siGFR2b-137 for 6 h
and subsequently stimulatedwith retinoic acid (5M), GDNF, or NTN (50 ng/ml). Pretreament of cells with siGFR2b-137 and
subsequent stimulation with GDNF or NTN resulted in the formation of neurite-like structures (arrows). D, Percentages of cells
bearingneurites thatwereat least twice the lengthof the cells bodieswere scored in thepresence () or absence () of the siRNA
siGFR2b-137. Similar results were obtained from replicates of three individual experiments. Significant differences in the
percentage of cells bearing neurites between ligand stimulated and control were calculated using the paired Student’s t test
(**p 0.002; *p	 0.05). Error bars indicate mean SD of triplicate measurements. RA, Retinoic acid.
5610 • J. Neurosci., May 23, 2007 • 27(21):5603–5614 Yoong and Too • Inhibitory Activity of GFR2b in GDNF Signaling
GDNF and NTN are known to similarly activate a number of
signaling pathways, including ERK, phosphatidylinositol 3-ki-
nase/AKT, p38 MAPK, and JNK (Trupp et al., 1999; Takahashi,
2001; Pezeshki et al., 2003; Ichihara et al., 2004), and regulate the
expressions of various immediate-early-response genes (Fukuda
et al., 2003; Pezeshki et al., 2003). In this study, it is intriguing to
note that the activation of specific signaling pathways but not the
early-response genes is dependent on the ligands used. For in-
stance, GDNF was found to potently activate ERK1/2 through
GFR2a andGFR2c in a dose- and time-dependentmanner but
did not activate GFR2b significantly. This was not attributable
to the failure of GDNF to interact with GFR2b because GDNF
displaced bound [125I]GDNF equally well with all three isoform
transfectants. Similarly, GDNF activated AKT through GFR2b
and GFR2c but not through GFR2a. However, NTN showed
similar activations of ERK1/2 and AKT through all of the three
isoforms. GDNF at lower concentrations appeared to be slightly
more potent than NTN in the activation of ERK1/2 but not at
higher concentrations in GFR2a and
GFR2c transfectants. The significance of
this, however, is unclear presently.
Both GDNF and NTN have previously
been shown to have similar properties in
activating the multicomponent receptor
complex (Baloh et al., 1997; Airaksinen et
al., 1999; Wang et al., 2000; Scott and
Ibanez, 2001; Coulpier et al., 2002;
Charlet-Berguerand et al., 2004). In addi-
tion, midbrain dopaminergic neurons
that only express GFR1 appear to survive
equally well with both GDNF and NTN in
vitro and in vivo (Horger et al., 1998).
However, there are observations of dis-
tinct functional differences with the use of
specific ligands. Although GDNF and
NTN promote the survival of dopaminer-
gic neurons through GFR1 (Cacalano et
al., 1998; Akerud et al., 1999), only GDNF
possess neuritogenic and hypertrophic ef-
fects (Akerud et al., 1999). In cultured
sympathetic neurons, GDNF was able to
promote the survival of culture sympa-
thetic neurons through GFR2, but NTN
could not promote survival through
GFR1 (Buj-Bello et al., 1997). Further-
more, GDNF but notNTN could promote
the axonal growth of DRG neurons
through GFR1 (Paveliev et al., 2004).
Consistent with these studies, recent ob-
servations show differential ligand signal-
ing through the activation of GFR1 (Lee
et al., 2006) and distinct activation of mi-
croRNAs by specific ligands through the
GFR2 receptor complexes (Yoong et al.,
2006), supporting the emerging view that
cross talk of exogenously applied GDNF
and NTN with a specific receptor may, in
some instances, result in distinct
functions.
It is well documented that GDNF and
NTN are potent trophic factors that have
potent effects on neuronal differentiation
and promote survival and sprouting of
ventral mesencephalic dopaminergic neurons in primary cul-
tures and other neuronal cultures (Lin et al., 1993; Akerud et al.,
1999; Baloh et al., 2000; Yan et al., 2003;Wanigasekara andKeast,
2005; Zihlmann et al., 2005). The finding in this study of a par-
ticular alternatively spliced variant of GFR2 inhibiting neurite
outgrowth was unexpected. Unlike GFR2a and GFR2c,
GFR2b transfectants did not induce neurite outgrowth when
activated by either GDNF or NTN. Both GFR2a and GFR2c
(but not GFR2b) activated the early-response gene egr1 (also
known as NGFI-A, krox-24, zif-268, and TIS-8), consistent with
a role of egr1 in neuronal differentiation (Pignatelli et al., 1999;
Knapska and Kaczmarek, 2004). In coexpression studies,
GFR2b was found to inhibit ligand-induced neurite outgrowth
by GFR2a and GFR2c. Similarly, in BE(2)-C cells endog-
enously expressing GFR2b isoform, both GDNF and NTN did
not significantly alter the morphology of the cells. However, the
silencing of GFR2b and subsequent treatment with either









































































































Figure 7. Ligand-regulated ERK1/2 signaling and expressions of immediate-early-response genes in Neuro2A coexpressing
GFR2band theotherGFR2 isoforms.A,Westernblot analyses of theactivationof ERK1/2.Neuro2A cells stably coexpressing the
isoforms GFR2a and GFR2b (GFR2a GFR2b) or GFR2c and GFR2b (GFR2c GFR2b) were treated with GDNF,
NTN, or Sorbitol for theperiodof time indicated. Phospho-specific antibodies to ERK1/2wereused for detection, and theblotswere
reprobedwith pan antibody serving as controls for protein loadings.B–E, Kinetic analyses of GDNF- or NTN-regulated expressions
of early-response genes in the coexpression models. Expressions of fosB, egr-1, and egr-2 were measured with quantitative
real-timePCR in cells stably coexpressingGFR2awithGFR2b (GFR2aGFR2b)when stimulatedwithGDNF (B) orNTN (C);
cells stably coexpressing GFR2c with GFR2b (GFR2c GFR2b) were stimulated with GDNF (D) or NTN (E). Significant
differences in expression of genes between ligand stimulated and controlwere calculated using the paired Student’s t test. A value
of p 0.05 was considered significant (**p 0.001).
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Interestingly, in coexpression studies, fosB
was upregulated and paralleled the up-
regulation of the immediate-response
gene observed in GFR2b transfectants by
GDNF or NTN. It is not known whether
the coexpression ofGFR2bwithGFR2a
or GFR2c may have affected the protein
expression levels of the latter two spliced
variants resulting in the attenuation of
neurite extension on ligand stimulation.
The possibility of GFR2b affecting the
expression of the other spliced variants
and the effects of expressions levels is cur-
rently investigated.
The inhibition of neurite outgrowth by
GFR2b is not restricted to the GFR2
family of isoforms. Ligand-activated
GFR2b also inhibited the neurite out-
growth induced by GFR1a, another
member of GFR. Intriguingly, the activa-
tion of GFR2b inhibited neurite out-
growth induced by retinoic acid. The un-
derlying GFR2b inhibitory mechanism
appears to involve the Rho family of GT-
Pases. RhoA is a member of the Rho GT-
Pase family, which includes RhoA, Rac,
and Cdc42 (Luo, 2000; Van Aelst and Cline, 2004). Although Rac
and Cdc42 have been shown to be involved in promoting neurite
and axonal outgrowth, RhoA has been the focus in studies of
molecular mechanisms for some glia-derived neurite outgrowth
inhibitory factors such as Nogo-A, myelin-associated glycopro-
tein (Niederost et al., 2002), and LPA (Sayas et al., 2002). More
recent findings have revealed that RhoA mediates neurite out-
growth inhibition by reorganization of actin and the microtubu-
lar network (Dickson, 2001; Leung et al., 2002). Consistent with
these findings is that GDNF and NTN increased the active form
of RhoA in GFR2b but not GFR2a or GFR2c transfectants.
Furthermore, the Clostridium botulinum C3 exoenzyme specifi-
cally ADP-ribosylates and inactivates Rho, thereby increasing
neurite outgrowths in GFR2a/GFR2b and GFR2c/GFR2b
coexpressionmodels. It is interesting to note that GDNF induced
RET-mediated phosphorylation of focal adhesion kinase, paxil-
lin, and p130C through the activation of the Rho family of GT-
Pase and inhibited the outgrowth of neurites in TGW-I-nu cells
(Murakami et al., 1999). It is, however, unclear whether this ob-
servation is mediated through GFR2b.
Compared with GFR2a, both GFR2b and GFR2c showed
deletion of eight cysteine residues andN-glycosylation sites at the
N terminus (Wong and Too, 1998). GFR2 is thought to be
structurally organized into three distinct domains. The
N-terminal domain has previously been shown to be dispensable
for ligand binding specificity and RET phosphorylation of GFR
receptors (Scott and Ibanez, 2001). Extending this observation,
the N-terminal domain encoding the unique sequences of
GFR2a, GFR2b, and GFR2c may serve to regulate distinct
biochemical and cellular processes. It is tempting to speculate
that the expression and interactions of specific GFR2 receptor
spliced isoforms may play an important role in neuronal differ-
entiation involving GDNF and NTN. The recent observation in
which the expressions of GFR2 isoforms are differentially regu-
lated in Nurr1-induced dorpaminergic differentiation of embry-
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Figure 9. Effects of RhoA and ROCK inhibitors in ligand-induced neurite outgrowth of
GFR2 isoform coexpression models and the ligand-induced activation of RhoA in GFR2 iso-
form transfectants. A, B, Effects of RhoA inhibitor exoenzyme C3 transferase (1 g/ml) and
ROCK inhibitor Y27632 (10M) on ligand-inducedneurite outgrowth in coexpressionmodels of
GFR2a and GFR2b (A) or GFR2c and GFR2b (B). LPAwas used as a positive control in this
study. LPA (10 M) antagonizes neurite outgrowth induced by 5 M retinoic acid (RA); such
neurite inhibition of LPA was attenuated by C3 (1g/ml) and Y27632 (10M). The means
SDwere calculated from results obtained in triplicates. The effects of RhoA and ROCK inhibitors
were compared with the effects of the inhibitors alone. With the concentrations of inhibitors
used, no significant cell deaths were observed. Significant differences in the percentage of cells
bearing neurites were calculated between ligand stimulated and control, using the paired Stu-
dent’s t test (*p 0.01). C, Analyses of RhoA activation in Neuro2A cells transfected with
GFR2 isoforms or pIRES control. After a 10minpretreatment of LPA (10M), GDNF, or NTN (50
ng/ml), GTP-bound RhoAwas pulled down from cell lysates using GST–Rhotekin and immuno-
blotted for RhoA. LPA served as a positive control for RhoA activation. Blotting of total RhoA in
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Figure 8. Ligand-activated GFR2b antagonizes the neurite outgrowth induced by retinoic acid (RA). RA (5 M) induced
neurite outgrowth in GFR2b-expressingNeuro2A cells.When treated togetherwith GDNF or NTN (50 ng/ml), neurite outgrowth
inducedbyRAwas significantly attenuated.A, Phase-contrast imagesofNeuro2Acells stably expressingGFR2b, treatedwithRA,
GDNF, or NTN for 3 d. B, Graph of the percentage of cells bearing neurite with at least two times the length of the cell bodies and
the effects of RA, GDNF, and NTN. Similar results were obtained from three independent clones. Significant differences in the
percentageof cells bearingneurites between ligand stimulatedand controlwere calculatedusing thepairedStudent’s t test (*p
0.002). Error bars indicate mean SD of triplicate measurements.
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In summary, this study provides the first evidence that GDNF
and NTN have distinct neuritogenic effects mediated through
specific GFR2 isoforms. GFR2b inhibited GFR1 andGFR2,
and retinoic acid mediated neuritogenesis through the Rho fam-
ily of GTPases. The emerging view is that the combinatorial in-
teractions of the spliced isoforms of GFR2, RET, and NCAM
may contribute to the complexity of a multicomponent signaling
system and may produce the myriad of observed biological
responses.
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the ligand-activated GFR2b attenuation of neurite extension induced by RA (5M). The same
concentration of exoenzyme C3 transferase also attenuated LPA (10 M) inhibition of RA-
induced neurite extension. B, Lack of effect of ROCK inhibitor Y27632 on the ligand-activated
GFR2b inhibition of RA inducedneurite extension. The same concentration of Y27632 (10M)
significantly attenuated the neurite outgrowth inhibition induced by LPA. The means SD
were calculated from results obtained in triplicates. The effects of RhoA and ROCK inhibitors
were compared with the effects of the inhibitors alone. With the concentrations of inhibitors
used, no significant cell deaths were observed. Significant differences in the percentage of cells
bearing neurites were calculated between ligand stimulated and control, using the paired Stu-
dent’s t test (*p 0.01).
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